

# BMJ Paediatrics Open

BMJ Paediatrics Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Paediatrics Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjpaedsopen.bmj.com>).

If you have any questions on BMJ Paediatrics Open's open peer review process please email [info.bmjpo@bmj.com](mailto:info.bmjpo@bmj.com)

# BMJ Paediatrics Open

## COVID-19 in pregnancy; The fetal perspective- a systematic review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2020-000859
Article Type:	Original research
Date Submitted by the Author:	03-Sep-2020
Complete List of Authors:	Dube, Rajani; RAK Medical and Health Sciences University, Obstetrics and Gynaecology Kar, Subhranshu; Ras Al Khaimah Medical and Health Sciences University, Pediatrics
Keywords:	Data Collection, Microbiology, Mortality, Neonatology, Virology

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Title Page

**A. Article Title-** COVID-19 in pregnancy; The fetal perspective- a systematic review

**B. Author information-**

**1. Rajani Dube-**

M.D. (Obstetrics and Gynaecology), Post graduate diploma in Reproductive Medicine and ART

Department of Obstetrics and Gynaecology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras al Khaimah, United Arab Emirates

E Mail ID- [rajnidube@yahoo.com](mailto:rajnidube@yahoo.com)

Phone No- +971 551383304

ORCID - <https://orcid.org/0000-0002-1539-6162>

**2. Subhranshu Sekhar Kar- Corresponding author**

M.D. (Paediatrics), Fellowship in Paediatric Critical Care

Department of Pediatrics, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras al Khaimah, United Arab Emirates

E Mail ID- [drsskar@gmail.com](mailto:drsskar@gmail.com)

Phone No- +971 504314392

ORCID - <https://orcid.org/0000-0002-9379-7447>

**C. Key Words-** COVID-19, SARS-CoV-2, vertical transmission, perinatal outcome, congenital anomaly

**D. Word Count-** 4978

**E. Reference Count-** 101

**Disclaimer-** The views expressed in the submitted article are our own and not an official position of the institution or funder.

**Source(s) of support-** None

**Number of figures and tables-** Tables- and two figures

**Disclosure of relationships and activities-** Nothing to disclose

## Title: COVID-19 in pregnancy; The fetal perspective- a systematic review

### Abstract:

**Objective:** We aimed to conduct a systematic review of the available literature to determine the effects of confirmed cases of COVID-19 in pregnant women from the fetal perspective by estimation of vertical transmission, perinatal outcome and possible teratogenicity.

### Methods

Data sources: Eligible studies published from November 1, 2019 up to August 10, 2020 were retrieved from PubMed, Embase, LitCovid, MedRxiv, BioRxiv, Google Scholar, EBSCO MEDLINE, CINAHL, and Scopus collection databases.

**Study eligibility criteria:** This systematic review included English language case reports, case series and cohort studies of pregnant women who had viral RNA RT PCR confirmed SARS-CoV-2 infection, and had reported data on perinatal outcome, congenital anomalies and vertical transmission of SARS-CoV-2. A total of 35 case reports and 34 cohort/case series studies describing 1213 tested neonates were included for evidence of vertical transmission. Similarly, 26 case reports and 31 case series/cohort studies describing 1255 fetuses were included for evaluation of perinatal outcome and congenital anomalies.

**Results:** Our review revealed that out of 1193 neonates from SARS-CoV-2 infected mothers, 48 neonates had SARS-CoV-2 viral RNA positive nasopharyngeal swab, indicating a pooled proportion of 4.02% for vertical transmission. Cord blood samples were positive for SARS-CoV-2 viral RNA in neonatal cord blood was positive in 5.4% (3/55) of samples, 6.9% (9/130) of placenta samples, 9.5% (4/42) of amniotic fluid, 9.6% (5/52) of fecal/rectal swabs and 0% of urine samples. In the perinatal outcomes, the rate of preterm labor is 325/1255 (OR=0.12) and Cesarean delivery was 750/1255 (OR=2.20). Most common neonatal symptom was shortness of breath. There were no congenital anomalies and still birth rate was 0.9 per 1000 total births in babies born to COVID-19 mothers.

**Conclusion:** Chances of vertical transmission of the virus is low. The perinatal outcome for the fetus is favourable. There is very low rate of stillbirth and neonatal deaths. There were no reported congenital anomalies in babies born to SARS CoV-2 positive mothers.

**Key words:** COVID-19, SARS-CoV-2, vertical transmission, perinatal outcome, congenital anomaly

### Key message:

#### A. What is known about the subject –

Studies specifically analyzing all aspects of fetus in SARS-CoV-2 positive mothers are not available. There is currently lack of large studies depicting fetal parameters and unlikely to be available in future as individual centers are still reporting cases in small

1  
2  
3 numbers. There are some systemic reviews reporting maternal outcomes and vertical  
4 transmission separately but aspects like fetal complications, teratogenicity, neonatal  
5 outcomes are missing.  
6

## 7 **B. What this study adds –**

8  
9 In this systematic review, we searched multiple databases to include evidence till 10<sup>th</sup>  
10 August 2020. 78 studies were included to collect data on more than 1200 fetuses. The  
11 mother to child transmission was found to be 4.02% (48/1193) by nasopharyngeal swab  
12 RT PCR testing. The risk of prematurity and caesarean delivery are high. There is  
13 evidence of fetal distress, low birth weight and neonatal respiratory symptoms in  
14 COVID-19 mothers but stillbirth is low. There are no associated congenital anomalies.  
15  
16

### 17 **Ethical Approval/ Consent:**

18  
19 This is a systemic review of the available literature on the fetal perspective of COVID-19  
20 in the mother. Since in this research, collected data is already reported with specific  
21 ethical approval and consent in each of the individual studies, and does not contain any  
22 patient identifying information, an ethical approval or consent from the patients is not  
23 required.  
24  
25

### 26 **Research Ethics Approval: Human Participants**

- 27 • Question is: Does this study involve human participants? **No**
- 28 • If ethical approval was not obtained, please provide an explanation in the free text  
29 field.
- 30 • If consent for participation was not obtained and NO is selected, please provide an  
31 explanation in the free text field.  
32  
33  
34  
35  
36  
37

## 38 **INTRODUCTION**

39  
40 Novel coronavirus infection and associated coronavirus disease-2019 (COVID -19)  
41 pandemic has changed our lives forever and has compelled us to reconsider almost  
42 everything we have long taken for granted. Among the different coronaviruses severely  
43 affecting human species, Middle East respiratory syndrome coronavirus (MERS-CoV),  
44 severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 are  
45 significant, causing MERS, SARS and COVID-19 respectively. SARS-CoV-2 strains show  
46 significant sequence homology to SARS-CoV and MERS-CoV [1]. As the pandemic  
47 evolved, there were significant advances in our knowledge about various aspects of the  
48 COVID-19 including epidemiology, clinical features, transmission, detection, and  
49 management modalities. Discoveries along the process of evolution are still contributing  
50 to our management practices.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 There were concerns regarding the maternal and fetal effects since the beginning of the  
4 pandemic. The earlier evidence of COVID-19 in pregnancy pointed towards pregnancy  
5 being considered as low risk for the disease and no difference in disease behavior in  
6 pregnant and non-pregnant women was reported. On the contrary, a newer study  
7 involving pooled data from more than 8000 women in the USA pointed towards a  
8 significantly higher rate of intensive care unit (ICU) admission and need for mechanical  
9 ventilation in pregnant women, even when adjusted for race/ethnicity and underlying  
10 comorbid conditions [2-4]. Similar findings were reported in another study from Sweden  
11 [5].  
12  
13  
14  
15

16 However, these studies did not specify fetal effects resulting from vertical transmission  
17 and consequent perinatal outcomes. Through this article, we want to analyze the  
18 published evidence on the fetal perspective of COVID-19 infection with respect to vertical  
19 transmission and perinatal outcome through a systematic review. This will aid in  
20 alleviating uncertainties faced while doing patient counseling and help in subsequent  
21 management during these testing times.  
22  
23

## 24 METHODS

25  
26 **Search strategy:** A systematic search of PubMed, Embase, LitCovid, MedRxiv, BioRxiv,  
27 Google Scholar, EBSCO MEDLINE, CINAHL, and Scopus electronic database was done.  
28 Medical subject handling terms (MeSH) and free text term keywords like vertical  
29 transmission, perinatal outcome, congenital anomaly, teratogenicity, fetal, neonate,  
30 newborn, pregnancy were used in combination with COVID-19, 2019-nCoV, SARS-CoV-  
31 2 to search for data from 1<sup>st</sup> November 2019 till 10<sup>th</sup> July 2020. Thereafter manual update  
32 was done on weekly basis till 10<sup>th</sup> August, 2020. The references of relevant studies were  
33 also searched.  
34  
35  
36

37  
38 **Selection criteria:** The search consisted of only English language articles including case  
39 reports, case series, and letters to editors containing case information. After a thorough  
40 screening, no randomized clinical trials were found.  
41

42 **Inclusion criteria:** The following studies were included for review.  
43

- 44 1- Studies reporting pregnant women with confirmed COVID-19 who had delivered.
- 45 2- Studies containing the results of SARS-CoV- 2 test [including reverse transcriptase  
46 polymerase chain reaction (RT-PCR) and serological tests] in both mothers and newborns  
47 samples.  
48
- 49 4- Studies that present the out-come of vertical transmission or perinatal outcome.  
50

51 Evidence of vertical transmission is indicated by positive RT-PCR status in different  
52 samples like neonatal nasopharyngeal swab, cord blood, amniotic fluid, breast milk, and  
53 placental tissue. Perinatal outcome measures included fetal complications in SARS-CoV  
54  
55  
56  
57

1  
2  
3 2 positive pregnant women, gestational age at delivery (preterm delivery), mode of  
4 delivery, birth weight, stillbirth, neonatal death, neonatal condition at birth (APGAR  
5 scores, neonatal ICU admissions) and symptoms in the early neonatal period. Any  
6 outcome measures not explicitly mentioned was considered not to have been reported.  
7  
8

9 **Exclusion criteria:** Exclusions consisted of studies in pregnant women yet to deliver,  
10 duplicated studies, review articles, articles in languages other than English where English  
11 translation is unavailable, studies where infection in mothers is not confirmed, or where  
12 neonatal testing was not done. Conference abstracts, expert opinions, and critical  
13 appraisals were also excluded.  
14  
15

16 Both the authors (RD, SSK) reviewed all titles independently. Potential relevance of the  
17 studies to be included for review, were agreed upon by discussion. Selected titles and  
18 abstracts were further screened between studies to reject overlap of cases.  
19  
20

21 Full-text copies of the selected papers were obtained and the relevant data regarding  
22 study characteristics, evidence of vertical transmission, and perinatal outcomes were  
23 extracted by the same two reviewers independently. In the case of individual case reports,  
24 if the same patient was included in more than 1 study with similar characteristics and  
25 findings, only the report with a larger number of patients was included. As far as possible,  
26 single case reports were cross-checked with other reports from the same location and  
27 hospital. If a case series included multiple locations, the individual reports from the same  
28 centers were excluded. Finally, studies were screened by assessing selection,  
29 comparability and exposure for inclusion into evidence acquisition of vertical transmission  
30 and/or perinatal outcome measures [Table-1 (a), 1 (b) in Supplementary material-1].  
31  
32  
33  
34  
35

36 **Statistical analysis:** Pooled proportions of categorical variables were calculated with  
37 percentage after obtaining the positive rates of each of the SARS-CoV-2 testing methods  
38 used, wherever applicable. Odds Ratio was calculated for the fetal outcome of preterm  
39 delivery and mode of delivery in the SARS-CoV-2 positive mothers from the pooled data.  
40 Percentage of most common variables were also calculated.  
41  
42  
43

#### 44 **Public and Patient Involvement statement:**

45

46 This research is not “co-produced” with patients, carers, or members of the public.  
47  
48

- 49 • At what stage in the research process were patients/public first involved in the  
50 research and how? – Not Applicable
- 51 • How were the research question(s) and outcome measures developed and informed  
52 by their priorities, experience, and preferences? – Not Applicable
- 53 • How were patients/public involved in the design of this study? – Not Applicable  
54  
55  
56  
57  
58  
59  
60



- How were they involved in the recruitment to and conduct of the study? – Not Applicable
- Were they asked to assess the burden of the intervention and time required to participate in the research? – Not Applicable

## RESULTS

### 1. Vertical transmission-

Vertical transmission generally includes transmission through germ cells or the placenta during pregnancy, via the birth canal during labor and delivery, and during the postpartum period through breastfeeding or close contact. The transfer of microorganisms during pregnancy is seen with many of the common pathogens with resultant effect ranging from asymptomatic infection, intrauterine growth restriction, intrauterine death, structural anomalies to a sequel of infection. Some pathogens like cytomegalovirus (CMV), or Zika virus produce mild to no symptoms in the pregnant patient but can cause congenital infection with severe consequences [6]. Viruses specifically can be transmitted to the fetus via the maternal blood when it enters the placental villus, containing the fetal blood vessels, or by direct access to the placenta from the lower genital tract by ascending infection [7]. Again even when transferred trans-placentally during the antenatal period, the specific timing of maternal infection can have different effects on the fetus. First trimester infections can cause severe structural anomalies whereas second and third-trimester infection is more likely to cause functional organ abnormality [8].

Several factors are contributing to the concerns of vertical transmission in Covid-19. It is known that the SARS-COV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors for entry into the cells. ACE-2 receptors are detected in various parts of the uterus, vagina, decidual cells and placenta [9-12]. Congenital infection is likely if an infectious agent is detected in amniotic fluid collected before the rupture of membranes or in the cord blood at birth. Similarly, if a neonate is born with a specific structural sequel of an infection, intrauterine infection is a probability. The detection of the agent later in life signifies postnatal infection. It also depends on the presence of the agent in the genital tract and time taken from exposure to detection by definitive tests to differentiate between intrapartum and postpartum infection. Furthermore, the sensitivity of RT-PCR testing is different for detecting SARS-CoV-2 in different samples. Therefore, it is rational to test samples from multiple sites to improve detection and reduce false-negative cases [8,13].

### Search Results:

Out of 97 records selected for full-text review, 69 studies fulfilled the eligibility criteria and were included in the qualitative synthesis. 35 studies were case reports containing 4 or fewer number of cases and 34 studies had 5 or more number of patients (**Figure-1**). Since evidence from randomized control trials were not available until the time of the search, 34

1  
2  
3 studies having 5 or more number of patients were considered for qualitative analysis  
4 **[14,15]**. The majority of earlier studies were from China but later studies contained cases  
5 from the rest of the world **[Table-1 (a),1 (b)]**.  
6  
7

### 8 **Systematic review:**

9

10 Tests for diagnosis of SARS-CoV-2 was done in a total of 1213 neonates. The most  
11 common type of sample tested was neonatal nasopharyngeal samples (NP swab) (64 out  
12 of 69 studies) followed by the placenta, amniotic fluid, and cord blood. In majority,  
13 samples were taken from more than one site. In few studies, the same type of sample  
14 was repeated at different intervals (e.g., NP swab and breast milk samples) **[Table-2]**.  
15  
16  
17  
18

#### 19 **i. Neonatal Nasopharyngeal swab**

20

21 In our review, a total of 1193 neonates born to mothers with COVID-19 infection were  
22 tested by NP swabs. 48 neonates were found positive by RT-PCR test indicating a pooled  
23 proportion of 4.02 % for mother to child transmission **[Table-3]**. The largest cohort study  
24 from the UK involved 427 pregnant women with COVID-19. 244 out of the 262 neonates  
25 were tested by NP swab. 6 of the neonates were positive for SARS-CoV-2 within 12 hours  
26 of birth and 6 more were positive after 12 hours of birth (12 out of 244; 4.9%) **[16]**. Studies  
27 involving 181 women and 116 women in China showed 2 positive neonates out of 181 (2  
28 out of 181; 1.1%) and no positive cases for SARS-CoV-2 in the other study **[17,18]**. An  
29 analysis of 141 women from a hospital in India showed that 3 of the 131 neonates were  
30 tested positive for SARS-CoV-2 by nasopharyngeal swab **[19]**. In another study in a New  
31 York Hospital, 48 neonates born to 55 women were all tested negative on Day 0 of life  
32 **[20]**. However, One Italian study found three infants positive by NP swab out of 42 tested  
33 within 48 hours after birth **[21]**.  
34  
35  
36  
37  
38

39 One recent case report revealed that RT-PCR was positive for SARS-CoV-2 in all of the  
40 samples for amniotic fluid, vaginal swab, blood, and non-bronchoscopic bronchoalveolar  
41 lavage fluid as well as NP swab and rectal swabs collected at 1 hour of life, and then  
42 repeated at 3 days and 18 days suggesting a trans-placental transmission **[22]**.  
43  
44

45 When the timing of NP swab test in the positive neonates was analyzed, it was found that  
46 only a few of the samples were positive within 24 hours of life (13 cases) **[23, 22,16, 19,**  
47 **22-24]** and the majority of the cases were positive after 24 hours of life. In one study the  
48 sample collected within 24 hours was negative but the second sample collected after 24  
49 hours was found positive **[25,26]**. This indicates a strong probability of having acquired  
50 the infection, after birth.  
51  
52

#### 53 **ii. Amniotic fluid**

54  
55  
56  
57  
58  
59  
60

1  
2  
3 In our review, 42 samples of amniotic fluid were tested in 18 studies with a positive result  
4 in 4 of them. The studies were case reports involving single and 2 cases. In one of these  
5 studies, the test was positive from all the maternal samples. All the neonatal samples  
6 were positive even at 18 days follow up [22].  
7  
8

### 9 iii. Placenta

10  
11 A total of 19 studies were identified in our review where the placenta was examined for  
12 the presence of SARS-CoV-2 or related pathological changes. A total of 130 placental  
13 samples were tested and 9 were found positive for SARS-CoV-2. PCR for SARS-CoV-2  
14 RNA was positive from placenta in two case reports where there were spontaneous  
15 miscarriage and dilatation and curettage respectively [27,28]. In one of them, the  
16 umbilical cord was also positive for the virus, but the fetal organs were tested negative.  
17 The virus was confirmed to be localized mostly in the syncytiotrophoblastic cells of the  
18 placenta by immunohistochemistry for the SARS-CoV-2 spike protein as well as electron  
19 microscopy and it was identical to the typically locally isolated virus [27]. Furthermore, in  
20 another study, electron microscopy showed the presence of the virus in the fetal side of  
21 the placenta. The virions were present in the mesenchymal core of the terminal villus and  
22 were demonstrated to be invading a syncytiotrophoblast and a microvillus. However, the  
23 neonate delivered at 28 weeks in this pregnancy was tested negative for the virus [29].  
24 Evidence of probable vertical transmission was obtained in another case where the  
25 newborn was found positive for the virus by nasopharyngeal swab, plasma, and stool  
26 samples along with the placenta [30]. Similarly, probable transplacental transmission of  
27 the virus was demonstrated by another study where SARS-CoV-2 was detected in  
28 amniotic fluid aspirated before the rupture of the membranes, vaginal swab, neonatal  
29 blood, bronchoalveolar lavage fluid, and neonatal swabs on repeated occasions at 1 hour,  
30 3<sup>rd</sup> day and 18<sup>th</sup> day of life. The trophoblastic cells showed SARS-CoV-2 N protein on  
31 immunostaining [22].  
32  
33

34 Placental pathological examination showed an array of changes including vascular  
35 malperfusion, fibrin deposition, and chronic villitis, intervillitis and villous infarctions in  
36 our review. Two of these studies showed vascular malperfusion in 10 out of 20 placentas  
37 and 12 out of 15 placentas respectively but there were no assessments of placentas in  
38 these studies for the presence of SARS-CoV-2 infection. However, neonatal swabs were  
39 negative for the virus [31,32]. Similar pathological changes were seen in another study  
40 involving five SARS-CoV-2 positive pregnant women but the placentas were negative for  
41 the virus on direct testing for SARS-CoV-2 [33]. Chronic intervillitis was also seen in  
42 the pathological examination of the placentas of two women where the neonates were  
43 positive for SARS-CoV2 by nasopharyngeal swab testing [34]. Examination showed  
44 severe chronic villitis in another case where there was a stillbirth at term but direct tests  
45 of fetal tissues and placenta did not show infection with the virus [35].  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### iv. Other samples

Various other samples were tested for SARS-CoV-2 by different studies. Anal swab, rectal swab, or fecal sample was positive in 9.6% of neonates in our study. The stool sample was positive in two of the studies at Day 2 and Day 7 [30,36]. The urine sample was tested in only 3 studies without any positive results [37-39]. Breast milk was tested by RT-PCR in 10 of the studies with a pooled positive rate of 5.3% (3 out of 56). In one of the studies, the breast milk sample was positive in 4 consecutive days coinciding with the maternal symptoms in one woman but it was negative in milk samples of another woman. Both the babies were positive by the nasopharyngeal swab test and were symptomatic [40]. A vaginal swab was tested in 23 women with one positive result (4.3%) [22]. It can be argued that since IgM cannot cross placenta, elevated IgM levels in the neonate can indicate intrauterine infection, as seen in some of the neonates in this review. However, the assay of IgM for detection of infection has significant false positive results.

## 2. Perinatal outcome-

Evidence of COVID-19 specifically focusing on fetal and neonatal outcomes are lacking. Most of the reported literature have smaller studies. Previous systematic reviews focusing on the outcomes of all coronaviruses have reported a higher risk of preterm birth, perinatal death, miscarriage, and pre-eclampsia.

### Search results:

Out of 73 records selected for full-text review, a total of 57 studies fulfilled the eligibility criteria and were included in the qualitative synthesis. 31 studies qualified as case series/cohort and 26 studies contained 4 or fewer cases in our review (Figure-2). No randomized control trials were available until the time of the search.

### Systematic Review:

#### 2.1 Fetal Outcomes:

##### i. Fetal complications in SARS-CoV-2 +ve pregnant women

In our review, a total of 28 studies reported any fetal effects excluding all pregnancy losses or intrauterine fetal deaths (IUFD) [Table no-4]. The most commonly reported effect was fetal distress in 36 out of 1255 pregnancies (2.8%). In addition to fetal distress, some studies have reported non-reassuring or pathological cardiotocography (CTG) (11 out of 1255; 0.87%), and some have mentioned meconium-stained amniotic fluid (3 out of 1255; 0.23%), both findings can also be considered as evidence of fetal distress [22, 41-47]. In another study involving 262 deliveries, the fetal compromise was seen in 37 fetuses and emergency caesarean section (CS) was done in 9 of them [16]. Thus the

1  
2  
3 cumulative chance of fetal distress in pregnant women with a positive test for SARS-CoV-  
4 2 is 6.9%.  
5

6 Premature rupture of membrane (PROM) was reported in 29 pregnancies from 12  
7 studies. Intrauterine growth restriction (IUGR) was reported in 11 fetuses in 4 studies [17,  
8 25, 48, 49]. The highest number of IUGR fetuses was reported in 6 out of 10 fetuses in  
9 another study [48]. In addition, small for gestational age was reported in another study  
10 in 2 out of 10 fetuses [42]. Chorioamnionitis was reported only in one study involving 3  
11 fetuses [4].  
12  
13

## 14 ii. Mode of delivery

15  
16  
17 Mode of delivery was available for a total of 1255 pregnancies out of which 750 women  
18 delivered by CS as compared to 505 by vaginal delivery (OR=2.20) [Table no-5]. CS was  
19 the only mode of delivery in the majority of early published case reports as in the early  
20 days of the pandemic, elective CS delivery was the mode preferred by most of the  
21 countries for maternal indications [22-24, 26, 30, 39, 50- 65]. As the pandemic  
22 progressed, favorable outcomes were reported from vaginal delivery by many studies [47,  
23 49, 66-69]. It was also demonstrated that the chances of the virus being present in the  
24 vaginal fluid is very remote. In the later and larger case series, CS deliveries were only  
25 done for obstetrical indications [19]. In a study involving 134 deliveries, there were 67 CS  
26 and 67 vaginal deliveries. The rate of CS was not statistically different in women with  
27 positive SARS-CoV-2 as compared to negative pregnancies [19]. In yet another study,  
28 there were significantly higher rates of CS deliveries in cases (14 out of 16) as compared  
29 to the control group (57 out of 121) ( $p < 0.001$ ) but there was no difference in the groups  
30 with regards to chronic illnesses or pregnancy complications [70]. However, when done  
31 for maternal COVID-19 indications, the rate of cesarean was found to increase with the  
32 severity of disease [18].  
33  
34  
35  
36  
37  
38

39 In the largest study in the UK, the CS delivery was seen in 156 women and vaginal birth  
40 was seen in 106 women from a total of 262 births. The indications of CS were maternal  
41 compromise (27%), fetal compromise (24%), failed induction of labor or failure to progress  
42 (19%), other obstetric reasons (16%), prior CS (10%) and maternal request (4%) [16].  
43 Maternal COVID -19 related conditions were predominant indications in another larger  
44 study reporting CS for COVID-19 pneumonia in (33 out of 85), previous CS (16 out of 85),  
45 fetal distress (9 out of 85), and failure to progress in 5 out of 85 patients [17]. Many other  
46 studies similarly reported maternal condition requiring delivery as the commonest  
47 indication for CS [18, 21, 62].  
48  
49  
50

## 51 iii. Preterm Delivery

52  
53 Preterm delivery is defined as delivery of a viable product of conception before 37  
54 completed weeks of gestation. In our study, the outcome of preterm delivery was reported  
55  
56  
57  
58  
59  
60



1  
2  
3 in a total of 42 studies involving 1255 fetuses out of which 325 were delivered preterm  
4 (25.8%) [Table no-5]. However, the majority of them were elective deliveries to stabilize  
5 maternal condition related to COVID-19. Spontaneous preterm labor was only seen in 23  
6 fetuses (1.8%). The other indications included the pre-labor rupture of membranes. In a  
7 substantial number of studies, data regarding the indications were not found. In a study  
8 involving 134 deliveries in COVID -19 patients, preterm delivery was seen in 38  
9 pregnancies with positive SARS-CoV-2 and 239 out of 836 SARS-CoV-2 negative  
10 deliveries, which was not significantly different [19]. A similar report was seen in another  
11 study where 4 preterm deliveries were seen out of 17 SARS-CoV-2 confirmed group as  
12 compared to 7 out of 121 in the control group [70].

13  
14  
15 Furthermore, comparing the outcomes of COVID-19 pregnancies with different disease  
16 severity involving 181 pregnant women, preterm delivery was seen in 13 out of 123  
17 (10.6%), 14 out of 29 (48.3%), and 23 out of 29 (79.3%) in women with non-severe,  
18 oxygen-requiring, and critical COVID-19, respectively. Delivery before 32 weeks was  
19 highest in 48.3% women in the critical COVID-19 group. In severe disease, urgent  
20 delivery is required to stabilize the maternal condition, even when it results in iatrogenic  
21 preterm delivery [18].

#### 22 23 24 25 26 27 28 **iv. Birth weight**

29  
30 Low birth weight (LBW) is defined as less than the 3<sup>rd</sup> percentile of the average birth  
31 weight in a population. This includes preterm, and small for gestational age neonates.  
32 Small for gestational age (SGA) neonates include intrauterine growth restriction (IUGR)  
33 as well as constitutionally small babies. In this review, LBW was defined as a birth weight  
34 of less than 2500 grams. In our review birth weight was missing in many studies and only  
35 the mean weight of the babies was mentioned in some of the series. However, extracted  
36 data identified 18 studies reporting LBW. Out of these, in 11 studies the LBW was most  
37 likely to be preterm birth [26, 31, 46, 50, 55, 60, 62-65, 71]. LBW was significantly higher  
38 in babies born to SARS-CoV-2 infected mothers than in the control groups in yet another  
39 study [70]. IUGR was found in 4 studies in 11 babies [17, 25, 48, 49]. Also, SGA was  
40 found in 2 studies in 5 babies [36, 42]. Furthermore, in one study there were 39 babies  
41 with LBW and 38 babies with preterm birth [19]. A maximum of 6 babies had IUGR in one  
42 study but they were described as mild [48].

#### 43 44 45 46 47 48 **v. Miscarriage and stillbirth**

49  
50 Stillbirth was seen in 12 fetuses in 7 studies in our review, among which seven were  
51 second-trimester miscarriages [16, 18, 19, 26, 35, 45, 72] [Table no-5]. 3 intrauterine  
52 deaths was observed in one of the studies which reported maternal deaths due to COVID-  
53 19 [26]. Similarly, we found 15 spontaneous miscarriages and 4 induced miscarriages  
54  
55  
56  
57

1  
2  
3 reported in 5 studies [16, 18, 19, 73, 74]. Induced miscarriages were done on maternal  
4 request in both studies [73, 74]. Among the spontaneous miscarriages, 6 were seen in  
5 141 pregnancies in one study and 5 in 181 pregnancies in another study [18, 19]. In one  
6 of the studies, there were 3 stillbirths and they were found to be causes unrelated to  
7 COVID-19 in the mother [16].  
8  
9

## 10 **2.2 Neonatal Outcomes:**

11  
12 The neonatal period is defined as the time period from birth until the end of the first 28  
13 days of life. Events in the early neonatal period (first 7 days) usually are related to the  
14 pregnancy more significantly and it is also included in the definition of the perinatal period.  
15 In this review, we have assessed the neonatal outcomes using APGAR score at 1minute  
16 and 5 minutes of life, neonatal symptoms, admission into neonatal intensive care unit  
17 (ICU), and neonatal death, as the parameters [Table no-6].  
18  
19  
20

### 21 **i. Neonatal symptoms**

22  
23 The most common neonatal symptoms were respiratory problems [42, 53, 56].  
24 Respiratory distress was the most common symptom reported in 12 neonates but the test  
25 for SARS-CoV-2 was positive in only 4 neonates and negative in 8 [21, 36, 44, 62, 63,  
26 65, 75]. Pneumonia was seen in 5 neonates who were positive for SARS-CoV-2 and 4  
27 neonates who were negative [24, 26, 36, 46, 51]. Although usually respiratory symptoms  
28 are seen more in preterm babies due to pulmonary immaturity, in a single case report  
29 there were no neonatal complications in a SARS-CoV-2 positive mother who delivered a  
30 preterm baby at 29 weeks 5 days by emergency CS for maternal indications [76].  
31  
32  
33

34 Diffuse bilateral granular and hazy opacities in chest radiograph and thickened lungs on  
35 x-ray were found in two neonates but the neonatal test for SARS-Cov-2 was negative in  
36 both of them [59, 65]. In another SARS-CoV-2 +ve, newborn chest X-ray was consistent  
37 with pulmonary infection, 53 hours after birth [73]. In another study, neonatal symptoms  
38 are extensively described. The most common first clinical symptom in the neonates of  
39 SARS-Cov-2 Positive women was shortness of breath (n=6), followed by gastrointestinal  
40 symptoms like feeding intolerance, bloating, refusing milk, and gastric bleeding (n=4).  
41 Other symptoms included fever, rapid heart rate, and vomiting. Chest radiographic  
42 abnormalities included infections (n=4), neonatal respiratory distress syndrome (n=2),  
43 and pneumothorax (n=1). Another preterm baby suffered from frequent oxygenation  
44 fluctuations and thrombocytopenia and was cured 15 days later [42]. It was reported in  
45 yet another study that most of the complications in neonates were a result of prematurity  
46 (often iatrogenic) rather than SARS-CoV-2 infection [36]. Other presentations in SARS-  
47 CoV-2 positive neonates included fever, cyanosis, lethargy, irritability, poor feeding, axial  
48 hypertonia, opisthotonus, and feeding difficulties [22, 34, 36].  
49  
50  
51  
52  
53

### 54 **ii. APGAR Score**

1  
2  
3 An APGAR score of less than 7 at 1 minute and 5 minutes after birth in a newborn is  
4 defined as low APGAR score in this study [77]. In our review, a total of 9 studies have  
5 reported a low APGAR score among babies born to SARS-CoV-2 positive mothers [19,  
6 21, 22, 36, 46, 56, 63-65]. Seven of the neonates were very preterm or preterm and were  
7 SARS-CoV-2 negative. The APGAR score in these is likely to be due to pulmonary  
8 immaturity [19, 21, 22, 56, 63-65]. Two other babies were term deliveries and tested  
9 positive for SARS-CoV-2 [36, 46]. However another study reported low APGAR scores  
10 of 0–3 in 2 babies of COVID positive mothers and in 15 babies in COVID negative  
11 mothers, indicating no statistically significant difference [19].  
12  
13  
14  
15

### 16 **iii. ICU admissions**

17 Admission to the neonatal ICU was done for various reasons. Majority of admissions were  
18 for observation and isolation. Neonates admitted due to complications of prematurity  
19 constitute another higher portion of the neonates. In a study, it was found that 16 babies  
20 were admitted due to low birth weight, 2 for low APGAR score, and 6 others for other  
21 uncommon reasons like ABO incompatibility, out of a total 24 ICU admissions [19]. In  
22 another study, it was found that rates of admission to ICU increased with the severity of  
23 the disease in the mother [18].  
24  
25  
26  
27

### 28 **iv. Neonatal death**

29 Neonatal death was reported among 5 neonates in 4 case reports. It was unclear whether  
30 COVID-19 in mothers contributed to the deaths in 2 neonates in one of the studies [16].  
31 In another study, neonatal death occurred in a preterm baby on the 9<sup>th</sup> day of life who  
32 was admitted with shortness of breath and moaning and later developed refractory shock,  
33 multiple organ failure, and disseminated intravascular coagulation (DIC) [42].  
34  
35  
36

## 37 **3. Congenital anomaly:**

38 We could not find any studies describing structural anomalies in the fetus associated with  
39 COVID-19. Due to an evolving pandemic, the teratogenicity of the virus has not been  
40 explored adequately. However, in a few of the studies, the findings of anomaly scans  
41 during pregnancy were included and they did not show any difference between fetuses  
42 of SARS-CoV-2 positive and negative women [42, 74]. In two case reports, multicystic  
43 dysplastic kidney was detected by antenatal ultrasound in one and after delivery in the  
44 other [31, 44]. In another study bilateral gliosis of the deep white periventricular and  
45 subcortical matter was detected in an 11 days old neonate born to SARS-CoV-2 positive  
46 mother by magnetic resonance imaging [22]. However, these cannot be attributed to  
47 SARS-CoV-2. Furthermore, autopsy finding in a stillborn baby born to COVID-19 mother  
48 did not show any abnormality in another report [35].  
49  
50  
51  
52  
53

## 54 **DISCUSSION AND CONCLUSION**



1  
2  
3 The present available data do not provide a clear conclusion into the fetal outcomes and  
4 its clinical implications. The possibility of vertical transmission in pregnant women with  
5 COVID-19 infection is low (4.02%). This is in accordance with other studies [78, 79].  
6 There is no reported teratogenicity or congenital anomalies associated with SARS-CoV-  
7 2 infection.  
8

9  
10 The chance for cesarean delivery is more in women with COVID-19 and in most instances  
11 for maternal indications. Preterm delivery is also high (25.8%) mostly due to maternal  
12 condition, although spontaneous preterm labor is low (1.8%). This is in accordance with  
13 another study with regards to the indication but they found a trend towards spontaneous  
14 prematurity [80].  
15

16 The outcome so far is favorable for the fetus despite the risks to the mother for ICU  
17 admissions and mechanical ventilation seen in other studies [3]. However, fetal distress  
18 was present in 6.93% of fetuses. Maternal outcomes were not explored in our study.  
19

20 There were very low rates of stillbirth and neonatal death in our study. The symptoms  
21 when present in the infected neonates were most often mild and neonatal outcomes were  
22 found to be good [81,82].  
23

24 Though the fetal perspective seems good in the case of maternal COVID-19, it will be  
25 reasonable to consider these findings with caution. Prospective studies and randomized  
26 control trials were missing from the evidence due to the recent nature of the infection.  
27 Therefore, larger and better quality studies are required to address the knowledge gaps  
28 and to reach at a definite guideline for management.  
29  
30

### 31 32 **Strengths and Limitations of the study** 33

34 There are many limitations to our study. Only a limited number of available case series  
35 and cohorts were included in this review as high-quality evidence involving a higher  
36 number of subjects are lacking due to the new kind of infection and still evolving nature  
37 of the pandemic. Almost all of the reports are retrospective reviews showing incomplete  
38 data with significant heterogeneity within the included studies with a chance of selection  
39 or recall bias. In the absence of clear guidelines for testing methods and samples,  
40 different types of samples were used for the diagnosis of SARS-CoV-2 in different studies.  
41 Though nasopharyngeal swab was used for diagnosis in most studies, there were  
42 different types of kits used. Again the same kit may have different sensitivity and  
43 specificity in different types of samples. Universal testing of pregnant women was not  
44 done in many studies, resulting in missing fetal and perinatal effects in asymptomatic  
45 women.  
46

47 Nonetheless, there are many strengths to this study. The studies included in the review  
48 contained only confirmed maternal cases by RT-PCR and not the suspected cases or  
49 clinically diagnosed cases. The studies contained the results of neonatal testing. Studies  
50 included in this review were from countries across the world and not restricted to a specific  
51 region, making the findings from the study globally applicable. The case series/cohorts  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 were chosen only when the total number of cases was more than 4. Moreover, various  
4 aspects of vertical transmission as well as fetal and neonatal outcomes were analyzed  
5 from the chosen studies.  
6

### 7 **Future Implications:**

8  
9 Whether there is intrauterine infection of the fetus with respect to SARS-CoV-2 needs to  
10 be studied. What are the effects of intrauterine infection, whether there is different  
11 susceptibility at different stages of pregnancy, and whether susceptibility depends on  
12 disease severity in the mother, needs to be explored. Follow up studies are required to  
13 see long term effects of neonatal infection with SARS-CoV-2.  
14  
15  
16

## 17 **AUTHORSHIP STATEMENT**

18  
19  
20 Manuscript title: **COVID-19 in pregnancy; The fetal perspective- a systematic review**  
21

22  
23 All persons who meet authorship criteria are listed as authors, and all authors certify  
24 that they have participated sufficiently in the work to take public responsibility for the  
25 content, including participation in the concept, design, analysis, writing, or revision of  
26 the manuscript. Furthermore, each author certifies that this material or similar material  
27 has not been and will not be submitted to or published in any other publication before its  
28 appearance in the BMJ Pediatrics-open access.  
29  
30  
31  
32  
33  
34

### 35 **Authorship contributions**

36  
37  
38 **Conception and design of study:** Rajani Dube ,Subhranshu Sekhar Kar

39 **Acquisition of data:** Subhranshu Sekhar Kar, Rajani Dube

40 **Analysis and/or interpretation of data:** Subhranshu Sekhar Kar, Rajani Dube

41 **Drafting the manuscript:** Rajani Dube, Subhranshu Sekhar Kar

42 **Revising the manuscript critically for important intellectual content:** Rajani Dube,  
43 Subhranshu Sekhar Kar

44 **Approval of the version of the manuscript to be published (the names of all  
45 authors must be listed):** Subhranshu Sekhar Kar, Rajani Dube

46 **Acknowledgements- None**

47  
48 Author's name  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Rajani Dube

4  
5  
6 Subhranshu Sekhar Kar

7  
8 **Disclaimer-** The views expressed in the submitted article are our own and not an  
9 official position of the institution or funder.

10  
11 **Source(s) of support/Funding** - None

12  
13 **Disclosure of relationships and activities-** Nothing to disclose

14  
15 **Patient consent for publication-** not required

16  
17 **Conflicts of interest-**None

18  
19  
20 **References:**

21  
22 [1] Rasmussen SA, Smulian JC, Lednicky JA, *et al.* Coronavirus disease 2019 (COVID-  
23 19) and pregnancy: what obstetricians need to know. *Am J Obstet Gynecol.*  
24 2020;222:415–26. doi: [10.1016/j.ajog.2020.02.017](https://doi.org/10.1016/j.ajog.2020.02.017)

25  
26 [2] Rajewska A, Mikołajek-Bedner W, Lebdowicz-Knul J, *et al.* COVID-19 and  
27 pregnancy – where are we now? A review. *J. Perinat. Med.* 2020;48:428–34. doi:  
28 [10.1515/jpm-2020-0132](https://doi.org/10.1515/jpm-2020-0132)

29  
30 [3] Ellington S, Strid P, Tong VT, *et al.* Characteristics of Women of Reproductive Age  
31 with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United  
32 States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:769–75. doi:  
33 <http://dx.doi.org/10.15585/mmwr.mm6925a1>

34  
35 [4] Woodward A. A pregnant mother infected with the coronavirus gave birth, and her  
36 baby tested positive 30 hours later. Available at:  
37 [https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-](https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2)  
38 [mother-2020-2](https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2) Accessed June 15, 2020.

39  
40 [5] Collin J, Byström E, Carnahan A, *et al.* Public Health Agency of Sweden’s brief  
41 report: pregnant and postpartum women with SARS-CoV-2 infection in intensive care in  
42 Sweden. *Acta Obstet Gynecol Scand* 2020;99:819-22. doi: 10.1111/aogs.13901.

43  
44 [6] Rogan SC, Beigi RH. Treatment of viral infections during pregnancy. *J Perinatol*  
45 2019;46:235–56.  
46 doi: 10.1016/j.clp.2019.02.009.

47  
48 [7] Racicot K, Mor G. Risks associated with viral infections during pregnancy. *J Clin*  
49 *Invest* 2017;127:1591–9. doi: 10.1172/JCI87490

50  
51 [8] Lamouroux A, Bitach TA, Martinovic J, *et al.* Evidence for and against vertical  
52 transmission for severe acute respiratory syndrome coronavirus 2 (coronavirus disease  
53 2019). *Am J Obstet Gynecol* 2020;223:91.e1–91.e4. doi: 10.1016/j.ajog.2020.04.039

- 1  
2  
3 [9] Li M, Chen L, Zhang J, *et al.* The SARS-CoV-2 receptor ACE2 expression of  
4 maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One.*  
5 2020;15:e0230295. <https://doi.org/10.1371/journal.pone.0230295>  
6  
7 [10] Jing Y, Run-Qian L, Hao-Ran W, *et al.* Potential influence of COVID-19/ACE2 on  
8 the  
9 female reproductive system. *Mol Hum Reprod.* 2020;gaaa030,  
10 <https://doi.org/10.1093/molehr/gaaa030>.  
11 [11] Levy A, Bursztyn M, Barkalifa R, *et al.* ACE2 expression and activity are enhanced  
12 during pregnancy. *Am J Physiol Regul Integr Comp Physiol.* 2008;295:R1953-61. doi:  
13 10.1152/ajpregu.90592.2008.  
14 [12] Valdes G, Neves LA, Anton L, *et al.* Distribution of angiotensin-(1-7) and ACE2 in  
15 human placentas of normal and pathological pregnancies. *Placenta.* 2006;27:200-7. doi:  
16 10.1016/j.placenta.2005.02.015.  
17 [13] Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in different types of clinical  
18 specimens. *JAMA* 2020;323:1843-4. doi:10.1001/jama.2020.3786  
19  
20 [14] Abu-Zidan FM, Abbas AK, Hefny AF. Clinical "case series": a concept analysis. *Afr*  
21 *Health Sci.* 2012;12:557-62. PMID: 23515566; PMCID: PMC3598300.  
22  
23 [15] Murad MH, Sultan S, Haffar S, *et al.* Methodological quality and synthesis of case  
24 series and case reports. *BMJEvidBasedMed* 2018;23:60–3.doi:10.1136/bmjebm-2017-  
25 110853.  
26  
27 [16] Knight M, Bunch K, Vousden N, *et al.* Characteristics and outcomes of pregnant  
28 women hospitalized with confirmed SARS-CoV- 2 infection in the UK: a national cohort  
29 study using the UK Obstetric Surveillance System (UKOSS). *BMJ* 2020;369:m2107. doi:  
30 <https://doi.org/10.1136/bmj.m2107>  
31  
32 [17] Yan J, Guo J, Fan C, *et al.* Coronavirus disease 2019 in pregnant women: a report  
33 based on 116 cases. *Am J Obstet Gynecol* 2020;223:111.e1- 14.  
34 doi:10.1016/j.ajog.2020.04.014.  
35  
36 [18] Kayem G, Alessandrini V, Azria E, *et al.* A snapshot of the Covid-19 pandemic  
37 among pregnant women in France. *Journal of Gynecology Obstetrics and Human*  
38 *Reproduction.* 2020 :101826. doi: 10.1016/j.jogoh.2020.101826.  
39  
40 [19] Nayak AH, Kapote DS, Fonseca M, *et al.* Impact of the Coronavirus Infection in  
41 Pregnancy: A Preliminary Study of 141 Patients. *J Obstet Gynecol India* 2020;70:256–  
42 61. <https://doi.org/10.1007/s13224-020-01335-3>  
43  
44 [20] London V, McLaren Jr R, Atallah F, *et al.* The relationship between status at  
45 presentation and outcomes among pregnant women with covid-19. *Am J Perinatol*  
46 2020;37:991–94. doi: 10.1055/s-0040-1712164  
47  
48 [21] Ferrazzi E, Frigerio L, Savasi V, *et al.* Vaginal delivery in SARS-CoV-2infected  
49 pregnant women in Northern Italy: a retrospective analysis. *BJOG.* 2020;127:1116-21.  
50 <https://doi.org/10.1111/1471-0528.16278>  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [22] Vivanti AJ, Vauloup-Fellous C, Prevot S, *et al.* Transplacental transmission of  
4 SARS-CoV-2 infection. *Nat Commun* 2020;11:3572. doi: 10.1038/s41467-020-17436-6  
5  
6 [23] Lyra J, Valente R, Rosario M, *et al.* Cesarean Section in a Pregnant Woman with  
7 COVID- 19: First Case in Portugal. *Acta Medica Portuguesa*. 2020;33:429-31.  
8 <https://doi.org/10.20344/amp.13883>  
9  
10 [24] Khan S, Jun L, Siddique R, Li Y, Han G, Xue M, *et al.* Association of COVID-19  
11 with pregnancy outcomes in health-care workers and general women. *Clin Microbiol*  
12 *Infect*. 2020;26:788-90. doi: [10.1016/j.cmi.2020.03.034](https://doi.org/10.1016/j.cmi.2020.03.034)  
13  
14 [25] Pierce-Williams RAM, Burd J, Felder L, *et al.* Clinical course of severe and critical  
15 COVID-19 in hospitalized pregnancies: a US cohort study. *Am J Obstet Gynecol MFM*.  
16 2020 May 8;100134.  
17 doi: 10.1016/j.ajogmf.2020.100134.  
18  
19 [26] Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, *et al.* Maternal death due to  
20 COVID-19 disease. *Am J Obstet Gynecol*. 2020; 223: 109.e1–109.e16. Published  
21 online 2020 Apr 28.  
22 doi: 10.1016/j.ajog.2020.04.030  
23  
24 [27] Hosier H, Farhadian S, Morotti RA, *et al.* First case of placental infection with SARS  
25 CoV-2. *medRxiv*. 2020; doi: <https://doi.org/10.1101/2020.04.30.20083907>  
26  
27 [28] Baud D, Greub G, Favre G, *et al.* Second-trimester miscarriage in a pregnant  
28 woman with SARS-CoV-2 infection. *JAMA*. 2020;323:2198-2200.  
29 doi:10.1001/jama.2020.7233  
30  
31 [29] Algarroba GN, Rekawek P, Vahanian SA, *et al.* Visualization of SARS-CoV-2 virus  
32 invading the human placenta using electron microscopy. *Am J Obstet Gynecol*.  
33 2020;223:275-78. doi: 10.1016/j.ajog.2020.05.023.  
34  
35 [30] Kirtsman M, Diambomba Y, Poutanen S, *et al.* Probable congenital SARS-CoV-2  
36 infection in a neonate born to a woman with active SARS-CoV-2 infection. *CMAJ*. 628  
37 2020;192:E647-E5. doi: 10.1503/cmaj.200821.  
38  
39 [31] Shanes ED, Mithal LB, Otero S, *et al.* Placental pathology in COVID-19. *Am J Clin*  
40 *Pathol*. 2020;154:23–32. doi: 10.1093/ajcp/aqaa089.  
41  
42 [32] Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers:  
43 Preliminary Findings. *Pediatr Dev Pathol*. 2020;23:177-80.  
44 doi: [10.1177/1093526620925569](https://doi.org/10.1177/1093526620925569)  
45  
46 [33] Mulvey JJ, Magro C, Ma LX, *et al.* Analysis of complement deposition and viral  
47 RNA in placentas of COVID-19 patients. *Ann Diagn Pathol*. 2020;46:151530. doi:  
48 10.1016/j.anndiagpath.2020.151530  
49  
50 [34] Patane L, Morotti D, Giunta MS, *et al.* Vertical transmission of COVID-19: SARS-  
51 CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 mothers and neonates at birth. *AJOG-MFM*. 2020;100145. doi:  
4 10.1016/j.ajogmf.2020.100145  
5

6 [35] Lokken EM, Walker CL, Delaney S, *et al*. Clinical characteristics of 46 pregnant  
7 women with as sars-cov-2 infection in Washington state. *Am J Obstet Gynecol* 2020.  
8 doi:10.1016/j.ajog.2020.05.031. [Epub ahead of print]  
9

10 [36] Zeng L, Xia S, Yuan W, *et al*. Neonatal Early-Onset Infection With SARS-CoV-2 in  
11 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr*.  
12 2020;174:722-25. doi: 10.1001/jamapediatrics.2020.0878.  
13  
14

15 [37] Hu X, Gao J, Luo X, *et al*. Severe Acute Respiratory Syndrome Coronavirus 2  
16 (SARS CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus  
17 Disease 2019 (COVID-19) Pneumonia. *Obstet Gynecol*.2020;136:65-67. doi:  
18 10.1097/AOG.0000000000003926.  
19

20 [38] Peng Z, Wang J, Mo Y, *et al*. Unlikely SARS-CoV-2 vertical transmission from  
21 mother to child: A case report. *J Infect Public Health*. 2020;13:818-20.  
22 <https://doi.org/10.1016/j.jiph.2020.04.004>  
23  
24

25 [39] Li Y, Zhao R, Zheng S, *et al*. Early release - lack of vertical transmission of severe  
26 acute respiratory syndrome coronavirus 2, China. *Emerging Infectious Diseases*  
27 2020;26:1335-36. <https://dx.doi.org/10.3201/eid2606.200287>  
28

29 [40] Groß R, Conzelmann C, Müller JA, *et al*. Detection of SARS-CoV-2 in human  
30 breastmilk. *Lancet*. 2020;395:1757–58. Published online 2020 May 21. doi:  
31 10.1016/S0140-6736(20)31181-8  
32  
33

34 [41] Liu W, Wang Q, Zhang Q, *et al*. Coronavirus disease 2019 (COVID-19) during  
35 pregnancy: a case series. *Preprints*.2020 ;2020020373.  
36

37 [42] Zhu H, Wang L, Fang C, *et al*. Clinical analysis of 10 neonates born to mothers with  
38 2019-nCoV pneumonia. *Transl Pediatr* 2020;9:51-60. doi: 10.21037/tp.2020.02.06  
39

40 [43] Chen Y, Peng H, Wang L, *et al*. Infants born to mothers with a new coronavirus  
41 (COVID-19). *Front. Pediatr*. 2020;8:104. doi: 10.3389/fped.2020.00104  
42

43 [44] Breslin N, Baptiste C, Gyamfi-Bannerman C, *et al*. COVID-19 infection among  
44 asymptomatic and symptomatic pregnant women: two weeks of confirmed  
45 presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol*  
46 *MFM*. 2020;2:100118. doi: 10.1016/j.ajogmf.2020.100118.  
47  
48

49 [45] Prabhu M, Cagino K, Matthews KC, *et al*. Pregnancy and postpartum outcomes in a  
50 universally tested population for SARS-CoV-2 in New York City: a prospective cohort  
51 study. *BJOG* 2020; <https://doi.org/10.1111/1471-0528.16403>. 00: 1– 9.  
52

53 [46] Govind A, Essien S, Karthikeyan A, *et al*. Re: Novel Coronavirus COVID-19 in late  
54 pregnancy: Outcomes of first nine cases in an inner city London hospital. *Eur J Obstet*  
55 *Gynecol Reprod Biol*. 2020;251: 272–74. doi:10.1016/j.ejogrb.2020.05.004.  
56  
57

- 1  
2  
3 [47] Lowe B, Bopp B. COVID 19 vaginal delivery - A case report. *Aust N Z J Obstet*  
4 *Gynaecol.* 2020;60:465-6. <https://doi.org/10.1111/ajo.13173>  
5  
6 [48] Doria M, Peixinho C, Laranjo M, *et al.* Covid-19 during pregnancy: a case series  
7 from an universally tested population from the north of Portugal. *Eur J Obstet Gynecol*  
8 *Reprod Biol.* 2020;250:261-2.  
9  
10 doi: 10.1016/j.ejogrb.2020.05.029. Epub 2020 May 15.  
11 [49] Perrone S, Deolmi M, Giordano M, *et al.* Report of a series of healthy term  
12 newborns from convalescent mothers with COVID-19. *Acta Bio Med [Internet].*  
13 2020;91:251-5. Available from:  
14 <https://mattioli1885journals.com/index.php/actabiomedica/article/view/9743>  
15  
16 [50] Chen H, Guo J, Wang C, *et al.* Clinical characteristics and intrauterine vertical  
17 transmission potential of COVID-19 infection in nine pregnant women: a retrospective  
18 review of medical records. *Lancet* 2020;395:809–815.  
19  
20 [51] Fan C, Lei D, Fang C, *et al.* Perinatal transmission of COVID-19 associated SARS-  
21 CoV-2: should we worry? *Clin Infect Dis.* 2020: ciaa226. [Published online 2020 Mar  
22 17]. doi: 10.1093/cid/ciaa226  
23  
24 [52] Zeng H, Xu C, Fan J, *et al.* Antibodies in infants born to mothers with COVID-19  
25 pneumonia. *JAMA.* 2020;323:1848-9. doi:10.1001/jama.2020.4861  
26  
27 [53] Gidlöf S, Savchenko J, Brune T, *et al.* CO-VID-19 in pregnancy with comorbidities:  
28 more liberal testing strategy is needed. *Acta Obstet Gynecol Scand.* 2020;99:948-9. doi:  
29 10.1111/aogs.13862. Epub 2020 Apr 17.  
30  
31 [54] Dong L, Tian J, He S, *et al.* Possible vertical transmission of SARS CoV- 2 from an  
32 infected mother to her newborn. *JAMA.* 2020;323:1846-8. doi:10.1001/jama.2020.4621  
33  
34 [55] Wang X, Zhou Z, Zhang J, *et al.* A Case of 2019 Novel Coronavirus in a Pregnant  
35 Woman With Preterm Delivery. *Clin Infect Dis.* 2020;71:844-6. doi:10.1093/cid/ciaa200  
36  
37 [56] Alzamora MC, Paredes T, Caceres D, *et al.* Severe COVID-19 during Pregnancy  
38 and Possible Vertical Transmission. *Am J Perinatol* 2020;37:861–5. doi: 10.1055/s-  
39 0040-1710050.  
40  
41 [57] Kalafat E, Yaprak E, Cinar G, *et al.* Lung ultrasound and computed tomographic  
42 findings in pregnant woman with COVID-19. *Ultrasound Obstet Gynecol.* 2020;55: 835-  
43 7. <https://doi.org/10.1002/uog.22034>  
44  
45 [58] Lee DH, Lee J, Kim E, *et al.* Emergency cesarean section on severe acute  
46 respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed patient. *Korean J*  
47 *Anesthesiol.* 2020;73:347-51. doi: 10.4097/kja.20116.  
48  
49 [59] Wang S, Guo L, Chen L, *et al.* A case report of neonatal 2019 coronavirus disease  
50 in China. *Clin Infect Dis.* 2020;71:853-7. doi: 10.1093/cid/ciaa225.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [60] Zamaniyan M, Ebadi A, Aghajanpoor Mir S, *et al.* Preterm delivery, maternal death,  
4 and vertical transmission in a pregnant woman with COVID-19 infection [published  
5 online ahead of print, 2020 Apr 17]. *Prenat Diagn.* 2020;10.1002/pd.5713.  
6 doi:10.1002/pd.5713  
7
- 8  
9 [61] Song L, Xiao W, Ling K, *et al.* Anesthetic Management for Emergent Cesarean  
10 Delivery in a Parturient with Recent Diagnosis of Coronavirus Disease 2019 (COVID-  
11 19): A Case Report. *Transl Perioper & Pain Med* 2020; 7:234-7. doi: 10.31480/2330-  
12 4871/118  
13
- 14 [62] Yang P, Wang X, Liu P, *et al.* Clinical characteristics and risk assessment of  
15 newborns born to mothers with COVID-19. *J Clin Virol.* 2020;127:104356. doi:  
16 10.1016/j.jcv.2020.104356.  
17
- 18 [63] Romagano MP, Guerrero K, Spillane N, *et al.* Perinatal outcomes in critically ill  
19 pregnant women with covid-19. *Am J Obstet Gynecol MFM.* 2020; 100151.  
20 <https://doi.org/10.1016/j.ajogmf.2020.100151>  
21
- 22 [64] Cooke WR, Billett A, Gleeson S, *et al.* SARS-CoV-2 infection in very preterm  
23 pregnancy: experiences from two cases. *Eur J Obstet Gynecol Reprod Biol.*  
24 2020;250:259–60. Published online 2020 May 15. doi: 10.1016/j.ejogrb.2020.05.025  
25
- 26 [65] Blauvelt CA, Chiu C, Donovan AL, *et al.* Acute Respiratory Distress Syndrome in a  
27 Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol.*  
28 2020;136:46-51. doi:10.1097/AOG.0000000000003949  
29
- 30 [66] Khan S, Peng L, Siddique R, *et al.* Impact of COVID-19 infection on pregnancy  
31 outcomes and the risk of maternal-to-neo-natal intrapartum transmission of COVID-19  
32 during natural birth. *Infect Control Hosp Epidemiol.* 2020;41:748-50.  
33 doi: [10.1017/ice.2020.84](https://doi.org/10.1017/ice.2020.84)  
34
- 35 [67] Huang JW, Zhou XY, Lu SJ, *et al.* Dialectical behavior therapy-based psy-  
36 chological intervention for woman in late preg-nancy and early postpartum suffering  
37 from COV-ID-19: a case report. *J Zhejiang Univ Sci B.* 2020; 21(5):394-9.  
38 doi: [10.1631/jzus.B2010012](https://doi.org/10.1631/jzus.B2010012)  
39
- 40 [68] Xiong X, Wei H, Zhang Z, *et al.* Vaginal delivery report of a healthy neonate born to  
41 a convalescent mother with COVID19. *J Med Virol.* 2020;10.1002/jmv.25857.  
42 doi:10.1002/jmv.25857. [E-pub ahead of print].  
43
- 44 [69] Zambrano L, Fuentes-Barahona I, Bejarano-Torres D, *et al.* A pregnant woman with  
45 COVID-19 in Central America. *Travel Med Infect Dis.* 2020;101639. doi:  
46 10.1016/j.tmaid.2020.101639. Online ahead of print.  
47
- 48 [70] Li N, Han L, Peng M, *et al.* Maternal and neonatal outcomes of pregnant women  
49 with COVID-19 pneumonia: a case-control study. *Clinical Infectious Diseases* 2020. doi:  
50 10.1093/cid/ciaa352  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 [71] Cao D, Yin H, Chen J, *et al.* Clinical analysis of ten pregnant women with COVID-  
4 19 in Wuhan, China: A retrospective study. *Int J Infect Dis.* 2020;95:294-300.  
5 <https://doi.org/10.1016/j.ijid.2020.04.047>.  
6  
7 [72] Pulinx B, Kieffer D, Michiels I, *et al.* Vertical transmission of SARS-CoV-2 infection  
8 and preterm birth. *Eur J Clin Microbiol Infect Dis* 2020. [https://doi.org/10.1007/s10096-](https://doi.org/10.1007/s10096-020-03964-y)  
9 [020-03964-y](https://doi.org/10.1007/s10096-020-03964-y)  
10  
11 [73] Nie R, Wang S, Qiong Y, *et al.* Clinical features and the maternal and neonatal  
12 outcomes of pregnant women with coronavirus disease 2019. medRxiv. 2020; doi:  
13 <https://doi.org/10.1101/2020.03.22.20041061>  
14  
15 [74] Yin M, Zhang L, Deng G, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2  
16 (SARS CoV-2) Infection During Pregnancy In China: A Retrospective Cohort Study.  
17 medRxiv. 2020. doi:<https://doi.org/10.1101/2020.04.07.20053744>.  
18  
19 [75] Pereira A, Cruz-Melguizo S, Adrien M, *et al.* Clinical course of coronavirus  
20 disease-2019 in pregnancy. *Acta Obstet Gynecol Scand.* 2020;99:839–47.  
21 <https://doi.org/10.1111/aogs.13921>  
22  
23 [76] González Romero D, Ocampo Pérez J, González Bautista L, *et al.* Pronóstico  
24 perinatal y de la paciente embarazada con infección por COVID-19. *Rev Clin Esp.*  
25 2020. doi: [10.1016/j.rceng.2020.04.005](https://doi.org/10.1016/j.rceng.2020.04.005) [Epub ahead of print]  
26  
27 [77] Razaz N, Cnattingius S, Persson M, *et al.* One-minute and five-minute Apgar  
28 scores and child developmental health at 5 years of age: a population-based cohort  
29 study in British Columbia, Canada. *BMJ Open* 2019;9:e027655 doi: [10.1136/bmjopen-](https://doi.org/10.1136/bmjopen-2018-027655)  
30 [2018-027655](https://doi.org/10.1136/bmjopen-2018-027655)  
31  
32 [78] Kotlyar A, Grechukhina O, Chen A, *et al.* Vertical Transmission of COVID-19: A  
33 Systematic Review and Meta-analysis. *American Journal of Obstetrics and Gynecology*  
34 2020, S0002-9378(20)30823-1. [Advance online publication].  
35 <https://doi.org/10.1016/j.ajog.2020.07.049>.  
36  
37 [79] Pique-Regi R, Romero R, Tarca A, *et al.* Does the human placenta express the  
38 canonical cell entry mediators for SARS-CoV-2? *eLife* 2020;9:e58716 doi:  
39 [10.7554/eLife.58716](https://doi.org/10.7554/eLife.58716)  
40  
41 [80] Gatta AND, Rizzo R, Pilu G, *et al.* Coronavirus disease 2019 during pregnancy: a  
42 systematic review of reported cases. *Am J Obstet Gynecol.* 2020;223: 36–41. doi:  
43 [10.1016/j.ajog.2020.04.013](https://doi.org/10.1016/j.ajog.2020.04.013)  
44  
45 [81] Wei M, Yuan J, Liu Y, *et al.* Novel Coronavirus Infection in Hospitalized Infants  
46 Under 1 Year of Age in China. *JAMA.* 2020;323:1313–4. doi:[10.1001/jama.2020.2131](https://doi.org/10.1001/jama.2020.2131)  
47  
48 [82] Dumpa V, Kamity R, Vinci AN, *et al.* Neonatal coronavirus 2019 (COVID-19)  
49 infection: a case report and review of literature. *Cureus* 2020;2019. e8165.  
50 doi:[10.7759/cureus.8165](https://doi.org/10.7759/cureus.8165)  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [83] Zhang I, Jiang Y, Wei M, *et al.* Analysis of the pregnancy outcomes in pregnant  
4 women with COVID-19 in Hubei Province [in Chinese]. *Zhonghua Fu Chan Ke Za Zhi.*  
5 2020;55:166-71. doi: 10.3760/cma.j.cn112141-20200218-00111.  
6  
7 [84] Penfield CA, Brubaker SG, Limaye MA, *et al.* Detection of SARS-CoV-2 in  
8 placental and fetal membrane samples. *Am J Obstet Gynecol MFM.* 2020;2:100133.  
9 <https://doi.org/10.1016/j.ajogmf.2020.100133>  
10  
11 [85] Liu Y, Chen H, Tang K, *et al.* Clinical manifestations and outcome of SARS-CoV-2  
12 infection during pregnancy. *J Infect.*2020. doi: 10.1016/j.jinf.2020.02.028. Online ahead  
13 of print.  
14  
15 [86] Chen S, Chen S, Huang B, *et al.* Pregnant women with new coronavirus infection: a  
16 clinical characteristics and placental pathological analysis of three cases. *Zhonghua*  
17 *Bing Li Xue Za Zhi.* 2020;49:418-23. doi: 10.3760/cma.j.cn112151-20200225-00138.  
18  
19 [87] Iqbal SN, Overcash R, Mokhtari N, *et al.* An uncomplicated delivery in a patient with  
20 COVID-19 in the United States. *N Engl J Med* 2020;382:e34. doi:  
21 10.1056/NEJMc2007605  
22  
23 [88] Liao X, Yang H, Kong J, *et al.* Chest CT findings in a pregnant patient with 2019  
24 novel corona-virus disease. *Balkan Med J.* 2020;37:226-8.  
25  
26 [89] Qiancheng X, Jian S, Lingling P, *et al.* sixth batch of Anhui medical team aiding  
27 Wuhan for COVID-19. Coronavirus disease 2019 in pregnancy. *Int J Infect Dis.*  
28 2020;95:376-83. doi: 10.1016/j.ijid.2020.04.065.  
29  
30 [90] Yu N, Li W, Kang Q, *et al.* No SARS-CoV-2 detected in amniotic fluid in mid-  
31 pregnancy. *The Lancet Infectious Diseases* 2020;S1473-3099(20)30320-0. doi:  
32 10.1016/S1473-3099(20)30320-0  
33  
34 [91] Savasi VM, Parisi F, Patane L, *et al.* Clinical findings and disease severity in  
35 hospitalized pregnant women with coronavirus disease 2019 (covid-19). *Obstet*  
36 *Gynecol.* 2020;136:252-8. doi: 10.1097/AOG.0000000000003979.  
37  
38 [92] Schnettler WT, Al Ahwel Y, Suhag A. Severe acute respiratory distress syndrome in  
39 coronavirus disease 2019–infected pregnancy: obstetric and intensive care  
40 considerations. *AJOG-MFM* 2020. doi.org/10.1016/j.ajogmf.2020.100120.  
41  
42 [93] Lang G, Zhao H. Can SARS-CoV-2-infected women breastfeed after viral  
43 clearance? *J Zhejiang Univ Sci B.* 2020;12:405-7. doi: 10.1631/jzus.B2000095  
44  
45 [94] Buonsenso D, Raffaelli F, Tamburrini E, *et al.* Clinical role of lung ultrasound for the  
46 diagnosis and monitoring of COVID19 pneumonia in pregnant women [published online  
47 ahead of print, 2020 Apr 26]. *Ultrasound Obstet Gynecol.* 2020;10.1002/uog.22055.  
48 doi:10.1002/uog.22055.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 [95] Yang H, Sun G, Tang F, *et al.* Clinical features and outcomes of pregnant women  
4 suspected of coronavirus disease 2019. *J Infect.* 2020;81:e40-e44. .  
5 doi: [10.1016/j.jinf.2020.04.003](https://doi.org/10.1016/j.jinf.2020.04.003)  
6

7 [96] Wu Y, Liu C, Dong L, *et al.* Coronavirus disease 2019 among pregnant Chinese  
8 women: case series data on the safety of vaginal birth and breastfeeding. *BJOG.*  
9 2020;127:1109-15.  
10 doi:10.1111/1471-0528.16276 [Published online ahead of print, 2020 May 5].

11 [97] Buonsenso D, Costa S, Sanguinetti M, *et al.* Neonatal Late Onset Infection with  
12 Severe Acute Respiratory Syndrome Coronavirus 2. *Am J Perinatol.* 2020;37:869-72.  
13 doi: 10.1055/s-0040-1710541.  
14

15 [98] Vintzileos WS, Muscat J, Hoffmann E, *et al.* Screening all pregnant women  
16 admitted to labor and delivery for the virus responsible for coronavirus disease 2019.  
17 *Am J Obstet Gynecol.* 2020;223:284-6. doi: 10.1016/j.ajog.2020.04.024.  
18


19 [99] Breslin N, Baptiste C, Miller R, *et al.* COVID-19 in pregnancy: early lessons. *Am J*  
20 *Obstet Gynecol MFM.* 2020;2:100111. <https://doi.org/10.1016/j.ajogmf.2020.100111>  
21


22 [100] Qadri F, Mariona F. Pregnancy affected by SARS-COV-2 infection: a flash report  
23 from Michigan. *J Matern Fetal Neonatal Med.*2020:13.  
24 doi:10.1080/14767058.2020.1765334  
25

26 [101] Sentilhes L, De Marcillac F, Jouffrieau C, *et al.* Coronavirus disease 2019 in  
27 pregnancy was associated with maternal morbidity and preterm birth. *Am J Obstet*  
28 *Gynecol.* 2020. doi: [10.1016/j.ajog.2020.06.022](https://doi.org/10.1016/j.ajog.2020.06.022) [Epub ahead of print]  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure-1- PRISMA 2009 Flow Diagram- Vertical transmission**



**Figure-2 PRISMA 2009 Flow Diagram- Perinatal outcome**

**Table-1 (a): Analysis of the studies [Case series/ Cohort]**

Serial number	Author (reference)	Number of pregnancies	Country	Outcomes included	Selection Contains diagnosed COVID-19 in Pregnancy	Comparability Data on pregnant women and fetus available	Outcome; Assessment and reporting	Evidence of vertical transmission	Perinatal Outcome
1.	Chen H et al (50)	9	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
2.	Zeng H et al (52)	6	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
3.	Zhu H et al (42)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
4.	Zhang I et al (83)	61	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
5.	Penfield CA et al (84)	11	China	Placental, membrane and neonatal samples	****		**	√	
6.	Liu Y et al (85)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
7.	Khan S et al (24)	17	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
8.	Zeng L et al (36)	33	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
9.	Breslin N et al (44)	18	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
10.	Qiancheng X et al (89)	23	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
11.	Yang P et al (62)	7	China	Symptoms, maternal characteristics, laboratory	****	**	***	√	√

				parameters, pregnancy and neonatal outcomes					
12.	Yang H et al (95)	55	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	*	*	√	√
13.	Wu Y et al (96)	13	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	*	*	√	
14.	Patane L et al (34)	22	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
15.	Ferrazzi E et al (21)	42	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
16.	Mulvey J et al (33)	5	USA	Placental characteristics	***			√	
17.	Govind A et al (46)	9	UK	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
18.	Vintzileos W et al (98)	32	US	Symptoms, maternal characteristics, Test results	***	*	***	√	
19.	Baergen R et al (32)	20	US	Maternal characteristics, maternal outcomes, Placental characteristics	***			√	
20.	Hantoushzadeh et al (26)	7	Iran	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
21.	Shanes E et al (31)	16	US	Symptoms, maternal characteristics, Placental pathology, pregnancy and neonatal outcomes	****	**	***	√	√
22.	Pereira A et al (75)	60	Spain	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
23.	Savasi V et al (91)	77	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
24.	London V et al (20)	68	USA	Symptoms, maternal characteristics, laboratory	****	**	***	√	√

				parameters, pregnancy and neonatal outcomes					
25.	Lokken E et al (35)	46	USA	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***		√
26.	Qadri F et al (100)	16	Michigan	Maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
27.	Yan J et al (17)	116	China	pregnancy and neonatal outcomes	****	**	***		√
28.	Knight M et al (16)	427	National, UK	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
29.	Williams R et al (25)	64	USA	Maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
30.	Kayem G et al (18)	617	France	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
31.	Nayak A et al (19)	141	India	Symptoms, maternal outcomes, neonatal outcomes	****	**	***		√
32.	Prabhu M et al (45)	70	US	Symptoms, obstetric and neonatal outcomes, and placental pathology	****	**	***	√	√
33.	Sentilhes, et al (101)	38	France	Symptoms, maternal outcomes, neonatal outcomes	****	**	***	√	√
34.	Li N et al (70)	16	China	Symptoms, maternal outcomes, neonatal outcomes	****	**	***		√
35.	Cao D et al (71)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
36.	Doria M et al (48)	10	Portugal	Symptoms, maternal characteristics, pregnancy outcomes	****	**	*		√
37.	Hu X et al (37)	7	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
38.	Breslin N et al (99)	7	US	Symptoms, maternal characteristics, test result	**	**	**	√	
39.	Nie R et al (73)	33	China	Symptoms, maternal characteristics, laboratory	****	**	***	√	√



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

				parameters, pregnancy outcomes					
40.	Romagano M et al (63)	7	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	*		√
41.	Yin M et al (74)	31	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√

**Table-1 (b): Analysis of the studies [Case reports]**

Serial number	Author (reference)	Number of pregnancies	Country	Outcomes included	Selection Contains diagnosed COVID-19 in Pregnancy	Comparability Data on pregnant women and fetus available	Outcome; Assessment and reporting	Evidence of vertical transmission	Perinatal Outcome
1.	Alzamora et al (56)	1	china	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
2.	Li Y et al (39)	1	china	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
3.	Dong L et al (54)	1	china	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
4.	Baud D et al (28)	1	Switzerland	Symptoms, maternal characteristics, laboratory parameters, second trimester miscarriage	***	*	***	√	
5.	Wang X et al (55)	1	china	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
6.	Huang J et al (67)	1	china	Symptoms, maternal characteristics, pregnancy outcomes	***	**	***	√	√
7.	Iqbal S et al (87)	1	US	Symptoms, maternal characteristics, pregnancy outcomes	***	**	***	√	√
8.	Kalafat E et al (57)	1	Turkey	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	***	**	***	√	√

9.	Lee D et al (58)	1	Korea	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	***	**	***	√	√
10.	Liao X et al (88)	1	China	Symptoms, maternal characteristics, pregnancy outcomes	***	**	***	√	√
11.	Xiong X et al (68)	1	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	***	**	***	√	√
12.	Wang S et al (59)	1	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	***	**	***	√	√
13.	Zamaniyan M et al (60)	1	Iran	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
14.	Zambrano L et al (69)	1	Central America	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	***	**	***	√	√
15.	Song L et al (61)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	***	**	***	√	√
16.	Vivanti A et al (22)	1	France	Symptoms, maternal outcomes, neonatal outcomes	***	**	***	√	√
17.	Lowe B et al (47)	1	Australia	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	***	**	**	√	√
18.	Schnettler W et al (92)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcome	***	**	**	√	
19.	Blauvelt C et al (65)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	***	**	**	√	√
20.	Kirtsman M et al (30)	1	Canada	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	***	**	**	√	√
21.	Lyra J et al (23)	1	Portugal	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	***	**	**	√	√
22.	Algorroba et al (29)	1	US	Symptoms, maternal characteristics, laboratory	***	*	**	√	

				parameters, pregnancy outcome					
23.	Fan C et al (51)	2	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
24.	Hosier H et al(27)	1	US	Symptoms, maternal characteristics, test result	**	**	**	√	
25.	Peng Z et al(38)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
26.	Buonsenso et al (97)	4	Italy	Symptoms, maternal findings, test results	***	*	**	√	
27.	Perrone S et al (49)	4	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***		√
28.	Groß R et al (40)	2	Germany	Symptoms, maternal findings, test results	***	*	**	√	
29.	Cooke W et al (64)	2	UK	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	*		√
30.	Pulinx B et al (72)	2	Belgium	Symptoms, maternal characteristics, laboratory parameters, second trimester miscarriage	***	*	***	√	
31.	Liu W et al (41)	3	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
32.	Chen S et al (86)	3	China	Symptoms, laboratory parameters, pregnancy outcomes, samples	***	**	***	√	√
33.	Chen Y et al (43)	4	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	***	**	***	√	√
34.	Gidlöf S et al (53)	2	Sweden	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	***	**	***	√	√
35.	Khan S et al (66)	3	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	***	**	***	√	√
36.	Yu N et al (90)	2	China	Symptoms, maternal characteristics, amniotic fluid in mid pregnancy	***	*	***	√	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

37.	Buonsenso D et al (94)	2	Italy	Maternal characteristics, Samples for detection	***	**	**	√	
-----	------------------------	---	-------	---	-----	----	----	---	--

Confidential: For Review Only

**Table -2 Studies and type of samples**

	Author (reference)	Number of neonates tested	Specimen tested	Neonatal result	Positive/ Total tested
1.	Chen H et al (50)	6	NP, AF, Cord blood, BM	Negative	
2.	Fan C et al (51)	2	NP, AF, Cord blood, BM, Placenta , Vaginal swab	Negative	
3.	Liu W et al (41)	3	NP, Cord blood, Neonatal whole blood	Negative (D2)	
4.	Zhu H et al (42)	10	NP	Negative [Within 72 hours (8); Between D7-D9 (2)]	
5.	Zhang I et al (83)	10	NP	Negative	
6.	Penfield C et al (84)	11	NP, Placental and membrane	NP- Negative (D1 and D5) Placenta and membrane +ve	3/11
7.	Chen S et al (86)	3	NP, Placenta	Negative	
8.	Chen Y et al (43)	4	NP	Negative	
9.	Gidlöf S et al (53)	2	NP	Negative (34 hours and 4.5 days)	
10.	Khan S et al (66)	3	NP	RT PCR -ve	
11.	Khan S et al (24)	17	NP	+ve within 24 hours	2/17
12.	Zeng L et al (36)	33	NP , anal swab	Both +ve D2 and D4	3/33
13.	Breslin N et al (44)	18	NP	+ve at D2 and D4	3/18
14.	Breslin N et al (99)	7	NP	Negative	
15.	Qiancheng X et al (89)	23	NP	Negative	
16.	Hantoushzadeh et al (26)	4	NP	Negative at D1; +ve at D7	1/4
17.	Shanes E et al (31)	16	NP , Placenta	Negative	
18.	Pereira A et al (75)	23	NP , Placenta, BM	Negative	
19.	Savasi V et al (91)	57	NP	+ve	4/57
20.	London V et al (20)	48	NP	Negative	
21.	William R et al (25)	33	NP	Negative at 24 hours, +ve at 48 hours	1/33
22.	Knight M et al (16)	262	NP (n=244) ,Blood or aspirate	+ve at <12 hours +ve at >12 hours	6/244 6/244
23.	Kayem G et al (18)	181	NP	+ve	2/181
24.	Nayak A et al (19)	134	NP (n=131)	+ve on D1 -ve on D5	3/131
25.	Yan J et al (17)	86	NP (n=86); Cord blood (n=10),AF (n=10)	Negative	

26.	Prabhu M et al (45)	71	NP	Negative at 24 hours	
27.	Cao et al (71)	5	NP	Negative	
28.	Hu X et al (37)	7	NP, Urine	NP +ve at 36 hours	1/7
29.	Nie R et al (73)	26	NP, Cord blood, Placenta	NP +ve at 36 hours Negative - All other samples, NP (D4, D8,D15)	1/26
30.	Yin M et al (74)	17	NP (n=17), BM (n=14), AF (n=2), placenta (n=2), Anal swab (n=5)	Negative	
31.	Buonsenso et al (97)	2	NP,AF, Placenta, Cord blood, Rectal swab	NP Negative on D1,D4 and +ve on D15 Placenta, cord blood +ve Weak IgG+ve, IgM negative	1/2
32.	Yang P et al(62)	7	NP , Cord blood, AF	Negative	
33.	Yang H et al (95)	55	NP	Negative	
34.	Wu Y et al(96)	5	NP , Anal swab, BM	Negative, BM +ve	1/5
35.	Patane L et al (34)	22	NP , Placenta	NP +ve	2/22
36.	Ferrazzi E et al (21)	42	NP	NP +ve	3/42
37.	Govind A et al (46)	9	NP , Placenta, AF	NP +ve	1/9
38.	Vintzileos W et al (98)	29	NP	Negative	
39.	Baergen R et al (32)	21	NP	Negative	
40.	Lowe B et al (47)	1	NP	Negative	
41.	Schnettler W et al (92)	1	NP, AF	Negative on D1,D2	
42.	Blauvelt C et al (65)	1	NP, Rectal swab D2 Ig G and IgM	NP Negative on D1, D2, D14 Rectal swab negative on D2 Ig G and IgM negative (D5)	
43.	Alzamora M et al (56)	1	NP, Cord blood	Negative for IgM and IgG; NP +ve at 16 hours and 48hours	1/1
44.	Vivanti A et al (22)	1	NP, AF, Vaginal swab, BAL, Neonatal blood and rectal swabs	NP +ve at 1hour, D3, D18; Rectal swab +ve at 1hour, D3, D18; Vaginal swab, NBAL, Neonatal blood +ve	1/1
45.	Song L et al (61)	1	NP, AF, Cord blood, BM	NP negative at D3,D7 All other negative	
46.	Zambrano L et al (69)	1	NP	Negative	
47.	Li Y et al (39)	1	NP, Neonatal Blood, feces, and urine	NP negative at birth and 48h All other negative	
48.	Dong L et al (54)	1	NP, Serum Vaginal swab	IgM level elevated NP negative at 2h,16h	1/1
49.	Baud D et al (28)	1	NP, AF, Placenta	Placenta +ve All other negative	1/1; 2 <sup>nd</sup> trimester

			Vaginal swabs		spontaneous miscarriage
50.	Wang X et al (55)	1	NP, AF, Placenta, Cord blood, gastric juice, feces	NP negative at D1, D3, D7, D9 All other negative	
51.	Huang J et al (67)	1	NP	Negative	
52.	Iqbal S et al (87)	1	NP	Negative	
53.	Kalafat E et al (57)	1	NP, Cord blood, Placenta	Negative	
54.	Lee D et al (58)	1	NP, AF, Cord blood, Placenta, neonatal serum, anal swab	Negative	
55.	Liao X et al (88)	1	NP, AF, Cord blood, Placenta	Negative	
56.	Xiong X et al (68)	1	NP, AF, BM, rectal swab	Negative	
57.	Wang S et al (59)	1	NP, AF, Cord blood, BM	NP +ve at 36 h Negative in all others	1/1
58.	Zamaniyan M et al (60)	1	NP, Cord blood, AF	NP +ve at D2, D4, D6 AF +ve	1/1
59.	Kirtsman M et al (30)	1	NP, Placental, Stool, BM Neonatal plasma D4	NP +ve at D1, D2, D7 Placenta +ve Stool +ve D7, BM +ve	1/1
60.	Lyra J et al(23)	1	NP	+ve at 0 h, D2, D7	1/1
61.	Algorroba G et al (29)	1	NP	Negative at 0 h, D2, D7	
62.	Zeng H et al (52)	6	NP Neonatal blood	NP negative; Elevated IgM and IgG (2); Elevated IgG, normal IgM (3)	Cytokine IL-6 elevated in all infants
63.	Peng Z et al(38)	1	NP, NBAL Fluid, Sputum, Urine	Negative	
64.	Groß R et al (40)	2	BM, NP	Both NP +ve (>D7), BM +ve (1)	2/2, 1/2
65.	Liu Y et al (85)	10	Fetal blood	Negative	
66.	Hosier H et al(27)	1	Placenta, cord blood	Both +ve	1/1; D&E at 22 weeks
67.	Pulinx B et al (72)	2	AF, Placental	Both +ve	2/2, DCDA twin at 24 weeks
68.	Mulvey J et al (33)	5	Placenta	Negative	
69.	Yu N et al (90)	2	AF in mid pregnancy	Negative	

AF= Amniotic fluid; NP= Neonatal Pharyngeal/throat swab; BM= Breast milk; NBAL= Non-bronchoscopic broncho-alveolar lavage fluid

**Table-3: Vertical Transmission (Pooled result)**

SAMPLE Tested by RT-PCR for SARS-CoV-2	Number of studies	Number Tested	Number Positive	Pooled Percentage
--	-------------------	---------------	-----------------	-------------------

Neonatal Naso-pharyngeal swab	<b>64</b>	<b>1193</b>	<b>48</b>	<b>4.02%</b>
Placenta ± Membranes	<b>19</b>	<b>130</b>	<b>9</b>	<b>6.9%</b>
Amniotic fluid	<b>18</b>	<b>42</b>	<b>4</b>	<b>9.5%</b>
Breast milk	<b>10</b>	<b>56</b>	<b>3</b>	<b>5.3%</b>
Cord blood/ plasma	<b>15</b>	<b>55</b>	<b>3</b>	<b>5.4</b>
Other neonatal samples				
-Anal swab	<b>11</b>	<b>52</b>	<b>5</b>	<b>9.6</b>
-Urine	<b>3</b>	<b>9</b>	<b>0</b>	
<b>Neonatal serology</b>				
IgM	<b>5</b>	<b>11</b>	<b>(Elevated) 3</b>	<b>27</b>
IgG	<b>4</b>	<b>10</b>	<b>(Elevated) 6</b>	<b>60</b>

**Table-4: Fetal outcome**

Serial number	Author (reference)	Number of neonates from SARS CoV-2 +ve pregnancies	Fetal complications	Mode of delivery (n)	Birth weight in grams	Preterm delivery (n)	Still birth(n)	Comments
1.	Chen H et al (50)	9	FD (2) PROM (1)	CS (9)	1880-3730	Yes (2)	-	
2.	Fan C et al (51)	2	-	CS (2)	3440-2890	Yes (1)	-	
3.	Zeng H et al (52)	6	-	CS (6)			-	
4.	Pulinx B et al (72)	2	IUFD (1)	VD (2)		Yes (1)	Yes (1)	DCDA twins
5.	Liu W et al (41)	3	FD (1); MSA ; chorioamnionitis	CS (2) VD (1)	3250-3670	-	-	
6.	Zhu H et al (42)	10	FD (6), PROM (3), MSA (n=2)	CS (7) VD (2)	SGA-2 LGA/Normal-8	Yes (6)	-	
7.	Chen Y et al(43)	4	DFM (1) Ab.CTG (1)	CS (3) VD(1)	3050-3550	-	-	
8.	Gildof S et al (53)	2	-	CS (2)	2680,2160	Yes (2)	-	
9.	Khan S et al (66)	3	-	VD (3)	2890-3750	Yes (1)	-	
10.	Khan S et al (24)	17	PROM	CS (17)	2300–3750 <2700-3	Yes (5)	-	
11.	Zeng L et al (36)	33	PROM (3); FD (1)	VD (7); CS (26)	SGA (3) 1580-3360	Yes(4)	-	
12.	Breslin N et al (44)	18	Ab.CTG (3)	CS (8); VD (10)		Yes (1)	-	
13.	Qiancheng X et al (89)	23	-	CS (17) VD (5)	3130 (2915– 3390)	Yes(1)	-	
14.	Hantoushzadeh S et al(26)	7	IUFD (3)	CS (4)	1180-3200	Yes (3)	Yes (1)	
15.	Zambrano L et al (69)	1	-	VD(1)	1500	Yes(1)	-	
16.	Pereira A et al (75)	23	-	VD (18) CS (5)	-	Yes(2)	-	
17.	Savasi V et al (91)	57	-	VD (34) CS (22)	3160 (840- 4350)	Yes(12)	-	
18.	London V et al (20)	56	DFM (1) IUFD (17 wks) (1)	CS (22) VD (33)	-	Yes(12)	-	
19.	Lokken E et al(35)	8	FD (3)	CS (3) VD (5)	-	Yes (1)	Yes(1)	
20.	Yan J et al (17)	99	FD (9); IUGR (2) PPROM (6)	CS (85) VD(14)	3108±526	Yes (21)	-	
21.	William R et al (25)	64	IUGR(2), PPROM (1)	CS (24) VD(8)	2403.3±858	Yes (19)	-	



22.	Knight M et al (16)	266	Miscarriage (4); Fetal compromise (37)	CS (156) VD (106)	-	Yes (66)	Yes (3)	
23.	Kayem G et al (18)	181	Fetal loss <21 weeks (5)	CS (87) VD (94)	-	Yes (50)	Yes (2)	
24.	Nayak A et al (19)	134	Miscarriage (6)	CS (67) VD(67)	>2500 (92) <2500 (39)	Yes (38)	Yes (3)	
25.	Prabhu M et al (45)	70	PROM and Ab.CTG (4)	CS (32) VD(38)	3060.9-3149.6	Yes (11)	Yes (1)	
26.	Li N et al (70)	17	FD(1); PROM (1)	CS (14) VD(2)	3078.2 ± 565.0	Yes (4)	-	
27.	Cao D et al (71)	11	FD (3); PROM (4)	CS (8) VD(2)	2050-3800	Yes (4)	-	
28.	Hu X et al(37)	7	PROM (1)	CS (6) VD(1)	3180-3670		-	
29.	Yang P et al (62)	7	-	CS(7)	2096 ± 660	Yes (4)	-	
30.	Yang H et al (95)	13	-	CS (9) VD(4)	3063.2 ± 536.4	-	-	
31.	Patane L et al (34)	2	-	VD (1) CS(1)	2660, 2686	Yes(1)	-	
32.	Ferrazzi E et al (21)	42	-	CS (18) VD(24)	2730-3226	Yes(11)	-	
33.	Govind A et al (46)	9	Ab.CTG (1)	CS (8) VD(1)	1200-4300	Yes(2)	-	
34.	Nie R et al (73)	28	FD (4); IM (1); PROM (3)	VD (5); CS (22)	2988(502)	Yes (10)	-	
35.	Yin M et al (74)	17	IM (3)	VD (4); CS (13)	2580-3035	Yes (5)	-	
36.	Doria M et al (48)	10	IUGR (6)	CS (6) VD(4)	2350–3380	-	-	
37.	Liu Y et al (85)	10	FD(3), PROM (1)	CS(10)		Yes (6)	Yes(1)	
38.	Perrone S et al (49)	4	IUGR(1)	VD(4)	2290-3790	-	-	
39.	Romagano M et al (63)	7	-	CS(7)	1290-2580 (AGA)	Yes (7)	-	
40.	Cooke W et al (64)	2	-	CS (2)	1530,1400	Yes(2)	-	
41.	Lowe B et al (47)	1	Ab.CTG (1)	VD (1)		-	-	
42.	Blauvelt C (65)	1	-	CS(1)	1880	Yes (1)	-	
43.	Kirtsman M et al (30)	1	-	CS(1)	2930	Yes (1)	-	
44.	Lyra J et al(23)	1	-	CS(1)	3110	-	-	
45.	Li Y et al (39)	1	FD(1)	CS(1)		Yes (1)	-	
46.	Dong L et al (54)	1	-	CS(1)	3120	Yes (1)	-	
47.	Wang X et al (55)	1	FD (1)	CS(1)	1830	Yes (1)	-	
48.	Alzamora M et al (56)	1	-	CS(1)	2970	-	-	
49.	Huang J et al (67)	1	-	VD(1)		-	-	
50.	Kalafat E et al (57)	1	-	CS(1)	2790	Yes (1)	-	
51.	Xiong S et al (68)	1	PROM	VD(1)	3070	-	-	
52.	Wang S et al (59)	1	FD (1)	CS(1)	3205	-	-	
53.	Zamaniyan M et al (60)	1	-	CS(1)	2350	Yes (1)	-	
54.	Song L et al (61)	1	-	CS(1)	3630	Yes (1)	-	
55.	Lee D et al (58)	1	-	CS (1)	3130	-	-	

56.	Iqbal S et al (87)	1		VD(1)				
57.	Vivanti A et al (22)	1	Ab.CTG (1)	CS(1)	2540	Yes (1)	-	

FD= Fetal distress; Ab.CTG= Non-reassuring/ Pathological fetal cardio-tocography ; PROM= Pre-labor rupture of membrane ; Fetal demise= IUFD ; MSA= Meconium stained amniotic fluid; DFM= Decreased fetal movement; IM= Induced miscarriage; CS= Caesarean Section; VD= Vaginal delivery; AGA= Appropriate for gestational age; IUGR= Intrauterine growth restriction; SGA= Small for gestational age; LGA= Large for gestational age

**Table-5; Fetal outcome (Pooled data)**

Number of studies	Outcomes	Indications	
Preterm birth 42 studies	Preterm birth=325 Term birth=930	Maternal indications due to COVID-19=140 Spontaneous preterm labor=23 Fetal compromise/ distress=17 Unknown/others	OR=0.12 Total Preterm birth in 25.4% of total births Spontaneous preterm birth-1.8% of total births
Mode of delivery 57 studies	CS=750 VD=505	Maternal COVID-19 related conditions most common indication	OR=2.20
Still birth 7 studies	Still birth=13	Defined as the number of fetal death beyond 24 weeks per 1000 total births	Stillbirth rate= 0.9

**Table-6; Neonatal outcome**

Serial number	Author (reference)	Number of neonates	APGAR score (1 minute, 5 minute)	Neonatal symptoms (n)	Neonatal ICU admission (n)	Neonatal death	Neonatal RTPCR status
1.	Alzamora M et al (56)	1	6, 8	Respiratory difficulty Cough on D6	(1) [due to maternal sedation]	-	<b>Negative</b>
2.	Chen H et al (50)	9	8-10	-	-	-	
3.	Fan C et al (51)	2	9-10	Fever, abdominal distension, lymphopenia (1) Mild NP, lymphopenia (1)	-	-	<b>Negative</b>
4.	Li Y et al (39)	1			-	-	
5.	Dong L et al (54)	1	9-10	-	-	-	
6.	Zeng H et al (52)	6	9-10		-	-	
7.	Pulinx B et al (72)	2			-	-	
8.	Liu W et al (41)	3	8-10	decreased responsiveness and decreased muscle tone	-	-	<b>Negative</b>
9.	Zhu H et al (42)	10	8-10 in all 7-8 in 1	Shortness of breath (6), vomiting (1), rash (1), Fever (3)	1	YES (1)	<b>Negative</b>
10.	Wang X et al (55)	1	9-10	-	1	-	
11.	Liu Y et al (85)	10	10	-	-	-	
12.	Chen Y et al (43)	4	8-9 (3) 7-8 (1)	Edema (2), Rash (2),Dyspnea and TTN (1)	1	-	<b>Negative</b>
13.	Gidlof S et al (53)	2	9-10	Breathing problem, cyanotic attack(1)			<b>Negative</b>

14.	Huang J et al (67)	1	8-9	-	-	-	
15.	Iqbal S et al (87)	1	9	-	-	-	
16.	Lee D et al (58)	1	9-10	-	1	-	
17.	Khan S et al (66)	3	9-10	-	-	-	
18.	Khan S et al (24)	17	9-10 (16) 7-9 (1)	NP (5)	-	-	<b>2 out of 5 with pneumonia were +ve</b>
19.	Xiong S et al (68)	1	9-10	-	-	-	
20.	Wang S et al (59)	1	8-9	Vomiting, lymphopenia, abnormal liver enzyme levels	1	-	<b>Negative</b>
21.	Zeng L et al (36)	33	Preterm newborn- 3,4 Term - Normal	RD (4=3 -ve, 1+ve). Cyanosis, feeding intolerance (3=2-ve,1+ve) Fever in 2, NP in 3 of the 3 +ve Lethargy, fever(1) lethargy, fever, NP, leukocytosis, lymphocytopenia, vomiting (1) Preterm- Neonatal RDS, NP, lymphocytopenia (1)	3	-	<b>+ve</b>
22.	Zamaniyan M et al (60)	1	8,9	Fever (1)	-	-	<b>+ve</b>
23.	Breslin N et al (44)	18	>7, >9	RD/ sepsis (1)	Yes (3)	-	<b>+ve</b>
24.	Qiancheng X et al (89)	23	10,10		-	-	
25.	Hantoushzadeh S et al(26)	4	7 (2), 9-10	NP, lymphopenia (1)	Yes (1)	-	<b>+ve</b>
26.	Shanes E et al (31)	15	7(8),8(7); 9				
27.	Zambrano L et al (69)	1	-	-	Yes (1)	-	
28.	Pereira A et al (75)	23		RD(1); Hemolytic anaemia (1)	Yes(2)	-	<b>Negative</b>
29.	Savasi V et al (91)	57	10	-	Yes(9)	-	
30.	London V et al (20)	55	-	-	-	-	
31.	Song L et al (61)	1	8,9	-	-	-	
32.	Lokken E et al (35)	8					
33.	Yan J et al (16)	99	9,10	Neonatal asphyxia (1)	Yes(47)	YES (1)	<b>Negative</b>
34.	William R et al (25)	32	7.9±1.7	-	Yes (21)	-	
35.	Knight M et al (16)	262		Neonatal encephalopathy (1)	Yes (67)	YES (2)	<b>Unclear whether symptomatic neonate was +ve</b>
36.	Kayem G et al (18)	181		-	Yes (37)	YES (1)	
37.	Nayak A et al (19)	131	7-10 (128) <7 (6)	Neonatal seizures (1), MAS (1)	Yes (24)		<b>Unclear whether symptomatic neonates were +ve</b>
38.	Prabhu et al (45)	73	9	-	Yes (13)	-	<b>Negative</b>
39.	Vivanti A et al (22)	1	4,7	irritability, poor feeding, axial	Yes (1)	-	<b>+ve</b>

				hypertonia and opisthotonos			
40.	Li N et al (70)	17	9.6 ± 0.5, 10	-	-	-	
41.	Cao D et al (71)	11	8-9,10	-	-	-	
42.	Hu X et al (37)	7	7-8,8-9	-	-	-	
43.	Yang P et al (62)	7	8-9,9-10	Vomiting(1), RD (2)	Yes (5)	-	<b>Negative</b>
44.	Yang H et al (95)	13	9,10	Fever(1)	-	-	
45.	Patane L et al (34)	2	9,10	Mild feeding difficulty (1)	Yes(1)	-	<b>+ve</b>
46.	Ferrazzi E et al (21)	42	<7 (2)	Gastrointestinal symptoms, RD (2)	Yes(3)	-	<b>+ve</b>
47.	Govind A et al(46)	9	<7 (2)	NP (1)	Yes(1)	-	<b>+ve</b>
48.	Nie R et al(73)	28	8-10, 10	Pulmonary infection (1)	Yes (1)	-	<b>+ve</b>
49.	Yin M et al(74)	17	8,9	-	-	-	
50.	Doria M et al (48)	10	9,10	-	-	-	
51.	Perrone S et al (49)	4	9,10	-	-	-	
52.	Romagano M et al (63)	7	1-7,4-9	RD	Yes(7)	-	<b>Negative</b>
53.	Cooke W et al (64)	2	1-6, 3-8	Bowel perforation D6(1)	Yes(2)	-	<b>Negative</b>
54.	Lowe B et al (47)	1	9,9	-	-	-	
55.	Blauvelt C (65)	1	4,8	RD	YES	-	<b>Negative</b>
56.	Kirtsman M et al (30)	1	9,9	-	-	-	
57.	Lyra J et al(23)	1	8,9	-	-	-	

RD= Respiratory distress; MAS= Meconium aspiration syndrome; TTN= Transient Tachypnea of Newborn; NP= Neonatal Pneumonia

# BMJ Paediatrics Open

## COVID-19 in pregnancy; The fetal perspective- a systematic review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2020-000859.R1
Article Type:	Original research
Date Submitted by the Author:	16-Oct-2020
Complete List of Authors:	Dube, Rajani; RAK Medical and Health Sciences University, Obstetrics and Gynaecology Kar, Subhranshu; Ras Al Khaimah Medical and Health Sciences University, Pediatrics
Keywords:	Data Collection, Microbiology, Mortality, Neonatology, Virology

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

## Title Page

**Article Title- COVID-19 in pregnancy; The fetal perspective- a systematic review**

**Author information-****1. Rajani Dube**

**Highest academic degree- M.D. (Obstetrics and Gynaecology)**

**The name of the department / institution – Department of Obstetrics and Gynaecology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras al Khaimah, United Arab Emirates**

**E Mail ID- [rajnidube@yahoo.com](mailto:rajnidube@yahoo.com)**

**Phone No- +971 551383304**

**ORCID - <https://orcid.org/0000-0002-1539-6162>**

**2. Subhranshu Sekhar Kar- Corresponding author**

**Highest academic degree- M.D. (Paediatrics), Fellowship in Paediatric Critical Care**

**The name of the department / institution – Department of Pediatrics, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras al Khaimah, United Arab Emirates**

**E Mail ID- [drsskar@gmail.com](mailto:drsskar@gmail.com)**

**Phone No- +971 504314392**

**ORCID - <https://orcid.org/0000-0002-9379-7447>**

**Disclaimer-** The views expressed in the submitted article are our own and not an official position of the institution or funder.

**Source(s) of support-** None

**Word count-** 6666 excluding its abstract, figures, tables, acknowledgments and references

**Number of figures and tables-** Tables- 6 and Figures-2

**Disclosure of relationships and activities-** Nothing to disclose

**Keywords:** COVID-19, SARS-CoV-2, mother to child transmission, perinatal outcome, congenital anomaly



## Title: COVID-19 in pregnancy; The fetal perspective- a systematic review

### Abstract:

**Objective:** We aimed to conduct a systematic review of the available literature to determine the effects of confirmed cases of COVID-19 in pregnant women from the fetal perspective by estimation of mother to child transmission, perinatal outcome and possible teratogenicity.

### Methods

Data sources: Eligible studies between November 1, 2019 and August 10, 2020 were retrieved from PubMed, Embase, LitCovid, Google Scholar, EBSCO MEDLINE, CENTRAL, CINAHL, MedRXiv, BioRXiv, and Scopus collection databases.

**Study eligibility criteria:** English language case reports, case series and cohort studies of SARS-CoV-2 confirmed pregnant women with data on perinatal outcome, congenital anomalies and mother to child transmission were analysed. 38 case reports, 34 cohort and case series describing 1408 neonates were included for evidence acquisition of mother to child transmission. 29 case reports and 30 case series and cohort studies describing 1318 fetuses were included for the evaluation of perinatal outcome and congenital anomalies.

**Results:** A pooled proportion of 3.67% neonates had positive SARS-CoV-2 viral RNA nasopharyngeal swab results and 7.1 % had positive cord blood samples. 11.7% of the placenta, 6.8% of amniotic fluid, 9.6% of fecal and rectal swabs, and none of the urine samples were positive. The rate of preterm labor was 26.4% (OR=1.45, 95% CI- 1.03 to 2.03 with  $p = 0.03$ ) and Cesarean delivery (CS) was 59.9% (OR=1.54, 95% CI- 1.17 to 2.03 with  $p = 0.002$ ). The most common neonatal symptom was breathing difficulty (1.79%). Stillbirth rate was 9.9 per 1000 total births in babies born to COVID-19 mothers.

**Conclusion:** Chances of mother to child transmission of the SARS-CoV-2 virus is low. The perinatal outcome for the fetus is favorable. There is increased chances of CS but not preterm delivery. The stillbirth and neonatal death rates are low. There are no reported congenital anomalies in babies born to SARS CoV-2 positive mothers.

**Keywords:** COVID-19, SARS-CoV-2, mother to child transmission, perinatal outcome, congenital anomaly

### KEY MESSAGE:

#### A. What is known about the subject –

Studies specifically analyzing all aspects of the fetus in SARS-CoV-2 positive mothers are not available. There is currently a lack of large studies depicting fetal outcomes and they are unlikely to be available in the near future as individual centers are still reporting cases in small numbers. There are some systematic reviews reporting maternal outcomes, vertical transmission and neonatal outcomes involving a lesser number of

1  
2  
3 pregnancies separately but aspects like fetal complications and teratogenicity are not  
4 adequately reported.

### 6 **B. What this study adds –**

7 In this systematic review, we searched multiple databases to include evidence until 10th  
8 August 2020. 80 studies were included to collect data on more than 1400 fetuses. The  
9 confirmed congenital transmission rate was found to be 9/1408 (0.63%). The risk of  
10 caesarean delivery is significantly higher in SARS-CoV-2 positive mothers but there is no  
11 significantly higher risk of prematurity. There is evidence of fetal distress, and neonatal  
12 respiratory symptoms in COVID-19 mothers but stillbirth is low. There are no associated  
13 congenital anomalies.

## 16 **INTRODUCTION**

18 Novel coronavirus infection and associated coronavirus disease-2019 (COVID -19)  
19 pandemic has changed our lives forever and has compelled us to reconsider almost  
20 everything we have long taken for granted. Among the different coronaviruses severely  
21 affecting human species, Middle East respiratory syndrome coronavirus (MERS-CoV),  
22 severe acute respiratory syndrome coronavirus (SARS-CoV), and SARS-CoV-2 are  
23 significant, causing MERS, SARS, and COVID-19 respectively. SARS-CoV-2 strains  
24 show significant sequence homology to SARS-CoV and MERS-CoV [1]. As the pandemic  
25 evolved, there were significant advances in our knowledge about various aspects of the  
26 COVID-19 including epidemiology, clinical features, transmission, detection, and  
27 management modalities. Discoveries along the process of evolution are still contributing  
28 to our management practices.

33 There were concerns regarding the maternal and fetal effects since the beginning of the  
34 pandemic. The earlier evidence of COVID-19 in pregnancy pointed towards pregnancy  
35 being considered as low risk for the disease and no difference in disease behavior in  
36 pregnant and non-pregnant women was reported [2]. On the contrary, a newer study  
37 involving pooled data from more than 8000 women in the USA pointed towards a  
38 significantly higher rate of intensive care unit (ICU) admission [adjusted relative risk (aRR)  
39 = 1.5] and need for mechanical ventilation (aRR = 1.7) in pregnant women as compared  
40 to non-pregnant women, even when adjusted for race/ethnicity and underlying comorbid  
41 conditions [3]. Similar findings were reported from other studies from the US and Sweden  
42 [4-6].

47 However, these studies did not specify adequately fetal effects resulting from congenital  
48 or neonatal infection in SARS-CoV-2 positive mothers and consequent perinatal  
49 outcomes. Evidence of COVID-19 specifically focusing on fetal and neonatal outcomes  
50 are lacking. Most of the reported literature have smaller studies. Previous systematic  
51 reviews focusing on the outcomes of all coronaviruses have reported a higher risk of pre-  
52 eclampsia, preterm birth, miscarriage, and perinatal death.

Through this article, we want to analyze the published evidence on the fetal perspective of COVID-19 infection concerning mother to child transmission (congenital or neonatal infection) and perinatal outcome through a systematic review. This will aid in alleviating uncertainties faced while doing patient counseling and help in subsequent management during these testing times.

## METHODS

**Search strategy:** A systematic search of PubMed, Embase, LitCovid, MedRxiv, BioRxiv, Google Scholar, EBSCO MEDLINE, CINAHL, and Scopus electronic database was done. Medical subject handling terms (MeSH) and free text term keywords like vertical transmission, perinatal outcome, fetal, neonate, newborn, pregnancy were used in combination with COVID-19, 2019-nCoV, SARS-CoV- 2 to search for data from 1<sup>st</sup> November 2019 till 10<sup>th</sup> July 2020. Thereafter manual update was done on weekly basis till 10<sup>th</sup> August 2020. The references of relevant studies were also searched.

The keywords detail and full search strategy used in each of PubMed, Embase, LitCovid, MedRxiv, BioRxiv, Google Scholar, EBSCO MEDLINE, CINAHL, and Scopus electronic database are as follows: Both medical subject headings (MeSH) and key-words: "2019 novel coronavirus infection" OR "COVID-19" OR "COVID19" OR "coronavirus disease 2019" OR "nCoV infection" OR "2019-nCoV" OR "2019 novel coronavirus" OR "2019 coronavirus" OR "novel coronavirus" OR (2019 AND coronavirus) OR "SARS CoV-2" OR "SARS CoV2" AND "vertical transmission" OR "fetal outcome" OR "perinatal outcome" OR "neonatal outcome" OR "pregnancy" OR "congenital infection" OR "mother-to-child transmission" OR "(transmission AND vertical)" OR "(transmission AND fetomaternal) " OR "teratogenicity".

**Selection criteria:** The search consisted of only English language articles (original English articles and other language articles with available English translation) including case reports, case series, and letters to editors containing case information. After a thorough screening, no randomized clinical trials or cohort studies were found.

**Inclusion criteria:** The studies fulfilling all of the following criteria (1,2 and 3) were included for review.

- 1- Studies reporting pregnant women with confirmed COVID-19 who had delivered.
- 2- Studies containing the results of the SARS-CoV-2 test [including reverse transcriptase-polymerase chain reaction (RT-PCR) and serological tests] in both mothers and newborns samples.
- 3- Studies that present the out-come of vertical transmission or congenital transmission or neonatal transmission or the perinatal outcome or congenital anomaly.

**Exclusion criteria:** Exclusions consisted of studies in pregnant women yet to deliver, duplicated studies, review articles, articles in languages other than English, studies where

1  
2  
3 infection in mothers is not confirmed, or where neonatal testing was not done. Conference  
4 abstracts, expert opinions, and critical appraisals were also excluded.  
5

6 Both the authors (RD, SSK) reviewed all titles independently. The potential relevance of  
7 the studies to be included for review were agreed upon by discussion. Selected titles and  
8 abstracts were further screened between studies to reject overlap of cases.  
9

10  
11 Full-text copies of the selected papers were obtained and the relevant data regarding  
12 study characteristics, evidence of vertical transmission, and perinatal outcomes were  
13 extracted by the same two reviewers independently. In the case of individual case reports,  
14 if the same patient was included in more than 1 study with similar characteristics and  
15 findings, only the report with a larger number of patients was included. As far as possible,  
16 single case reports were cross-checked with other reports from the same location and  
17 hospital. If a case series included multiple locations, the individual reports from the same  
18 centers were excluded. Similarly, if the time-frame of the reported cases matched from the  
19 same center, the characteristics were compared to decide regarding the inclusion or  
20 exclusion from the study. Finally, studies were screened by assessing selection,  
21 comparability, and exposure for inclusion into evidence acquisition of mother to child  
22 transmission (congenital or neonatal transmission ) and/or perinatal outcome measures  
23 **[Table-1a,1b]**.  
24  
25  
26  
27  
28  
29

## 30 **Study Outcomes**

### 31 1. Mother to child transmission-

32  
33 Evidence of mother to child transmission (congenital or neonatal transmission) is indicated  
34 by positive RT-PCR status in different samples like the neonatal nasopharyngeal swab,  
35 cord blood, amniotic fluid, breast milk, and placental tissue. Transmission of infection from  
36 mother to fetus generally includes transmission through germ cells or the placenta during  
37 pregnancy, via the birth canal during labor and delivery, and the postpartum period  
38 through breastfeeding or close contact. The transfer of microorganisms during pregnancy  
39 is seen with many of the common pathogens with resultant effects ranging from  
40 asymptomatic infection, intrauterine growth restriction, intrauterine death, and structural  
41 anomalies as a sequel of infection. Some pathogens like cytomegalovirus (CMV) or Zika  
42 virus produce mild to no symptoms in the pregnant patient but can cause congenital  
43 infection with severe consequences **[7]**. Viruses specifically can be transmitted to the  
44 fetus via the maternal blood when it enters the placental villus, containing the fetal blood  
45 vessels, or by direct access to the placenta from the lower genital tract by ascending  
46 infection **[8]**. Again even when transferred trans-placentally during the antenatal period,  
47 the specific timing of maternal infection can have different effects on the fetus. The first-  
48 trimester infection can cause severe structural anomalies whereas second and third-  
49 trimester infections are more likely to cause functional organ abnormalities **[9]**.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Several factors are contributing to the concerns of mother to child transmission in Covid-19. It is known that the SARS-COV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors for entry into the cells. ACE-2 receptors are detected in various parts of the uterus, vagina, decidual cells, and placenta [10-13]. Recently, the case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates has been published with a categorization of infection into confirmed, probable, possible, unlikely, and not infected groups [14].

Congenital infection with intrauterine fetal death/stillbirth is [14]-

- confirmed from fetal tissue or autopsy material if the virus is detected by PCR from fetal or placental tissue or electron microscopic detection of the viral particle in tissue or viral growth in culture from fetal or placental tissue.
- a probable infection if the virus is detected by PCR in the surface swab from the fetus or placental swab on the fetal side.
- unlikely if it is positive in the maternal side of the placenta but fetal tissues are not tested and not present if it is not detected in fetal tissue in an autopsy.

Similarly, congenital infection in live-born symptomatic neonate is [14]-

- confirmed when the virus is detected by PCR in umbilical cord blood or neonatal blood collected within the first 12 hours of birth or amniotic fluid collected prior to the rupture of the membrane.
- a probable infection when there is the detection of the virus by PCR in nasopharyngeal swab at birth (collected after cleaning baby) AND placental swab from the fetal side of the placenta in a neonate born via cesarean section before rupture of membrane or placental tissue.
- possible when there are anti-SARS-CoV-2 IgM antibodies in umbilical cord blood or neonatal blood collected within the first 12 hours of birth or placental tissue but nasopharyngeal swab test at birth is negative.
- unlikely or absent when samples are negative within 12 hours of birth (nasopharyngeal swab, umbilical cord blood, or neonatal blood) and antibody testing is not done or negative, respectively.

If a live-born neonate has no clinical features of infection, congenital infection is [14]-

- confirmed by detection of the virus by PCR in cord blood or neonatal blood collected within the first 12 hours of birth.
- probable if the virus is detected by PCR in amniotic fluid collected prior to rupture of the membrane but no detection in umbilical cord blood or neonatal blood collected within the first 12 hours of birth.



- possible when there is anti-SARS-CoV-2 IgM in umbilical cord blood or detection of the virus by PCR in placental tissue but PCR in umbilical cord blood, amniotic fluid, and neonatal blood (<12hours of life) is negative.

Furthermore, infection acquired intrapartum in a symptomatic neonate is confirmed if the virus is detected by PCR in nasopharyngeal swab at birth (collected after cleaning the baby) AND at 24-48 hours of age AND alternate explanation for clinical features excluded **[14]**.

Intrapartum neonatal infection in asymptomatic neonate is confirmed by detection of the virus by PCR in nasopharyngeal swab at birth (collected after cleaning the baby) AND at 24-48 hours of age **[14]**.

Postpartum infection is confirmed if a neonate shows symptoms beyond 48 hours of life and the nasopharyngeal swab is positive beyond 48hours which was negative at birth**[14]**.

If a neonate is born with a specific structural sequel of an infection, intrauterine infection is a probability. The probability of infection also depends on the presence of the agent in the genital tract and time taken from exposure to detection by definitive tests to differentiate between intrapartum and postpartum infection. Furthermore, the sensitivity of RT-PCR testing is different for detecting SARS-CoV-2 in different samples. Therefore, it is rational to test samples from multiple sites to improve detection and reduce false-negative cases **[9, 15]**.

## **2. Perinatal outcome**

Perinatal outcome measures included fetal outcomes like fetal complications in SARS-CoV 2 positive pregnant women, gestational age at delivery (preterm delivery), mode of delivery, birth weight, and stillbirth. The neonatal period is defined as the time period from birth until the end of the first 28 days of life. Events in the early neonatal period (first 7 days) usually are related to the pregnancy more significantly and it is also included in the definition of the perinatal period. In this review, we have assessed the neonatal outcomes using the APGAR score at 1 minute and 5 minutes of life, neonatal symptoms, admission into neonatal intensive care unit (ICU), and neonatal death, as the parameters. An APGAR score of less than 7 at 1 minute and 5 minutes after birth in a newborn is defined as a low APGAR score in this study **[16]**. Any outcome measures not explicitly mentioned were considered not to have been reported.

- Fetal distress (FD) is assessed during labor by non-reassuring or pathological cardiotocographic (CTG) findings and meconium-stained amniotic fluid **[17, 18]**. For this research, studies reporting FD, abnormal or non-re-assuring or pathological CTG, fetal compromise, meconium-stained amniotic fluid are included

1  
2  
3 under FD. Other fetal complications were pre-labor rupture of membranes and  
4 preterm prelabor rupture of membranes.

- 5  
6 • Preterm delivery is defined as delivery of a viable product of conception before 37  
7 completed weeks of gestation.  
8  
9 • Delivery can be vaginal delivery (including instrumental) and by caesarean section  
10 (CS). For this research, instrumental vaginal deliveries and normal vaginal  
11 deliveries were considered together (VD).  
12  
13 • Both the Royal College of Obstetrics and Gynecology and the American College  
14 of Obstetricians and Gynecologists have adopted the definition of Intrauterine  
15 growth restriction (IUGR) is defined as an estimated fetal weight less than 10<sup>th</sup>  
16 percentile. The term is IUGR has been used interchangeably with Small for  
17 gestational age (SGA). SGA is a term commonly used for a neonate with birth  
18 weight less than 10 percent [19,20].  
19  
20 • For this research, stillbirth was considered as fetal death beyond 24 weeks of  
21 gestation, and stillbirth rate (SBR) is calculated as the number of stillbirths per  
22 1000 total births.  
23  
24

25 **Statistical analysis:** Pooled proportions of categorical variables were calculated with  
26 percentage after obtaining the positive rates of each of the SARS-CoV-2 testing methods  
27 used, wherever applicable. Odds Ratio was calculated for the fetal outcome of preterm  
28 delivery and mode of delivery in the SARS-CoV-2 positive mothers from the pooled data  
29 (combining the studies where the control group of SARS-CoV-2 negative pregnant  
30 women was available) with 95% confidence interval and p values. The percentage of the  
31 most common variables were also calculated.  
32  
33  
34  
35

36 **Public and patient involvement statement:** This research is not “coproduced” with  
37 patients, carers or members of the public.  
38  
39

## 40 RESULTS

### 41 1. Mother to child transmission-

#### 42 Search Results:

43  
44 Out of 100 records selected for full-text review, 72 studies fulfilled the eligibility criteria  
45 and were included in the qualitative synthesis. 38 studies were case reports containing 4  
46 or fewer number of cases and 34 studies had 5 or more number of patients (**Figure-1**).  
47 Since evidence from randomized control trials were not available until the time of the  
48 search, 34 studies having 5 or more number of patients were considered for qualitative  
49 analysis [21, 22]. However, the findings from the case reports were also noted. The  
50 majority of earlier studies were from China but later studies contained cases from the rest  
51 of the world [Table-1a,1b].  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table-1 (a): Analysis of the studies [Case series/ Cohort] -Supplimental material****Table-1 (b): Analysis of the studies [Case reports] -Supplimental material****Systematic review:**

Tests for diagnosis of SARS-CoV-2 was done in a total of 1408 neonates. The most common type of sample tested was neonatal nasopharyngeal samples (NP swab) (67 out of 72 studies) followed by the placenta, amniotic fluid, and cord blood. In the majority, samples were taken from more than one site. In a few studies, the same type of sample was repeated at different intervals (e.g., NP swab and breast milk samples) [Table-2].

**Table -2 Studies and type of samples -Supplimental material****i. Neonatal Nasopharyngeal swab**

In our review, a total of 1388 neonates born to mothers with COVID-19 infection were tested by NP swabs. 51 neonates were found positive by the RT-PCR test constituting 3.67% of total pooled samples. [Table-3a].

**Table-3 (a): Mother to child transmission-Test positive (Pooled result) -  
Supplimental material**

The largest cohort study from the UK involved 427 pregnant women with COVID-19. 244 out of the 262 neonates were tested by NP swab. 6 of the neonates were positive for SARS-CoV-2 within 12 hours of birth and 6 more were positive after 12 hours of birth (12 out of 244; 4.9%) [23]. Studies involving 181 women and 116 women in China showed 2 positive neonates out of 181 (2 out of 181; 1.1%) and no positive cases for SARS-CoV-2 in the other study [24, 25]. An analysis of 141 women from a hospital in India showed that 3 of the 131 neonates were tested positive for SARS-CoV-2 by NP swab [26]. In another study in a New York Hospital, 48 neonates born to 55 women were all tested negative on Day 0 of life [27]. However, One Italian study found three infants positive by NP swab out of 42 tested within 48 hours after birth [28].

One recent case report revealed that RT-PCR was positive for SARS-CoV-2 in all of the samples for amniotic fluid, vaginal swab, blood, and non-bronchoscopic bronchoalveolar lavage fluid as well as NP swab and rectal swabs collected at 1 hour of life, and then repeated at 3 days and 18 days suggesting a trans-placental transmission [29].

As stated earlier NP swab positivity at different neonatal ages plays an important role in confirming or ruling out the viral transmission from a SARS-CoV-2 positive mother.

On further analysis of the positive samples, the congenital infection was confirmed in 5 live-born neonates, possible in 5 neonates, and probable in 2 neonates. Neonatal infection acquired intrapartum was confirmed in 2 neonates, probable in 5 neonates, and

possible in 14 neonates. Similarly, neonatal infection acquired postpartum was confirmed in 7 neonates and infection was unlikely in 1 neonate [Table-3b].

### **Table-3 (b): Analysis of evidence of congenital/ inpartum/ postpartum transmission -Supplemental material**

However, in a larger study, out of 12 neonates with positive NP result [6 within 12 hours of life and 6 at more than 12 hours of life], further analysis was not possible due to lack of followup swab results and unavailability of test results of other maternal samples like placenta and amniotic fluid [23].

#### **ii. Amniotic fluid**

In our review, 58 samples of amniotic fluid were tested in 19 studies with a positive result in 4 samples [29, 30, 31]. Congenital infection is confirmed in 2 of the studies in live-born neonates [29, 30]. Congenital infection is also confirmed in a dichorionic, diamniotic (DCDA) twin expelled at 24 weeks by positive amniotic fluid result [31].

#### **iii. Placenta**

A total of 22 studies were identified in our review where the placenta was examined for the presence of SARS-CoV-2 or related pathological changes. A total of 111 placental samples were tested and 13 were found positive for SARS-CoV-2. PCR for SARS-CoV-2 RNA was positive from the placenta in two case reports where there were spontaneous miscarriage and dilatation and curettage respectively confirming a congenital infection [32, 33]. In one of them, the umbilical cord was also positive for the virus, but the fetal organs were tested negative. The virus was confirmed to be localized mostly in the syncytiotrophoblastic cells of the placenta by immunohistochemistry for the SARS-CoV-2 spike protein as well as electron microscopy and it was identical to the typically locally isolated virus [32]. In another study, electron microscopy showed the presence of the virus in the fetal side of the placenta. The virions were present in the mesenchymal core of the terminal villus and were demonstrated to be invading a syncytiotrophoblast and a microvillus. However, the neonate delivered at 28 weeks in this pregnancy was tested negative for the virus [34].

Evidence of probable mother to child transmission was obtained in another case where the newborn was found positive for the virus by nasopharyngeal swab, plasma, and stool samples along with the placenta [35]. Similarly, confirmed congenital transmission of the virus was demonstrated by another study where SARS-CoV-2 was detected in amniotic fluid aspirated before the rupture of the membranes, vaginal swab, neonatal blood, bronchoalveolar lavage fluid, and neonatal swabs on repeated occasions at 1 hour, 3<sup>rd</sup> day and 18<sup>th</sup> day of life. The trophoblastic cells showed SARS-CoV-2 N protein on immunostaining [29].

Placental pathological examination showed an array of changes including vascular malperfusion, fibrin deposition, and chronic villitis, intervillitis, and villous infarctions in

our review. Two of these studies showed vascular malperfusion in 10 out of 20 placentas and 12 out of 15 placentas respectively but there were no assessments of placentas in these studies for the presence of SARS-CoV-2 infection. However, neonatal swabs were negative for the virus [36, 37]. Similar pathological changes were seen in another study involving five SARS-CoV-2 positive pregnant women but the placentas were negative for the virus on direct testing for SARS-CoV-2 [38]. Chronic intervillitis was also seen in the pathological examination of the placentas of two women where the neonates were positive for SARS-CoV2 by nasopharyngeal swab testing [39]. Examination showed severe chronic villitis in another case where there was a stillbirth at term but direct tests of fetal tissues and placenta did not show infection with the virus [40].

#### iv. Other samples

Various other samples were tested for SARS-CoV-2 by different studies. Anal swab, rectal swab, or fecal sample was positive in 9.6% of neonates in our study. The stool sample was positive in two of the studies on Day 2 and Day 7 of life [35, 41]. The urine sample was tested in only 3 studies without any positive results [42- 44]. Breast milk was tested by RT-PCR in 10 of the studies with a pooled positive rate of 5.3% (3 out of 56) [35, 45- 53]. In one of the studies, the breast milk sample was positive in 4 consecutive days coinciding with the maternal symptoms in one woman but it was negative in milk samples of another woman. Both the babies were positive by the nasopharyngeal swab test and were symptomatic [52]. A vaginal swab was tested in 23 women with one positive result (4.3%) [29]. Since IgM cannot cross the placenta, elevated IgM levels in the neonate indicate possible congenital infection, as seen in some of the neonates in this review [54, 55]. However, the assay of IgM for the detection of infection has significant false-positive results.

## 2. Perinatal outcome-

### Search results:

Out of 73 records selected for full-text review, a total of 60 studies fulfilled the eligibility criteria and were included in the qualitative synthesis. 31 studies qualified as case series/cohort and 29 studies contained 4 or fewer cases in our review (Figure-2). No randomized control trials were available until the time of the search.

### Systematic Review:

#### 2.1 Fetal Outcomes:

##### i. Fetal complications in SARS-CoV-2 +ve pregnant women

1  
2  
3 In our review, a total of 30 studies reported any fetal effects excluding all pregnancy  
4 losses or intrauterine fetal deaths (IUFD) [Table no-4]. The most commonly reported  
5 effect was fetal distress in 36 out of 1311 pregnancies (2.74%). In addition to fetal  
6 distress, some studies have reported non-reassuring or pathological cardiotocography  
7 (CTG) (11 out of 1311; 0.83 %), and some have mentioned meconium-stained amniotic  
8 fluid (3 out of 1311; 0.22%), both findings can also be considered as evidence of fetal  
9 distress [29, 56- 62]. In another study involving 262 deliveries, the fetal compromise was  
10 seen in 37 fetuses and an emergency caesarean section (CS) was done in 9 of them [23].  
11 Thus, the cumulative chance of fetal distress in pregnant women with a positive test for  
12 SARS-CoV-2 is 6.63%.  
13  
14  
15  
16

17 Premature rupture of membrane (PROM) was reported in 42 pregnancies from 13 studies  
18 and Preterm PROM was reported in (PPROM) in 14 pregnancies [24, 41, 42, 45, 50, 57,  
19 60, 63-70]. Intrauterine growth restriction (IUGR) was reported in 12 fetuses in 5 studies  
20 [24, 63, 65, 71, 72]. The highest number of IUGR fetuses was reported in 6 out of 10  
21 fetuses in another study [71]. Besides, small for gestational age was reported in another  
22 study in 2 out of 10 fetuses [57]. Chorioamnionitis was reported only in one study involving  
23 3 fetuses [5].  
24  
25  
26

#### 27 **Table-4: Fetal outcome- Supplemental material**

##### 28 **ii. Mode of delivery**

29  
30  
31 Mode of delivery was available for a total of 1311 out of which 8 were twin pregnancies.  
32 761 (60%) delivered by CS 506 (40%) by VD out of 1267 pregnancies in case series. In  
33 case reports, out of 44 deliveries, 25 were CS (56.8%) and 19 (43.2%) were VD bringing  
34 the percentage of CS to 59.9% and VD to 40.1% in the pooled data. [Table no-5]. Few  
35 studies in our data compared the CS in the SARS-CoV-2 positive pregnant women to  
36 negative controls comprising 122 CS in the positive group out of 233 and 650 CS in the  
37 control group out of 1562 in the pooled data. ODDs Ratio (OR) for CS in SARS-CoV-2  
38 positive mothers is 1.5421 [95% CI- 1.1701 to 2.0324] and P = 0.0021. which is  
39 statistically significant [26, 60, 66, 73].  
40  
41  
42

43 CS was the only mode of delivery in the majority of early published case reports as in the  
44 early days of the pandemic, elective CS delivery was the mode preferred by most of the  
45 countries for maternal indications [29, 30, 35, 44, 45, 48, 49, 51, 54, 55, 64, 74-84]. As  
46 the pandemic progressed, favorable outcomes were reported from vaginal delivery by  
47 many studies [50, 62, 72, 85- 87]. It was also demonstrated that the chances of the virus  
48 being present in the vaginal fluid is very remote. In the later and larger case series, CS  
49 deliveries were only done for obstetrical indications [26]. In a study involving 134  
50 deliveries, there were 67 CS and 67 vaginal deliveries. The rate of CS was not statistically  
51 different in women with positive SARS-CoV-2 as compared to negative pregnancies [26].  
52 In yet another study, there were significantly higher rates of CS deliveries in cases (14  
53 out of 16) as compared to the control group (57 out of 121) ( $p < 0.001$ ) but there was no  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 difference in the groups with regards to chronic illnesses or pregnancy complications [66].  
4 However, when done for maternal COVID-19 indications, the rate of cesarean was found  
5 to increase with the severity of the disease [25]. In another study, out of 41 CS deliveries,  
6 12 were for COVID-19 symptoms without other obstetrical indications [4 with severe  
7 symptoms and 8 with mild/moderate symptoms] [65].  
8  
9

10 In the largest study in the UK, the CS delivery was seen in 156 women and vaginal birth  
11 was seen in 106 women from a total of 262 births. The indications of CS were maternal  
12 compromise (27%), fetal compromise (24%), failed induction of labor or failure to progress  
13 (19%), other obstetric reasons (16%), prior CS (10%), and maternal request (4%) [23].  
14 Maternal COVID -19 related conditions were predominant indications in another larger  
15 study reporting CS for COVID-19 pneumonia in (33 out of 85), previous CS (16 out of 85),  
16 fetal distress (9 out of 85), and failure to progress in 5 out of 85 patients [24]. Many other  
17 studies similarly reported maternal condition requiring delivery as the commonest  
18 indication for CS [25, 28, 81].  
19  
20  
21  
22

### 23 **Table-5: Perinatal outcome (Pooled data)- Supplemental material**

#### 24 **iii. Preterm Delivery**

25  
26  
27 In our study, the outcome of preterm delivery was reported in a total of 43 studies involving  
28 1318 fetuses out of which 330 out of 1273 neonates in the case series and cohort (25.9%)  
29 and 19 out of 45 neonates in the case reports (42.2%) were delivered preterm. The  
30 pooled Preterm birth was seen in 26.4% of total births [Table no- 5]. However, the  
31 majority of them were elective deliveries to improve maternal respiratory conditions  
32 related to COVID-19. Spontaneous preterm delivery was only seen in 1.8% of neonates.  
33 The other indications included the preterm pre-labor rupture of membranes. In a  
34 substantial number of studies, data regarding the indications were not found. Few studies  
35 in our data compared the preterm delivery in the SARS-CoV-2 positive pregnant women  
36 to negative controls comprising of 52 preterm deliveries in the positive group out of 220  
37 and 267 preterm deliveries in the control group out of 1520 in the pooled data. ODDs  
38 Ratio (OR) for preterm delivery in SARS-CoV-2 positive mothers is 1.4526 [95% CI-  
39 1.0360 to 2.0366] and  $p = 0.0304$  [26, 60, 66].  
40  
41

42 In a study involving 134 deliveries in COVID -19 patients, preterm delivery was reported  
43 in 38 pregnancies with positive SARS-CoV-2 and 239 out of 836 SARS-CoV-2 negative  
44 deliveries, which was not significantly different [26]. A similar report was seen in another  
45 study where 4 preterm deliveries were seen out of 17 SARS-CoV-2 confirmed group as  
46 compared to 7 out of 121 in the control group [66]. In another study, out of a total of 25  
47 preterm deliveries, iatrogenic preterm delivery was done in 12 and 13 were spontaneous  
48 preterm deliveries [65].  
49  
50  
51

52 Furthermore, comparing the outcomes of COVID-19 pregnancies with different disease  
53 severity involving 181 pregnant women, preterm delivery was seen in 13 out of 123  
54 (10.6%), 14 out of 29 (48.3%), and 23 out of 29 (79.3%) in women with non-severe,  
55  
56  
57



1  
2  
3 oxygen-requiring, and critical COVID-19, respectively. Delivery before 32 weeks was  
4 highest in 48.3% of women in the critical COVID-19 group. In severe disease, urgent  
5 delivery is required to stabilize the maternal condition, even when it results in iatrogenic  
6 preterm delivery [25].  
7  
8

#### 9 iv. Birth weight

10  
11 In our review, birth weight was missing in many studies and only the mean weight of the  
12 babies was mentioned in some of the series. IUGR was reported in 4 studies in 11 babies  
13 [24, 63, 71, 72]. Also, SGA was found in 2 studies in 5 babies [41, 57]. A maximum of 6  
14 babies had IUGR in one study but they were described as mild [71].  
15  
16

#### 17 v. Miscarriage and stillbirth

18  
19 Stillbirth was seen in 13 fetuses in 8 studies in our review and seven were second-  
20 trimester miscarriages [23, 25, 26, 31, 40, 60, 69, 75] [Table no-5]. 3 intrauterine deaths  
21 were observed in one of the studies which reported maternal deaths due to COVID-19  
22 [75]. Similarly, we found 15 spontaneous miscarriages, and 4 induced miscarriages  
23 reported in 5 studies [23, 25, 26, 46, 68]. Induced miscarriages were done on maternal  
24 request in both studies [46, 68]. Among the spontaneous miscarriages, 6 were seen in  
25 141 pregnancies in one study and 5 in 181 pregnancies in another study [25, 26]. In one  
26 of the studies, there were 3 stillbirths. However, the causes of these 3 stillbirths reported,  
27 were not related to COVID-19 in the mother [23].  
28  
29  
30  
31

## 32 2.2 Neonatal Outcomes:

### 33 Table-6: Neonatal outcome- Supplemental material

#### 34 i. Neonatal symptoms

35  
36  
37  
38 The most common neonatal symptoms were respiratory problems reported as respiratory  
39 distress, shortness of breath, respiratory difficulty, dyspnea, and breathing problems [28,  
40 41, 52, 57- 59, 65, 70, 76, 78, 81, 82, 84]. Respiratory distress was the most common  
41 symptom reported in 14 neonates but the test for SARS-CoV-2 was positive in only 4  
42 neonates and negative in 8 [28, 41, 59, 65, 81, 82, 84]. Pneumonia was seen in 5  
43 neonates who were positive for SARS-CoV-2 and 4 neonates who were negative [41, 48,  
44 61, 64, 75]. Although usually respiratory symptoms are seen more in preterm babies due  
45 to pulmonary immaturity, in a single case report there were no neonatal complications in  
46 a SARS-CoV-2 positive mother who delivered a preterm baby at 29 weeks 5 days by  
47 emergency CS for maternal indications [88].  
48  
49  
50  
51

52 Diffuse bilateral granular and hazy opacities in chest radiograph and thickened lungs on  
53 x-ray were found in two neonates but the neonatal test for SARS-Cov-2 was negative in  
54 both of them [51, 84]. In another SARS-CoV-2 +ve, newborn chest X-ray was consistent  
55  
56  
57  
58  
59  
60

1  
2  
3 with pulmonary infection, 53 hours after birth [68]. In another study, neonatal symptoms  
4 are extensively described. The most common first clinical symptom in the neonates of  
5 SARS-CoV-2 Positive women was shortness of breath (n=6), followed by gastrointestinal  
6 symptoms like feeding intolerance, bloating, refusing milk, and gastric bleeding (n=4).  
7 Other symptoms included fever, rapid heart rate, and vomiting. Chest radiographic  
8 abnormalities included infections (n=4), neonatal respiratory distress syndrome (n=2),  
9 and pneumothorax (n=1). Another preterm baby suffered from frequent oxygenation  
10 fluctuations and thrombocytopenia and was cured 15 days later [57]. It was reported in  
11 yet another study that most of the complications in neonates were a result of prematurity  
12 (often iatrogenic) rather than SARS-CoV-2 infection [41]. Other presentations in SARS-  
13 CoV-2 positive neonates included fever, cyanosis, lethargy, irritability, poor feeding, axial  
14 hypertonias, opisthotonus, and feeding difficulties [29, 39, 41].

#### 19 20 ii. APGAR Score

21  
22 In our review, a total of 9 studies have reported a low APGAR score among babies born  
23 to SARS-CoV-2 positive mothers [26, 28, 29, 41, 61, 78, 82-84]. Seven of the neonates  
24 were very preterm or preterm and were SARS-CoV-2 negative. The APGAR score in  
25 these is likely to be due to pulmonary immaturity [26, 28, 29, 78, 82-84]. Two other babies  
26 were term deliveries and tested positive for SARS-CoV-2 [41, 61]. However, another  
27 study reported low APGAR scores of 0–3 in 2 babies of COVID positive mothers and 15  
28 babies in COVID negative mothers, indicating no statistically significant difference [26].

#### 31 32 iii. ICU admissions

33  
34 Admission to the neonatal ICU was done for various reasons. The majority of admissions  
35 were for observation and isolation. Neonates admitted due to complications of prematurity  
36 constitute another higher portion of the neonates. In a study, out of a total of 24 ICU  
37 admissions, it was found that 16 babies were admitted due to low birth weight, 2 for low  
38 APGAR score, and 6 others for other uncommon reasons like ABO incompatibility [26].  
39 In another study, it was found that rates of admission to ICU increased with the severity  
40 of the disease in the mother [25]. In our review, ICU admissions for suspected or  
41 confirmed neonatal sepsis was reported in 6 neonates out of which Enterobacter and  
42 Respiratory syncytial virus was found in 2 neonates. The culture was negative for 4 others  
43 [35,41,51,52,59,70].

#### 47 48 iv. Neonatal death

49  
50 Neonatal death was reported among 7 neonates in 5 studies [23-25, 57, 75]. It was  
51 unclear whether COVID-19 in mothers contributed to the deaths in 2 neonates in one of  
52 the studies [23]. In another study, neonatal death occurred in a preterm baby on the 9<sup>th</sup>  
53 day of life who was admitted with shortness of breath and moaning and later developed  
54



1  
2  
3 refractory shock, multiple organ failure and disseminated intravascular coagulation (DIC)  
4 [57]. The calculated neonatal death rate is 5.47 per 1000 live births. [Table-6]  
5

### 6 7 **3. Congenital anomaly:**

8 We could not find any studies describing structural anomalies in the fetus associated with  
9 COVID-19. Due to an evolving pandemic, the teratogenicity of the virus has not yet been  
10 explored adequately. However, in a few of the studies, the findings of anomaly scans  
11 during pregnancy were included and they did not show any difference between fetuses  
12 of SARS-CoV-2 positive and negative women [46, 57]. In two case reports, a multicystic  
13 dysplastic kidney was detected by antenatal ultrasound in one and after delivery in the  
14 other [36, 59]. In another study bilateral gliosis of the deep white periventricular and  
15 subcortical matter was detected in an 11 days old neonate born to SARS-CoV-2 positive  
16 mother by magnetic resonance imaging [29]. However, these cannot be attributed to  
17 SARS-CoV-2. Furthermore, autopsy finding in a stillborn baby born to COVID-19 mother  
18 did not show any abnormality in another report [40].  
19  
20  
21  
22

## 23 **DISCUSSION AND CONCLUSION**

24 We wanted to analyze the published evidence on the fetal perspective of COVID-19  
25 infection concerning mother to child transmission, perinatal outcome, and congenital  
26 anomalies through a systematic review.  
27  
28  
29

30 The present available data do not provide a clear conclusion into the fetal outcomes and  
31 its clinical implications. Few other reviews have explored the evidence of vertical  
32 transmission. There is varied positivity rate of different samples. The positivity of NP swab  
33 in this study is 3.67% which is in accordance with other reviews reporting 3.2% (22/936),  
34 2% (9/493), and 3.48% (3/86), respectively [89- 91]. In a couple of other reviews, however,  
35 the NP samples were negative [(0/113) and (0/9)] [92, 93]. No evidence of vertical  
36 transmission was found in other reviews [2, 94, 95].  
37  
38  
39

40 The placental sample was positive in our review in 11.7% of pregnancies. It is similar to  
41 the review by Kotlyar reporting 9.7% (3/31) sample positivity [89]. The placenta was  
42 extensively studied in another review where it was shown that there is a low likelihood of  
43 placental infection and vertical transmission of SARS-CoV-2 since the receptors and  
44 proteases, are only minimally expressed by the human placenta throughout pregnancy  
45 [96]. Placenta was also negative for 54 samples in another review [90].  
46  
47

48 Amniotic fluid collected before the rupture of membranes was positive in 6.8% of  
49 pregnancies in our review, in contrast to the review by Kotlyar (0/51) and Ashraf (1/16)  
50 [89, 91].  
51

52 The serological analysis was found in some studies within our review showing IgM  
53 positive results at birth indicating possible congenital transmission. Using the criteria by  
54 shah et al, we found that there is confirmed congenital transmission in 5 live-born  
55 neonates and 2 DCDA twins expelled at 24 weeks [14]. Similarly, the possible congenital  
56  
57  
58  
59  
60

1  
2  
3 transmission was found in 5 neonates and probable in 2 neonates. These analyses were  
4 not reported in earlier reviews involving more than 1300 pregnancies in total.

5  
6 The chance for CS is more in women with COVID-19 and in most instances for maternal  
7 indications. Preterm delivery is also high (26.4%) most commonly due to adverse  
8 maternal condition, although spontaneous preterm labor is low (1.8%). This is in  
9 accordance with another systematic review with regards to the indication but they found  
10 a trend towards spontaneous preterm labour [97]. In contrast, an earlier review reported  
11 6.4% of preterm deliveries as spontaneous [98].

12  
13 Fetal distress (6.63%) was the most common complication seen in the fetus followed by  
14 PROM and PPRM (4.27%) in our review. Similar findings were seen in other reviews  
15 [91, 94]. One earlier review did not report any fetal complications [92]. PPRM was  
16 reported in 14 pregnancies in our review. While PROM and PPRM are unlikely to  
17 contribute to mother to child transmission as the SARS-CoV-2 has not been positive in  
18 the vaginal swab, PPRM is a significant cause of preterm labor. Through our review, it  
19 was not possible to ascertain whether COVID-19 in mothers increases the risk for PROM.  
20 IUGR was reported in 12 fetuses in 5 studies (0.9%). IUGR can be multifactorial and need  
21 to be analyzed with the presence of maternal risk factors. SARS-CoV-2 has not been  
22 associated with IUGR and it was not possible to ascertain whether COVID-19 in mother  
23 increases the risk for IUGR in our study.

24  
25 The rates of stillbirth and neonatal death in our study were 9.9 and 5.46 respectively. In  
26 another study, it was found that stillbirth was significantly higher during the pandemic  
27 compared to the non-pandemic period due to reasons non-associated with COVID-19  
28 (difference, 6.93 [95% CI, 1.83-12.0] per 1000 births; P= .01) [99]. So it is unlikely that the  
29 stillbirth and neonatal death rate are increased in COVID-19 mothers. The symptoms  
30 when present in the infected neonates were most often mild and neonatal outcomes were  
31 found to be good [100, 101]. There is no reported teratogenicity or congenital anomalies  
32 associated with SARS-CoV-2 infection.

33  
34 The outcome so far is favorable for the fetus despite the risks to the mother for ICU  
35 admissions and mechanical ventilation seen in other studies [3]. Maternal outcomes were  
36 not explored in this study. There is no significant increase in preterm birth but there is a  
37 significantly increased risk of CS in mothers with COVID-19.

38  
39 Though the fetal perspective seems good in the case of maternal COVID-19, it will be  
40 reasonable to consider these findings with caution. Prospective studies and randomized  
41 control trials were missing from the evidence due to the recent nature of the infection.  
42 Therefore, larger and better quality studies are required to address the knowledge gaps  
43 and to reach at a definite guideline for management.

## 44 45 46 47 48 49 50 51 52 53 **Strengths and Limitations of the study**

1  
2  
3 There are many strengths to this study. The studies included in the review contained only  
4 confirmed maternal cases by RT-PCR and not the suspected cases or clinically  
5 diagnosed cases. The studies contained the results of neonatal testing. Studies included  
6 in this review were from countries across the world and not restricted to a specific region,  
7 making the findings from the study globally applicable. The case series/cohorts were  
8 chosen only when the total number of cases was more than 4. Moreover, various aspects  
9 of vertical transmission as well as fetal and neonatal outcomes were analyzed from the  
10 chosen studies.  
11  
12  
13

14 Nonetheless, there are many limitations to our study. Only a limited number of available  
15 case series and cohorts were included in this review as high-quality evidence involving a  
16 higher number of subjects is lacking due to the new kind of infection and still evolving  
17 nature of the pandemic. Almost all of the reports are retrospective reviews showing  
18 incomplete data with significant heterogeneity within the included studies with a chance  
19 of selection or recall bias. Different types of samples were used for the diagnosis of  
20 SARS-CoV-2 in different studies. Though nasopharyngeal swab was used for diagnosis  
21 in most studies, there were different types of kits used. Again the same kit may have  
22 different sensitivity and specificity in different types of samples. Universal testing of  
23 pregnant women was not done in many studies, resulting in missing fetal and perinatal  
24 effects in asymptomatic women. As maternal outcomes were not studied, the effects of  
25 the severity of maternal disease on the fetal outcomes could not be looked into.  
26  
27  
28  
29  
30

### 31 **Future Implications:**

32  
33 Whether there is an intrauterine infection of the fetus with respect to SARS-CoV-2 needs  
34 to be studied. What are the effects of intrauterine infection, whether there is different  
35 susceptibility at different stages of pregnancy, and whether susceptibility depends on  
36 disease severity in the mother, needs to be explored. Follow up studies are required to  
37 see long term effects of neonatal infection with SARS-CoV-2.  
38  
39  
40

### 41 **AUTHORSHIP STATEMENT**

42  
43 Manuscript title: **COVID-19 in pregnancy; The fetal perspective- a systematic review**  
44  
45

46 All persons who meet authorship criteria are listed as authors, and all authors certify that  
47 they have participated sufficiently in the work to take public responsibility for the content,  
48 including participation in the concept, design, analysis, writing, or revision of the  
49 manuscript. Furthermore, each author certifies that this material or similar material has  
50 not been and will not be submitted to or published in any other publication before its  
51 appearance in the BMJ Pediatrics-open access.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Authorship contributions**

**Conception and design of the study:** Rajani Dube, Subhranshu Sekhar Kar

**Acquisition of data:** Subhranshu Sekhar Kar, Rajani Dube

**Analysis and/or interpretation of data:** Subhranshu Sekhar Kar, Rajani Dube

**Drafting the manuscript:** Rajani Dube, Subhranshu Sekhar Kar

**Revising the manuscript critically for important intellectual content:** Rajani Dube, Subhranshu Sekhar Kar

**Approval of the version of the manuscript to be published (the names of all authors must be listed):** Subhranshu Sekhar Kar, Rajani Dube

**Acknowledgments- None**

Author's name

Rajani Dube

Subhranshu Sekhar Kar

**Disclaimer-** The views expressed in the submitted article are our own and not an official position of the institution or funder.

**Source(s) of support/Funding - None**

**Disclosure of relationships and activities-** Nothing to disclose

**Patient consent for publication-** not required

**Conflicts of interest-**None

**References:**

[1] Rasmussen SA, Smulian JC, Lednicky JA, *et al.* Coronavirus disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. *Am J Obstet Gynecol.* 2020;222:415–26. doi: [10.1016/j.ajog.2020.02.017](https://doi.org/10.1016/j.ajog.2020.02.017)

[2] Muhidin S, Behboodi Moghadam Z, Vizheh M. Analysis of Maternal Coronavirus Infections and Neonates Born to Mothers with 2019-nCoV; a Systematic Review. *Arch Acad Emerg Med.* 2020;8:e49. PMID: 32440660; PMCID: PMC7211430.

[3] Ellington S, Strid P, Tong VT, *et al.* Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United

1  
2  
3 States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:769–75. doi:  
4 <http://dx.doi.org/10.15585/mmwr.mm6925a1>

5  
6 [4] Rajewska A, Mikołajek-Bedner W, Lebdowicz-Knul J, *et al.* COVID-19 and  
7 pregnancy – where are we now? A review. *J. Perinat. Med.* 2020;48:428–34. doi:  
8 [10.1515/jpm-2020-0132](https://doi.org/10.1515/jpm-2020-0132)

9  
10 [5] Woodward A. A pregnant mother infected with the coronavirus gave birth, and her  
11 baby tested positive 30 hours later. Available at:  
12 [https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-](https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2)  
13 [mother-2020-2](https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2) Accessed June 15, 2020.

14  
15 [6] Collin J, Byström E, Carnahan A, *et al.* Public Health Agency of Sweden’s brief  
16 report: pregnant and postpartum women with SARS-CoV-2 infection in intensive care in  
17 Sweden. *Acta Obstet Gynecol Scand* 2020;99:819-22. doi: 10.1111/aogs.13901.

18  
19 [7] Rogan SC, Beigi RH. Treatment of viral infections during pregnancy. *J Perinatol*  
20 2019;46:235–56.  
21 doi: 10.1016/j.clp.2019.02.009.

22  
23 [8] Racicot K, Mor G. Risks associated with viral infections during pregnancy. *J Clin*  
24 *Invest* 2017;127:1591–9. doi: 10.1172/JCI87490

25  
26 [9] Lamouroux A, Bitach TA, Martinovic J, *et al.* Evidence for and against vertical  
27 transmission for severe acute respiratory syndrome coronavirus 2 (coronavirus disease  
28 2019). *Am J Obstet Gynecol* 2020;223:91.e1–91.e4. doi: 10.1016/j.ajog.2020.04.039

29  
30 [10] Li M, Chen L, Zhang J, *et al.* The SARS-CoV-2 receptor ACE2 expression of  
31 maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One.*  
32 2020;15:e0230295. <https://doi.org/10.1371/journal.pone.0230295>

33  
34 [11] Jing Y, Run-Qian L, Hao-Ran W, *et al.* Potential influence of COVID-19/ACE2 on  
35 the female reproductive system. *Mol Hum Reprod.* 2020;gaaa030,  
36 <https://doi.org/10.1093/molehr/gaaa030>.

37  
38 [12] Levy A, Bursztyn M, Barkalifa R, *et al.* ACE2 expression and activity are enhanced  
39 during pregnancy. *Am J Physiol Regul Integr Comp Physiol.* 2008;295:R1953-61. doi:  
40 10.1152/ajpregu.90592.2008.

41  
42 [13] Valdes G, Neves LA, Anton L, *et al.* Distribution of angiotensin-(1-7) and ACE2 in  
43 human placentas of normal and pathological pregnancies. *Placenta.* 2006;27:200-7. doi:  
44 10.1016/j.placenta.2005.02.015.

45  
46 [14] Shah PS, Diambomba Y, Acharya G, Morris SK, Bitnun A. Classification system and  
47 case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates.  
48 *Acta Obstet Gynecol Scand* 2020;99: 565-8. doi:10.1111/aogs.13870

49  
50 [15] Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in different types of clinical  
51 specimens. *JAMA* 2020;323:1843-4. doi:10.1001/jama.2020.3786



- 1  
2  
3 [16] Razaz N, Cnattingius S, Persson M, *et al.* One-minute and five-minute Apgar  
4 scores and child developmental health at 5 years of age: a population-based cohort  
5 study in British Columbia, Canada. *BMJ Open* 2019;9:e027655  
6 doi:10.1136/bmjopen-2018-027655  
7
- 8  
9 [17] Desai D, Chauhan K, Chaudhary S. A study of meconium stained amniotic fluid, its  
10 significance and early maternal and neonatal outcome. *Int J Reprod Contracept Obstet*  
11 *Gynecol.* 2013;2:190–3. doi: 10.5455/2320-1770.ijrcog20130616.  
12
- 13 [18] Ajah LO, Ibekwe PC, Onu FA, Onwe OE, Ezeonu TC, Omeje I. Evaluation of  
14 Clinical Diagnosis of Fetal Distress and Perinatal Outcome in a Low Resource Nigerian  
15 Setting. *J Clin Diagn Res.* 2016;10:QC08-11. doi:10.7860/JCDR/2016/17274.7687.  
16
- 17 [19] Royal College of Obstetricians and Gynaecologists.  
18  
19 [http:// www.rcog.org.uk/womens-health/investigation-and-managementsmall-](http://www.rcog.org.uk/womens-health/investigation-and-managementsmall-gestational-age-fetus-green-top-31)  
20 [gestational-age-fetus-green-top-31.](http://www.rcog.org.uk/womens-health/investigation-and-managementsmall-gestational-age-fetus-green-top-31) Published November 1,2002. Accessed 9 Oct 2020.  
21
- 22 [20] American College of Obstetricians and Gynecologists. Intrauterine growth  
23 restriction. Practice Bulletin no. 12, 2000, Washington DC. <http://www.acog.org>.  
24 Accessed 9 Oct 2020.  
25
- 26 [21] Abu-Zidan FM, Abbas AK, Hefny AF. Clinical "case series": a concept analysis. *Afr*  
27 *Health Sci.* 2012;12:557-62. PMID: 23515566; PMCID: PMC3598300.  
28
- 29 [22] Murad MH, Sultan S, Haffar S, *et al.* Methodological quality and synthesis of case  
30 series and case reports. *BMJEvidBasedMed* 2018;23:60–3.doi:10.1136/bmjebm-2017-  
31 110853.  
32
- 33 [23] Knight M, Bunch K, Vousden N, *et al.* Characteristics and outcomes of pregnant  
34 women hospitalized with confirmed SARS-CoV- 2 infection in the UK: a national cohort  
35 study using the UK Obstetric Surveillance System (UKOSS). *BMJ* 2020;369:m2107. doi:  
36 <https://doi.org/10.1136/bmj.m2107>  
37
- 38 [24] Yan J, Guo J, Fan C, *et al.* Coronavirus disease 2019 in pregnant women: a report  
39 based on 116 cases. *Am J Obstet Gynecol* 2020;223:111.e1- 14.  
40 doi:10.1016/j.ajog.2020.04.014.  
41
- 42 [25] Kayem G, Alessandrini V, Azria E, *et al.* A snapshot of the Covid-19 pandemic  
43 among pregnant women in France. *Journal of Gynecology Obstetrics and Human*  
44 *Reproduction.* 2020 :101826. doi: 10.1016/j.jogoh.2020.101826.  
45
- 46 [26] Nayak AH, Kapote DS, Fonseca M, *et al.* Impact of the Coronavirus Infection in  
47 Pregnancy: A Preliminary Study of 141 Patients. *J Obstet Gynecol India* 2020;70:256–  
48 61. <https://doi.org/10.1007/s13224-020-01335-3>  
49
- 50 [27] London V, McLaren Jr R, Atallah F, *et al.* The relationship between status at  
51 presentation and outcomes among pregnant women with covid-19. *Am J Perinatol*  
52 2020;37:991–94. doi: 10.1055/s-0040-1712164  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [28] Ferrazzi E, Frigerio L, Savasi V, *et al.* Vaginal delivery in SARS-CoV-2infected  
4 pregnant women in Northern Italy: a retrospective analysis. *BJOG*. 2020;127:1116-21.  
5 <https://doi.org/10.1111/1471-0528.16278>  
6
- 7 [29] Vivanti AJ, Vauloup-Fellous C, Prevot S, *et al.* Transplacental transmission of  
8 SARS-CoV-2 infection. *Nat Commun* 2020;11:3572. doi: 10.1038/s41467-020-17436-6  
9
- 10 [30] Zamaniyan M, Ebadi A, Aghajanpoor Mir S, *et al.* Preterm delivery, maternal death,  
11 and vertical transmission in a pregnant woman with COVID-19 infection [published  
12 online ahead of print, 2020 Apr 17]. *Prenat Diagn*. 2020;10.1002/pd.5713.  
13 doi:10.1002/pd.5713  
14
- 15 [31] Pulinx B, Kieffer D, Michiels I, *et al.* Vertical transmission of SARS-CoV-2 infection  
16 and preterm birth. *Eur J Clin Microbiol Infect Dis* 2020. [https://doi.org/10.1007/s10096-](https://doi.org/10.1007/s10096-020-03964-y)  
17 [020-03964-y](https://doi.org/10.1007/s10096-020-03964-y)  
18
- 19 [32] Hosier H, Farhadian S, Morotti RA, *et al.* First case of placental infection with SARS  
20 CoV-2. *medRxiv*. 2020; doi: <https://doi.org/10.1101/2020.04.30.20083907>  
21
- 22 [33] Baud D, Greub G, Favre G, *et al.* Second-trimester miscarriage in a pregnant  
23 woman with SARS-CoV-2 infection. *JAMA*. 2020;323:2198-2200.  
24 doi:10.1001/jama.2020.7233  
25
- 26 [34] Algarroba GN, Rekawek P, Vahanian SA, *et al.* Visualization of SARS-CoV-2 virus  
27 invading the human placenta using electron microscopy. *Am J Obstet Gynecol*.  
28 2020;223:275-78. doi: 10.1016/j.ajog.2020.05.023.  
29
- 30 [35] Kirtsman M, Diambomba Y, Poutanen S, *et al.* Probable congenital SARS-CoV-2  
31 infection in a neonate born to a woman with active SARS-CoV-2 infection. *CMAJ*. 628  
32 2020;192:E647-E5. doi: 10.1503/cmaj.200821.  
33
- 34 [36] Shanes ED, Mithal LB, Otero S, *et al.* Placental pathology in COVID-19. *Am J Clin*  
35 *Pathol*. 2020;154:23–32. doi: 10.1093/ajcp/aqaa089.  
36
- 37 [37] Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers:  
38 Preliminary Findings. *Pediatr Dev Pathol*. 2020;23:177-80.  
39 doi: [10.1177/1093526620925569](https://doi.org/10.1177/1093526620925569)  
40
- 41 [38] Mulvey JJ, Magro C, Ma LX, *et al.* Analysis of complement deposition and viral  
42 RNA in placentas of COVID-19 patients. *Ann Diagn Pathol*. 2020;46:151530. doi:  
43 10.1016/j.anndiagpath.2020.151530  
44
- 45 [39] Patane L, Morotti D, Giunta MS, *et al.* Vertical transmission of COVID-19: SARS-  
46 CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive  
47 mothers and neonates at birth. *AJOG-MFM*. 2020;100145. doi:  
48 10.1016/j.ajogmf.2020.100145  
49
- 50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 [40] Lokken EM, Walker CL, Delaney S, *et al.* Clinical characteristics of 46 pregnant  
4 women with as sars-cov-2 infection in Washington state. *Am J Obstet Gynecol* 2020.  
5 doi:10.1016/j.ajog.2020.05.031. [Epub ahead of print]  
6  
7 [41] Zeng L, Xia S, Yuan W, *et al.* Neonatal Early-Onset Infection With SARS-CoV-2 in  
8 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr.*  
9 2020;174:722-25. doi: 10.1001/jamapediatrics.2020.0878.  
10  
11 [42] Hu X, Gao J, Luo X, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2  
12 (SARS CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus  
13 Disease 2019 (COVID-19) Pneumonia. *Obstet Gynecol.*2020;136:65-67. doi:  
14 10.1097/AOG.0000000000003926.  
15  
16 [43] Peng Z, Wang J, Mo Y, *et al.* Unlikely SARS-CoV-2 vertical transmission from  
17 mother to child: A case report. *J Infect Public Health.* 2020;13:818-20.  
18 https://doi.org/10.1016/j.jiph.2020.04.004  
19  
20 [44] Li Y, Zhao R, Zheng S, *et al.* Early release - lack of vertical transmission of severe  
21 acute respiratory syndrome coronavirus 2, China. *Emerging Infectious Diseases*  
22 2020;26:1335-36. https://dx.doi.org/10.3201/eid2606.200287  
23  
24 [45] Chen H, Guo J, Wang C, *et al.* Clinical characteristics and intrauterine vertical  
25 transmission potential of COVID-19 infection in nine pregnant women: a retrospective  
26 review of medical records. *Lancet* 2020;395:809–815.  
27  
28 [46] Yin M, Zhang L, Deng G, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2  
29 (SARS CoV-2) Infection During Pregnancy In China: A Retrospective Cohort Study.  
30 medRxiv. 2020. doi.org/10.1101/2020.04.07.20053744.  
31  
32 [47] Wu Y, Liu C, Dong L, *et al.* Coronavirus disease 2019 among pregnant Chinese  
33 women: case series data on the safety of vaginal birth and breastfeeding. *BJOG.*  
34 2020;127:1109-15. doi:10.1111/1471-0528.16276 [Published online ahead of print,  
35 2020 May 5].  
36  
37 [48] Fan C, Lei D, Fang C, *et al.* Perinatal transmission of COVID-19 associated SARS-  
38 CoV-2: should we worry? *Clin Infect Dis.* 2020: ciaa226. [Published online 2020 Mar  
39 17]. doi: 10.1093/cid/ciaa226  
40  
41 [49] Song L, Xiao W, Ling K, *et al.* Anesthetic Management for Emergent Cesarean  
42 Delivery in a Parturient with Recent Diagnosis of Coronavirus Disease 2019 (COVID-  
43 19): A Case Report. *Transl Perioper & Pain Med* 2020; 7:234-7. doi: 10.31480/2330-  
44 4871/118  
45  
46 [50] Xiong X, Wei H, Zhang Z, *et al.* Vaginal delivery report of a healthy neonate born to  
47 a convalescent mother with COVID19. *J Med Virol.* 2020;10.1002/jmv.25857.  
48 doi:10.1002/jmv.25857. [E-pub ahead of print].  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [51] Wang S, Guo L, Chen L, *et al.* A case report of neonatal 2019 coronavirus disease  
4 in China. *Clin Infect Dis.* 2020;71:853-7. doi: 10.1093/cid/ciaa225.  
5  
6 [52] Groß R, Conzelmann C, Müller JA, *et al.* Detection of SARS-CoV-2 in human  
7 breastmilk. *Lancet.* 2020;395:1757–58. Published online 2020 May 21. doi:  
8 10.1016/S0140-6736(20)31181-8  
9  
10 [53] Buonsenso D, Costa S, Sanguinetti M, *et al.* Neonatal Late Onset Infection with  
11 Severe Acute Respiratory Syndrome Coronavirus 2. *Am J Perinatol.* 2020;37:869-72.  
12 doi: 10.1055/s-0040-1710541.  
13  
14 [54] Zeng H, Xu C, Fan J, *et al.* Antibodies in infants born to mothers with COVID-19  
15 pneumonia. *JAMA.* 2020;323:1848-9. doi:10.1001/jama.2020.4861  
16  
17 [55] Dong L, Tian J, He S, *et al.* Possible vertical transmission of SARS CoV- 2 from an  
18 infected mother to her newborn. *JAMA.* 2020;323:1846-8. doi:10.1001/jama.2020.4621  
19  
20 [56] Liu W, Wang Q, Zhang Q, *et al.* Coronavirus disease 2019 (COVID-19) during  
21 pregnancy: a case series. *Preprints.*2020 ;2020020373.  
22  
23 [57] Zhu H, Wang L, Fang C, *et al.* Clinical analysis of 10 neonates born to mothers with  
24 2019-nCoV pneumonia. *Transl Pediatr* 2020;9:51-60. doi: 10.21037/tp.2020.02.06  
25  
26 [58] Chen Y, Peng H, Wang L, *et al.* Infants born to mothers with a new coronavirus  
27 (COVID-19). *Front. Pediatr.* 2020;8:104. doi: 10.3389/fped.2020.00104  
28  
29 [59] Breslin N, Baptiste C, Gyamfi-Bannerman C, *et al.* COVID-19 infection among  
30 asymptomatic and symptomatic pregnant women: two weeks of confirmed  
31 presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol*  
32 *MFM.* 2020;2:100118. doi: 10.1016/j.ajogmf.2020.100118.  
33  
34 [60] Prabhu M, Cagino K, Matthews KC, *et al.* Pregnancy and postpartum outcomes in a  
35 universally tested population for SARS-CoV-2 in New York City: a prospective cohort  
36 study. *BJOG* 2020; <https://doi.org/10.1111/1471-0528.16403>. 00: 1– 9.  
37  
38 [61] Govind A, Essien S, Karthikeyan A, *et al.* Re: Novel Coronavirus COVID-19 in late  
39 pregnancy: Outcomes of first nine cases in an inner city London hospital. *Eur J Obstet*  
40 *Gynecol Reprod Biol.* 2020;251: 272–74. doi:10.1016/j.ejogrb.2020.05.004.  
41  
42 [62] Lowe B, Bopp B. COVID 19 vaginal delivery - A case report. *Aust N Z J Obstet*  
43 *Gynaecol.* 2020;60:465-6. <https://doi.org/10.1111/ajo.13173>  
44  
45 [63] Pierce-Williams RAM, Burd J, Felder L, *et al.* Clinical course of severe and critical  
46 COVID-19 in hospitalized pregnancies: a US cohort study. *Am J Obstet Gynecol MFM.*  
47 2020 May 8;100134. doi: 10.1016/j.ajogmf.2020.100134.  
48  
49 [64] Khan S, Jun L, Siddique R, *et al.* Association of COVID-19 with pregnancy  
50 outcomes in health-care workers and general women. *Clin Microbiol Infect.*  
51 2020;26:788-90. doi: 10.1016/j.cmi.2020.03.034  
52  
53  
54  
55  
56
- 
-

1  
2  
3  
4 [65] Martínez-Perez O, Vouga M, Cruz Melguizo S, et al. Association between mode of  
5 delivery among pregnant women with COVID-19 and maternal and neonatal outcomes  
6 in Spain. *JAMA*. 2020. <https://doi.org/10.1001/jama.2020.10125> .  
7

8  
9 [66] Li N, Han L, Peng M, et al. Maternal and neonatal outcomes of pregnant women  
10 with COVID-19 pneumonia: a case-control study. *Clinical Infectious Diseases* 2020. doi:  
11 10.1093/cid/ciaa352  
12

13 [67] Cao D, Yin H, Chen J, et al. Clinical analysis of ten pregnant women with COVID-  
14 19 in Wuhan, China: A retrospective study. *Int J Infect Dis*. 2020;95:294-300.  
15 <https://doi.org/10.1016/j.ijid.2020.04.047>.  
16

17  
18 [68] Nie R, Wang S, Qiong Y, et al. Clinical features and the maternal and neonatal  
19 outcomes of pregnant women with coronavirus disease 2019. medRxiv. 2020; doi:  
20 <https://doi.org/10.1101/2020.03.22.20041061>  
21

22  
23 [69] Liu Y, Chen H, Tang K, et al. Clinical manifestations and outcome of SARS-CoV-2  
24 infection during pregnancy. *J Infect*.2020. doi: 10.1016/j.jinf.2020.02.028. Online ahead  
25 of print.  
26

27 [70] Sisman J, Jaleel M, Moreno W, et al. Intrauterine transmission of SARS-CoV-2  
28 infection in a preterm infant. *Pediatr Infect Dis J*. 2020.  
29 <https://doi.org/10.1097/inf.0000000000002815>.  
30

31  
32 [71] Doria M, Peixinho C, Laranjo M, et al. Covid-19 during pregnancy: a case series  
33 from an universally tested population from the north of Portugal. *Eur J Obstet Gynecol*  
34 *Reprod Biol*. 2020;250:261-2. doi: 10.1016/j.ejogrb.2020.05.029. Epub 2020 May 15.  
35

36 [72] Perrone S, Deolmi M, Giordano M, et al. Report of a series of healthy term  
37 newborns from convalescent mothers with COVID-19. *Acta Bio Med [Internet]*.  
38 2020;91:251-5. Available from:  
39 <https://mattioli1885journals.com/index.php/actabiomedica/article/view/9743>  
40

41  
42 [73] Yang H, Sun G, Tang F, et al. Clinical features and outcomes of pregnant women  
43 suspected of coronavirus disease 2019. *J Infect*. 2020;81:e40-e44. .  
44 doi: [10.1016/j.jinf.2020.04.003](https://doi.org/10.1016/j.jinf.2020.04.003)  
45

---

---

46  
47  
48  
49 [74] Lyra J, Valente R, Rosario M, et al. Cesarean Section in a Pregnant Woman with  
50 COVID- 19: First Case in Portugal. *Acta Medica Portuguesa*. 2020;33:429-31.  
51 <https://doi.org/10.20344/amp.13883>  
52

53 [75] Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, et al. Maternal death due to  
54 COVID-19 disease. *Am J Obstet Gynecol*. 2020; 223: 109.e1–109.e16. Published  
55 online 2020 Apr 28. doi: 10.1016/j.ajog.2020.04.030  
56  
57

- 1  
2  
3  
4 [76] Gidlöf S, Savchenko J, Brune T, et al. CO-VID-19 in pregnancy with comorbidities:  
5 more liberal testing strategy is needed. *Acta Obstet Gynecol Scand.* 2020;99:948-9. doi:  
6 10.1111/aogs.13862. Epub 2020 Apr 17.
- 7  
8 [77] Wang X, Zhou Z, Zhang J, et al. A Case of 2019 Novel Coronavirus in a Pregnant  
9 Woman With Preterm Delivery. *Clin Infect Dis.* 2020;71:844-6. doi:10.1093/cid/ciaa200  
10  
11 [78] Alzamora MC, Paredes T, Caceres D, et al. Severe COVID-19 during Pregnancy  
12 and Possible Vertical Transmission. *Am J Perinatol* 2020;37:861–5. doi: 10.1055/s-  
13 0040-1710050.
- 14  
15 [79] Kalafat E, Yaprak E, Cinar G, et al. Lung ultrasound and computed tomographic  
16 findings in pregnant woman with COVID-19. *Ultrasound Obstet Gynecol.* 2020;55: 835-  
17 7. <https://doi.org/10.1002/uog.22034>
- 18  
19 [80] Lee DH, Lee J, Kim E, et al. Emergency cesarean section on severe acute  
20 respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed patient. *Korean J*  
21 *Anesthesiol.* 2020;73:347-51. doi: 10.4097/kja.20116.
- 22  
23 [81] Yang P, Wang X, Liu P, et al. Clinical characteristics and risk assessment of  
24 newborns born to mothers with COVID-19. *J Clin Virol.* 2020;127:104356. doi:  
25 10.1016/j.jcv.2020.104356.
- 26  
27 [82] Romagano MP, Guerrero K, Spillane N, et al. Perinatal outcomes in critically ill  
28 pregnant women with covid-19. *Am J Obstetr Gynecol MFM.* 2020; 100151.  
29 <https://doi.org/10.1016/j.ajogmf.2020.100151>
- 30  
31 [83] Cooke WR, Billett A, Gleeson S, et al. SARS-CoV-2 infection in very preterm  
32 pregnancy: experiences from two cases. *Eur J Obstet Gynecol Reprod Biol.*  
33 2020;250:259–60. Published online 2020 May 15. doi: 10.1016/j.ejogrb.2020.05.025
- 34  
35 [84] Blauvelt CA, Chiu C, Donovan AL, et al. Acute Respiratory Distress Syndrome in a  
36 Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol.*  
37 2020;136:46-51. doi:10.1097/AOG.0000000000003949
- 38  
39 [85] Khan S, Peng L, Siddique R, et al. Impact of COVID-19 infection on pregnancy  
40 outcomes and the risk of maternal-to-neo-natal intrapartum transmission of COVID-19  
41 during natural birth. *Infect Control Hosp Epidemiol.* 2020;41:748-50.  
42 doi: [10.1017/ice.2020.84](https://doi.org/10.1017/ice.2020.84)
- 43  
44 [86] Huang JW, Zhou XY, Lu SJ, et al. Dialectical behavior therapy-based psy-  
45 chological intervention for woman in late pregnancy and early postpartum suffering  
46 from COV-ID-19: a case report. *J Zhejiang Univ Sci B.* 2020; 21(5):394-9.  
47 doi: [10.1631/jzus.B2010012](https://doi.org/10.1631/jzus.B2010012)
- 48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [87] Zambrano L, Fuentes-Barahona I, Bejarano-Torres D, *et al.* A pregnant woman with  
4 COVID-19 in Central America. *Travel Med Infect Dis.* 2020;101639. doi:  
5 10.1016/j.tmaid.2020.101639. Online ahead of print.  
6  
7 [88] González Romero D, Ocampo Pérez J, González Bautista L, *et al.* Pronóstico  
8 perinatal y de la paciente embarazada con infección por COVID-19. *Rev Clin Esp.*  
9 2020. doi: 10.1016/j.rceng.2020.04.005 [Epub ahead of print]  
10  
11 [89] Kotlyar A, Grechukhina O, Chen A, *et al.* Vertical Transmission of COVID-19: A  
12 Systematic Review and Meta-analysis. *American Journal of Obstetrics and Gynecology*  
13 2020, S0002-9378(20)30823-1. [Advance online publication].  
14 <https://doi.org/10.1016/j.ajog.2020.07.049>.  
15  
16 [90] Lopes de Sousa AF, Félix de Carvalho HE, Braz de Oliveira L, *et al.* Effects of  
17 COVID-19 Infection during Pregnancy and Neonatal Prognosis: What Is the Evidence?  
18 *Int. J. Environ. Res. Public Health* 2020;17:4176. doi:10.3390/ijerph17114176.  
19 Available at [www.mdpi.com/journal/ijerph](http://www.mdpi.com/journal/ijerph)  
20  
21 [91] Ashraf MA, Keshavarz P , Hosseinpour P, *et al.* Coronavirus Disease 2019  
22 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical  
23 Transmission. *J Reprod Infertil.* 2020;21:157-68.  
24  
25 [92] J.Juan, Gil M M , Rong Z *et al* Effect of coronavirus disease 2019 (COVID-19) on  
26 maternal, perinatal and neonatal outcome: systematic review. *Ultrasound Obstet*  
27 *Gynecol* 2020;56:15–27 Published online in Wiley Online Library  
28 ([wileyonlinelibrary.com](http://wileyonlinelibrary.com)). DOI: 10.1002/uog.22088.  
29  
30 [93] Irani M, Pakfetrat A,Mask MK. Novel coronavirus disease 2019 and perinatal  
31 outcomes. *J Edu Health Promot* 2020;9:78.  
32  
33 [94] Akhtar H, Patel C, Abuelgasim E, Harky A: COVID-19 (SARS-CoV-2) Infection in  
34 Pregnancy: A Systematic Review. *Gynecol Obstet Invest* 2020;85:295-306. doi:  
35 10.1159/000509290  
36  
37 [95] Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, *et al.* Vertical Transmission of  
38 Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A  
39 Review, *Fetal and Pediatric Pathology.*2020;39:246-50, DOI:  
40 10.1080/15513815.2020.1747120  
41  
42 [96] Pique-Regi R, Romero R, Tarca A, *et al.* Does the human placenta express the  
43 canonical cell entry mediators for SARS-CoV-2? *eLife* 2020;9:e58716 doi:  
44 10.7554/eLife.58716  
45  
46 [97] Gatta AND, Rizzo R, Pilu G, *et al.* Coronavirus disease 2019 during pregnancy: a  
47 systematic review of reported cases. *Am J Obstet Gynecol.* 2020;223: 36–41. doi:  
48 10.1016/j.ajog.2020.04.013  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 [98] Huntley BJF, Huntley ES, Di Mascio D, *et al.* Rates of Maternal and Perinatal  
4 Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute  
5 Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review.  
6 *Obstet Gynecol.* 2020;136:303-12. doi: 10.1097/AOG.0000000000004010. PMID:  
7 32516273.  
8  
9  
10 [99] Khalil A, Von Dadelszen P, Draycott T, *et al.* Change in the Incidence of Stillbirth  
11 and Preterm Delivery During the COVID-19 Pandemic. *JAMA.* 2020;324:705-6;  
12 Available at <https://jamanetwork.com/> on 10/11/2020  
13  
14 [100] Wei M, Yuan J, Liu Y, *et al.* Novel Coronavirus Infection in Hospitalized Infants  
15 Under 1 Year of Age in China. *JAMA.* 2020;323:1313–4. doi:10.1001/jama.2020.2131  
16  
17 [101] Dumpa V, Kamity R, Vinci AN, *et al.* Neonatal coronavirus 2019 (COVID-19)  
18 infection: a case report and review of literature. *Cureus* 2020;2019. e8165.  
19 doi:10.7759/cureus.8165  
20  
21  
22 [102] Zhang I, Jiang Y, Wei M, *et al.* Analysis of the pregnancy outcomes in pregnant  
23 women with COVID-19 in Hubei Province [in Chinese]. *Zhonghua Fu Chan Ke Za Zhi.*  
24 2020;55:166-71. doi: 10.3760/cma.j.cn112141-20200218-00111.  
25  
26 [103] Penfield CA, Brubaker SG, Limaye MA, *et al.* Detection of SARS-CoV-2 in  
27 placental and fetal membrane samples. *Am J Obstet Gynecol MFM.* 2020;2:100133.  
28 <https://doi.org/10.1016/j.ajogmf.2020.100133>  
29  
30  
31 [104] Chen S, Chen S, Huang B, *et al.* Pregnant women with new coronavirus infection:  
32 a clinical characteristics and placental pathological analysis of three cases. *Zhonghua*  
33 *Bing Li Xue Za Zhi.* 2020;49:418-23. doi: 10.3760/cma.j.cn112151-20200225-00138.  
34  
35 [105] Iqbal SN, Overcash R, Mokhtari N, *et al.* An uncomplicated delivery in a patient  
36 with COVID-19 in the United States. *N Engl J Med* 2020;382:e34. doi:  
37 10.1056/NEJMc2007605  
38  
39 [106] Liao X, Yang H, Kong J, *et al.* Chest CT findings in a pregnant patient with 2019  
40 novel corona-virus disease. *Balkan Med J.* 2020;37:226-8.  
41  
42 [107] Qiancheng X, Jian S, Lingling P, *et al.* sixth batch of Anhui medical team aiding  
43 Wuhan for COVID-19. *Coronavirus disease 2019 in pregnancy.* *Int J Infect Dis.*  
44 2020;95:376-83. doi: 10.1016/j.ijid.2020.04.065.  
45  
46 [108] Yu N, Li W, Kang Q, *et al.* No SARS-CoV-2 detected in amniotic fluid in mid-  
47 pregnancy. *The Lancet Infectious Diseases* 2020;S1473-3099(20)30320-0. doi:  
48 10.1016/S1473-3099(20)30320-0  
49  
50 [109] Savasi VM, Parisi F, Patane L, *et al.* Clinical findings and disease severity in  
51 hospitalized pregnant women with coronavirus disease 2019 (covid-19). *Obstet*  
52 *Gynecol.* 2020;136:252-8. doi: 10.1097/AOG.0000000000003979.  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 [110] Schnettler WT, Al Ahwel Y, Suhag A. Severe acute respiratory distress syndrome  
4 in coronavirus disease 2019–infected pregnancy: obstetric and intensive care  
5 considerations. *AJOG-MFM* 2020. doi.org/10.1016/j.ajogmf.2020.100120.  
6

7 [111] Lang G, Zhao H. Can SARS-CoV-2-infected women breastfeed after viral  
8 clearance? *J Zhejiang Univ Sci B*. 2020;12:405-7. doi: 10.1631/jzus.B2000095  
9

10 [112] Buonsenso D, Raffaelli F, Tamburrini E, *et al*. Clinical role of lung ultrasound for  
11 the diagnosis and monitoring of COVID19 pneumonia in pregnant women [published  
12 online ahead of print, 2020 Apr 26]. *Ultrasound Obstet Gynecol*.  
13 2020;10.1002/uog.22055. doi:10.1002/uog.22055.  
14  
15

16 [113] Vintzileos WS, Muscat J, Hoffmann E, *et al*. Screening all pregnant women  
17 admitted to labor and delivery for the virus responsible for coronavirus disease 2019.  
18 *Am J Obstet Gynecol*. 2020;223:284-6. doi: 10.1016/j.ajog.2020.04.024.  
19  
20

21 [114] Breslin N, Baptiste C, Miller R, *et al*. COVID-19 in pregnancy: early lessons. *Am J*  
22 *Obstet Gynecol MFM*. 2020;2:100111. <https://doi.org/10.1016/j.ajogmf.2020.100111>  
23


24 [115] Qadri F, Mariona F. Pregnancy affected by SARS-COV-2 infection: a flash report  
25 from Michigan. *J Matern Fetal Neonatal Med*.2020:13.  
26 doi:10.1080/14767058.2020.1765334  
27

28 [116] Sentilhes L, De Marcillac F, Jouffrieau C, *et al*. Coronavirus disease 2019 in  
29 pregnancy was associated with maternal morbidity and preterm birth. *Am J Obstet*  
30 *Gynecol*. 2020. doi: [10.1016/j.ajog.2020.06.022](https://doi.org/10.1016/j.ajog.2020.06.022) [Epub ahead of print]  
31


32 [117] Kulkarni R, Rajput U, Dawre R, *et al*. Early-onset symptomatic neonatal COVID-19  
33 infection with high probability of vertical transmission. *Infection* (2020).  
34 <https://doi.org/10.1007/s15010-020-01493-6>  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



### PRISMA 2009 Flow Diagram- Mother to child transmission



**Figure-2 PRISMA 2009 Flow Diagram- Perinatal outcome**



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table-1 (a): Analysis of the studies [Case series/ Cohort]**

Serial number	Author (reference)	Number of pregnancies	Country	Outcomes included	Selection Contains diagnosed COVID-19 in Pregnancy	Comparability Data on pregnant women and fetus available	Outcome; Assessment and reporting	Evidence of mother to child transmission	Perinatal Outcome
1.	Chen H et al (45)	9	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
2.	Zeng H et al (54)	6	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
3.	Zhu H et al (57)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
4.	Zhang I et al (102)	61	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
5.	Penfield CA et al (103)	11	China	Placental, membrane and neonatal samples	****		**	√	
6.	Liu Y et al (69)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
7.	Khan S et al (64)	17	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
8.	Zeng L et al (41)	33	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
9.	Qiancheng X et al (107)	23	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
10.	Yang P et al (81)	7	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
11.	Yang H et al (73)	55	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	*	*	√	√

12.	Wu Y et al (47)	13	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	*	*	√	
13.	Yan J et al (24)	116	China	pregnancy and neonatal outcomes	****	**	***		√
14.	Li N et al (66)	16	China	Symptoms, maternal outcomes, neonatal outcomes	****	**	***		√
15.	Cao D et al (67)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
16.	Yin M et al (46)	31	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
17.	Hu X et al (42)	7	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
18.	Nie R et al (68)	33	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
19.	Patane L et al (39)	22	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
20.	Ferrazzi E et al (28)	42	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
21.	Savasi V et al (109)	77	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
22.	Mulvey J et al (38)	5	US	Placental characteristics	***			√	
23.	Vintzileos W et al (113)	32	US	Symptoms, maternal characteristics, Test results	***	*	***	√	
24.	Breslin N et al (59)	18	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
25.	Baergen R et al (37)	20	US	Maternal characteristics, maternal outcomes, Placental characteristics	***			√	

26.	Williams R et al (63)	64	US	Maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
27.	Shanes E et al (36)	16	US	Symptoms, maternal characteristics, Placental pathology, pregnancy and neonatal outcomes	****	**	***	√	√
28.	Breslin N et al (114)	7	US	Symptoms, maternal characteristics, test result	**	**	**	√	
29.	London V et al (27)	68	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
30.	Lokken E et al (40)	46	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***		√
31.	Qadri F et al (115)	16	US	Maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	_*		√
32.	Prabhu M et al (60)	70	US	Symptoms, obstetric and neonatal outcomes, and placental pathology	****	**	***	√	√
33.	Romano M et al (82)	7	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	*		√
34.	Govind A et al (61)	9	UK	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
35.	Knight M et al (23)	427	UK	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
36.	Sentilhes, et al (116)	38	France	Symptoms, maternal outcomes, neonatal outcomes	****	**	***	√	√
37.	Kayem G et al (25)	617	France	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
38.	Nayak A et al (26)	141	India	Symptoms, maternal outcomes, neonatal outcomes	****	**	***		√
39.	Hantoushzadeh et al (75)	7	Iran	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√



40.	Perez O et al (65)	82	Spain	Symptoms, maternal characteristics, pregnancy outcomes	****	**	**	√	√
41.	Doria M et al (48)	10	Portugal	Symptoms, maternal characteristics, pregnancy outcomes	****	**	*		√

**Table-1 (b): Analysis of the studies [Case reports]**

Serial number	Author (reference)	Number of pregnancies	Country	Outcomes included	Selection Contains diagnosed COVID-19 in Pregnancy	Comparability Data on pregnant women and fetus available	Outcome; Assessment and reporting	Evidence of vertical transmission	Perinatal Outcome
1.	Alzamora et al (78)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
2.	Li Y et al (44)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
3.	Dong L et al (55)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
4.	Liao X et al (106)	1	China	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
5.	Wang X et al (77)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
6.	Huang J et al (86)	1	China	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
7.	Xiong X et al (50)	1	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
8.	Wang S et al (51)	1	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
9.	Song L et al (49)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
10.	Fan C et al (48)	2	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√

11.	Chen Y et al (58)	4	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
12.	Peng Z et al(43)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
13.	Liu W et al (56)	3	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
14.	Chen S et al (104)	3	China	Symptoms, laboratory parameters, pregnancy outcomes, samples	****	**	***	√	√
15.	Khan S et al (85)	3	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
16.	Yu N et al (108)	2	China	Symptoms, maternal characteristics, amniotic fluid in mid pregnancy	****	*	*	√	
17.	Schnettler W et al (110)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcome	****	**	**	√	
18.	Blauvelt C et al (84)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
19.	Iqbal S et al (105)	1	US	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
20.	Algorroba et al (34)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcome	***	*	*	√	
21.	Hosier H et al(32)	1	US	Symptoms, maternal characteristics, test result	****	**	**	√	
22.	Sisman J et al (70 )	1	US	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
23.	Kalafat E et al (79)	1	Turkey	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
24.	Kirtsman M et al (35)	1	Canada	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√

25.	Lyra J et al (74)	1	Portugal	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
26.	Buonsenso et al (53)	4	Italy	Symptoms, maternal findings, test results	****	*	**	√	
27.	Perrone S et al (72)	4	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
28.	Buonsenso D et al (112)	2	Italy	Maternal characteristics, Samples for detection	****	**	*	√	
29.	Groß R et al (52)	2	Germany	Symptoms, maternal findings, test results	****	*	*	√	
30.	Cooke W et al (83)	2	UK	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	_*		√
31.	Pulinx B et al (31)	2	Belgium	Symptoms, maternal characteristics, laboratory parameters, second trimester miscarriage	****	*	*	√	
32.	Lee D et al (80)	1	Korea	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
33.	Gidlöf S et al (76)	2	Sweden	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
34.	Baud D et al (33)	1	Switzerland	Symptoms, maternal characteristics, laboratory parameters, second trimester miscarriage	****	*	*	√	
35.	Zamaniyan M et al (30)	1	Iran	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
36.	Zambrano L et al (87)	1	Central America	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
37.	Vivanti A et al (29)	1	France	Symptoms, maternal outcomes, neonatal outcomes	****	**	***	√	√
38.	Lowe B et al (62)	1	Australia	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√

39.	Kulkarni et al (117)	1	India	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
-----	----------------------	---	-------	---	------	----	-----	---	---

**Selection-** \* Representativeness of the patients \*Ascertained exposure to SARS-CoV-2 \*Ascertained outcome- Symptoms of COVID-19 in the mother \* Ruling out other causes- Test result of mother positive [\*\*\*\*-Contains all 4 components; \*\*\*-Contains first 3 out of 4 components; \*\*- Contains first 2 out of 4 components;\*- Contains first 1 out of 4 components]

**Comparability-** Data on both mother and fetus available [\*\*- Both maternal and fetal data available; \*- Only maternal data available ]

**Outcome-** \* Evidence of mother to fetal/neonatal transmission, \* Evidence of Fetal outcome, \*Evidence of neonatal outcome [\*\*\*-Contains all 3 components; \*\*- Contains first 2 out of 3 components;\*- Contains first 1 out of 3 components]

√- Included in analysis of mother to fetal/neonatal transmission or included in analysis of perinatal outcome or both

**Table -2 Studies and type of samples**

	Author (reference)	Number of neonates tested	Specimen tested	Results- neonatal and others	Positive/ Total tested
1.	Chen H et al (45)	6	NP, AF, Cord blood, BM	Negative	
2.	Cao et al (67)	5	NP	Negative	
3.	Hu X et al (42)	7	NP, Urine, AF	NP +ve at 36 hours, others negative	1/7
4.	Zhu H et al (57)	10	NP	Negative [Within 72 hours (8); Between D7-D9 (2)]	
5.	Zhang I et al (102)	10	NP	Negative	
6.	Penfield C et al (103)	11	NP, Placental and membrane	NP- Negative (D1 and D5) Placenta and membrane +ve	3/11
7.	Knight M et al (23)	262	NP (n=244) ,Blood or aspirate	+ve at <12 hours +ve at >12 hours	6/244 6/244
8.	Kayem G et al (25)	181	NP	+ve	2/181
9.	Nayak A et al (26)	134	NP (n=131)	+ve on D1 -ve on D5	3/131
10.	Yan J et al (24)	86	NP (n=86); Cord blood (n=10),AF (n=10)	Negative	
11.	Khan S et al (64)	17	NP	+ve within 24 hours	2/17
12.	Zeng L et al (41)	33	NP , anal swab	Both +ve D2 and D4, negative on D6	3/33
13.	Breslin N et al (59)	18	NP	Negative	
14.	Breslin N et al (114)	7	NP	Negative	
15.	Qiancheng X et al (107)	23	NP	Negative	
16.	Prabhu M et al (60)	71	NP	Negative at 24 hours	
17.	Shanes E et al (36)	16	NP , Placenta	Negative	
18.	Savasi V et al (109)	57	NP	+ve	4/57
19.	London V et al (27)	48	NP	Negative	
20.	William R et al (63)	33	NP	Negative at 24 hours, +ve at 48 hours	1/33

21.	Perez O et al (65)	82	NP	NP +ve at birth and negative at 48 hours (3); NP negative at birth but +ve at D10 (2)	5/82
22.	Nie R et al (68)	26	NP, Cord blood, Placenta	NP +ve at 36 hours Negative - All other samples, NP (D4, D8,D15)	1/26
23.	Yin M et al (46)	17	NP (n=17), BM (n=14), AF (n=2), placenta (n=2), Anal swab (n=5)	Negative	
24.	Yang P et al(81)	7	NP , Cord blood, AF	Negative	
25.	Yang H et al (73)	55	NP	Negative	
26.	Wu Y et al (47)	5	NP , Anal swab, BM	Negative, BM +ve	1/5
27.	Patane L et al (39)	22	NP , Placenta	NP +ve , Placenta- Chronic intervillitis, PCR +ve in placenta	2/22
28.	Ferrazzi E et al (28)	42	NP	NP +ve on D1,D3(2) NP equivocal at birth but +ve on D3(1)	3/42
29.	Govind A et al (61)	9	NP , Placenta, AF	NP +ve	1/9
30.	Vintzileos W et al (113)	29	NP	Negative	
31.	Baergen R et al (37)	21	NP	Negative	
32.	Zeng H et al (54)	6	NP Neonatal blood	NP negative; Elevated IgM and IgG (2); Elevated IgG ,normal IgM (3)	Cytokine IL-6 elevated in all infants
33.	Liu Y et al (69)	10	Fetal blood	Negative	
34.	Mulvey J et al (38)	5	Placenta	Negative	
35.	Hantoushzadeh et al (75)	4	NP	Negative at D1; +ve at D7	1/4
36.	Buonsenso et al (53)	2	NP,AF, Placenta, Cord blood, Rectal swab, BM	1 <sup>st</sup> - NP Negative on D1,D4 and +ve on D15 , Placenta, AF, rectal swab- Negative, Weak IgG+ve, IgM negative 2 <sup>nd</sup> - Placenta, Breast milk- +ve but cord blood negative in neonate with NP negative result	1/2
37.	Fan C et al (48)	2	NP, AF, Cord blood, BM, Placenta , Vaginal swab	Negative	
38.	Liu W et al (56)	3	NP, Cord blood, Neonatal whole blood	Negative (D2)	
39.	Lowe B et al (62)	1	NP	Negative	
40.	Chen S et al (104)	3	NP, Placenta	Negative	
41.	Chen Y et al (58)	4	NP	Negative	
42.	Gidlöf S et al (76)	2	NP	Negative (34 hours and 4.5 days)	
43.	Khan S et al (85)	3	NP	Negative	
44.	Schnettler W et al (110)	1	NP, AF	AF Negative, NP negative on D1,D2	

45.	Blauvelt C et al (84)	1	NP, Rectal swab D2 Ig G and IgM	NP Negative on D1, D2, D14 Rectal swab negative on D2 Ig G and IgM negative (D5)	
46.	Alzamora M et al (78)	1	NP, Cord blood	Negative for IgM and IgG; NP +ve at 16 hours and 48hours	1/1
47.	Vivanti A et al (29)	1	NP, AF, Vaginal swab, NBAL, Neonatal blood and rectal swabs	NP +ve at 1hour, D3, D18; Rectal swab +ve at 1hour, D3, D18; Vaginal swab, NBAL, Neonatal blood, AF +ve,	1/1
48.	Song L et al (49)	1	NP, AF, Cord blood, BM	NP negative at D3,D7 All other negative	
49.	Zambrano L et al (87)	1	NP	Negative	
50.	Li Y et al (44)	1	NP, Neonatal Blood, feces, and urine	NP negative at birth and 48h All other negative	
51.	Dong L et al (55)	1	NP, Serum Vaginal swab	IgM level elevated NP negative at 2h,16h	1/1
52.	Baud D et al (33)	1	NP, AF, Placenta Vaginal swabs	Placenta +ve All other negative	1/1; 2 <sup>nd</sup> trimester spontaneous miscarriage
53.	Wang X et al (77)	1	NP, AF, Placenta, Cord blood, gastric juice, feces	NP negative at D1, D3, D7, D9 All other negative	
54.	Huang J et al (86)	1	NP	Negative	
55.	Iqbal S et al (105)	1	NP	Negative	
56.	Kalafat E et al (79)	1	NP, Cord blood, Placenta	Negative	
57.	Lee D et al (80)	1	NP, AF, Cord blood, Placenta, neonatal serum, anal swab	Negative	
58.	Liao X et al (106)	1	NP, AF, Cord blood, Placenta	Negative	
59.	Xiong X et al (50)	1	NP, AF, BM, rectal swab	Negative	
60.	Wang S et al (51)	1	NP, Placenta, Cord blood, BM	NP +ve at 36 h Negative in all others	1/1
61.	Zamaniyan M et al (30)	1	NP, Cord blood, AF, Vaginal secretion	NP – Negative at 0 hours, +ve at D2, D4, D6 AF +ve, all others negative	1/1
62.	Kirtsman M et al (35)	1	NP, Placental, Stool, BM Neonatal plasma D4	NP +ve at D1, D2, D7 Placenta +ve Stool +ve D7, BM +ve	1/1
63.	Lyra J et al(74)	1	NP	Negative	
64.	Algorroba G et al (34)	1	NP	Negative at 0 h,D2, D7	



65.	Peng Z et al (43)	1	NP, NBAL Fluid, Sputum, Urine	Negative	
66.	Groß R et al (52)	2	BM, NP	Both NP +ve (>D7) , BM +ve (1)	2/2,1/2
67.	Perrone S et al (72)	4	NP (3),Placenta (1)	NP negative on D1, Placenta-negative	
68.	Hosier H et al (32)	1	Placenta, cord blood	Both +ve	1/1; D& E at 22 weeks
69.	Pulinx B et al (31)	2	AF, Placental	Both +ve	2/2, DCDA twin at 24 weeks
70.	Yu N et al (108)	2	AF in mid pregnancy	Negative	
71.	Kulkarni et al (117)	1	NP, Placenta, Cord stump, Neonatal blood	All +ve at 12 hours of life; Serology negative on D10 but +ve on D21	1/1
72.	Sisman J et al (70)	1	NP, Placenta	NP +ve at 24 hours, 48 hours, D14; Placenta +ve by electron microscopy	1/1

AF= Amniotic fluid; NP= Neonatal Pharyngeal/throat swab; BM= Breast milk; NBAL= Non-bronchoscopic broncho-alveolar lavage fluid; D&E- dilatation and evacuation; D1= 1<sup>st</sup> day of life, D4= 4<sup>th</sup> day of life...

**Table-3 (a): Mother to child transmission-Test positive (Pooled result)**

SAMPLE Tested by RT-PCR for SARS-CoV-2	Number of studies	Number Tested	Number Positive	Pooled Percentage
Neonatal Naso-pharyngeal swab	67 [32 case series/cohort +35 case reports]	1388 [1335 case series/cohort+53 case reports]	51 [40 out of 1335 in case series/cohort+ 11 out of 53 case reports]	3.67% [3% in case series/cohort; 2.07% in case reports]
Placenta ± Membranes	22	111	13	11.7%
Amniotic fluid	19	58	4	6.8%
Breast milk	10	56	3	5.3%
Cord blood/ plasma	16	56	4	7.1%
Other neonatal samples				
-Anal swab	11	52	5	9.6%
-Urine	3	9	0	
<b>Neonatal serology</b>				
IgM	5	11	(Elevated) 3	27%
IgG	4	10	(Elevated) 6	60%

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table-3 (b): Analysis of evidence of congenital/ intrapartum/ postpartum transmission**

<b>Author (reference) [samples positive/ total tested]</b>	<b>Samples +ve</b>	<b>Fetal/ Neonatal status</b>	<b>Alternate explanation for clinical features</b>	<b>Mother to child transmission (n)</b>
Groß R et al (52) [2/2]	NP >D7	Respiratory symptoms (2), icterus (1)	Alternate explanation-excluded in 1 ; Respiratory syncytial virus +ve in 1	Neonatal infection acquired postpartum-Confirmed (1) Unlikely (1)
Buonsenso et al (53) [1/2]	1st- NP Negative on D1, D4 and +ve on D15, Placenta, AF, rectal swab-Negative, Weak IgG+ve, IgM negative 2nd - Placenta, Breast milk- +ve but cord blood negative in neonate with NP negative result	Symptoms- Absent	-	Neonatal infection acquired postpartum-Confirmed (asymptomatic) (1 <sup>st</sup> ) Possible congenital infection (2 <sup>nd</sup> )
Vivanti A et al (29) [1/1]	NP +ve at 1hour, D3, D18; Rectal swab +ve at 1hour, D3, D18; Vaginal swab, NBAL, Neonatal blood +ve	Irritability, poor feeding, axial hypertonia and opisthotonos	Alternate explanation-excluded	Confirmed congenital infection
Kirtsman M et al (35) [1/1]	NP +ve at birth, D2, D7 Placenta (fetal side) +ve Stool +ve D7, BM +ve	Hypothermia, feeding difficulties, hypoglycemia, neutropenia	Alternate explanation-excluded	Probable congenital infection
Zamaniyan M et al (30) [1/1]	NP - negative at 0 hours, +ve at D2, D4, D6 AF before rupture of membranes +ve Cord blood and vaginal secretion - negative	Fever (1)	Alternate explanation- not identified	Confirmed congenital infection
Wang S et al (51) [1/1]	NP +ve at 36 hours Placenta, Cord blood, BM- Negative	Vomiting, lymphopenia, abnormal liver enzyme levels	Alternate explanation-excluded	Neonatal infection acquired intrapartum possible
Khan S et al (64) [2/17]	NP +ve within 24 hours	NNP	Alternate explanation- not identified	Neonatal infection acquired intrapartum- possible
Zeng L et al (41) [3/33]	NP +ve at D2, D4, negative at D6	RD (1); Cyanosis, feeding intolerance(1); Fever (2); NNP(3); Lethargy, fever(1); lethargy, fever, NNP, vomiting leukocytosis,lymphocytopenia, (1); Preterm- Neonatal RDS, NNP, lymphocytopenia (1)	Alternate explanation-excluded	Neonatal infection acquired intrapartum-possible NP not done at birth, no other samples tested
Hu X et al (42) [1/7]	NP +ve at 36 hours; fetal urine, AF are negative	Symptoms- Absent	-	Neonatal infection acquired intrapartum- Possible NP not done at birth

1 2 3 4 5	Knights M et al (23) [12/244]	NP +ve at <12 hours (6) NP +ve at >12 hours (6)	Neonatal encephalopathy (1)	-	Congenital infection possible(1) Other evidences lacking
6 7 8	Alzamora M et al (78) [1/1]	NP +ve at 16 hours and 48 hours Cord Blood IgM and Ig G negative at D1 and D5	Respiratory difficulty and cough	Alternate explanation-excluded	Neonatal infection acquired intrapartum - confirmed NP not done at birth
9 10	Hantoushzadeh et al (75) [1/4]	NP -ve on D1, +ve on D7	NNP, lymphopenia (1)	-	Neonatal infection acquired postpartum-Confirmed
11 12	William R et al (63) [1/33]	Negative at 24 hours, +ve at 48 hours	Symptoms- Absent	-	Neonatal infection acquired postpartum-Confirmed
13 14	Nayak A et al (26) [3/131]	NP +ve on D1;-ve on D5	Neonatal seizures, MAS (1)	-	Probable neonatal infection acquired intrapartum
15 16 17	Nie R et al (68) [1/26]	NP +ve at 36 hours, negative - D4, D8,D15; Cord blood, placenta-negative	Pulmonary infection (1)	Alternate explanation- not identified	Neonatal infection acquired intrapartum - Possible NP not done at birth
18	Savasi V et al (109) [4/57]	Timing of NP test could not be ascertained (early postpartum period)	-	-	-
19 20	Kayem G et al (25) [2/181]	Timing of test could not be ascertained	-	-	-
21 22 23	Patane L et al (39) [2/22]	1 <sup>st</sup> - NP +ve at birth,>24hours, >7 days 2 <sup>nd</sup> - NP negative at birth, +ve on D7 Placenta- Chronic intervillitis, PCR +ve in both placenta	Mild feeding difficulty (2)	-	Probable congenital infection (1) Possible congenital infection (1)
24 25 26 27 28	Ferrazzi E et al (28) [3/42]	NP +ve on D1, D3(2) NP equivocal at birth but +ve on D3(1)	Gastrointestinal symptoms, RD (2)	Alternate explanation- not identified	Neonatal infection acquired postpartum-Confirmed (1) Neonatal infection acquired intrapartum - possible(2) Other evidences lacking
29 30 31	Govind A et al (61) [1/9]	NP at birth	NNP (1)	Alternate explanation-excluded	Neonatal infection acquired intrapartum - confirmed? NP not done after 24 hours
32 33	Penfield C et al (103) [3/11]	NP- Negative (D1 and D5) Placenta and membrane +ve	Symptoms- Absent		Neonatal infection acquired intrapartum - Possible
34 35	Baud D et al (33) [1/1]	NP, AF, Vaginal swabs- Negative Placenta +ve	2nd trimester spontaneous miscarriage		Confirmed congenital infection
36 37	Hosier H et al (32) [1/1]	Placenta, cord blood-both +ve	D& E at 22 weeks		Confirmed congenital infection
38 39	Pulinx B et al (31) [2/2]	AF, Placenta-both +ve	DCDA twin at 24 weeks expelled		Confirmed congenital infection
40 41	Dong L et al (55) [1/1]	IgM level elevated NP negative at 2h,16h	Symptoms-absent	-	Possible congenital infection
42 43 44 45 46 47	Zeng H et al (54) [1/1]	NP negative;	Symptoms-absent	-	Possible congenital infection

	Elevated IgM and IgG (2); Elevated IgG ,normal IgM (3)			
Perez O et al (65) [5/82]	NP +ve at birth and negative at 48 hours (3); NP negative at birth but +ve at D10 (2)	RD (2) Symptoms-absent (3)	Alternate explanation- not identified (2)	Neonatal infection acquired intrapartum – Probable (2) Neonatal infection acquired intrapartum – Possible (1) Neonatal infection acquired postpartum-Confirmed (2)
Kulkarni et al (117) [1/1]	NP, placenta, Cord stump RT PCR- All +ve at 12 hours of life NP at D5 and D10 +ve	Fever, icterus, and poor feeding	Alternate explanation-excluded	Confirmed congenital infection
Sisman J et al (70) [1/1]	NP +ve at 24 hours, 48 hours, D14 Placenta +ve by electron microscopy	Fever, RD, Icterus	Alternate explanation-excluded	Confirmed congenital infection

AF= Amniotic fluid; NP= Neonatal Pharyngeal/throat swab; BM= Breast milk; NBAL= Non-bronchoscopic broncho-alveolar lavage fluid;  
NPN=Neonatal Pneumonia; D&E- dilatation and evacuation; RD= Respiratory distress; DCDA- Dichorionic diamniotic twin

**Table-4: Fetal outcome**

Serial number	Author (reference)	Number of neonates from SARS CoV-2 +ve pregnancies	Fetal complications (n)	Mode of delivery (n)	Birth weight in grams	Preterm delivery (n)	Still birth(n)	Comments
1.	Chen H et al (45)	9	FD (2) PROM (1)	CS (9)	1880-3730	Yes (2)	-	
2.	Romagano M et al (82)	7	-	CS(7)	1290-2580 (AGA)	Yes (7)		
3.	Zeng H et al (54)	6		CS (6)			-	
4.	Zhu H et al (57)	10	FD (6), PROM (3), MSA (2)	CS (7) VD (2)	SGA-2 LGA/Normal-8	Yes (6)	-	1 twin delivery
5.	Khan S et al (64)	17	PROM	CS (17)	2300–3750 <2700-3	Yes (5)	-	
6.	Zeng L et al (41)	33	PROM (3); FD (1)	VD (7); CS (26)	SGA (3) 1580-3360	Yes(4)	-	
7.	Breslin N et al (59)	18	Ab.CTG (3)	CS (8); VD (10)		Yes (1)	-	
8.	Qiancheng X et al (107)	23	-	CS (17) VD (5)	3130 (2915–3390)	Yes(1)	-	1 twin delivery
9.	Hantoushzadeh S et al (75)	5	IUFD (3)	CS (4)	1180-3200	Yes (3)	Yes (1)	1 twin delivery
10.	Perez O et al (65)	82	PROM (18) PPROM (7) IUGR (1)	VD (41) CS (41)	1450-3210	Yes (25)	-	
11.	Savasi V et al (109)	57	-	VD (34) CS (22)	3160 (840-4350)	Yes(12)	-	1 twin delivery
12.	London V et al (27)	56	DFM (1) IUFD (17 wks) (1)	CS (22) VD (33)	-	Yes(12)	-	

13.	Lokken E et al (40)	8	FD (3)	CS (3) VD (5)	-	Yes (1)	Yes(1)	
14.	Yan J et al (24)	99	FD (9); IUGR (2) PPROM (6)	CS (85) VD(14)	3108±526	Yes (21)	-	
15.	William R et al (63)	32	IUGR(2), PPR0M (1)	CS (24) VD(8)	2403.3±858	Yes (19)	-	
16.	Knight M et al (23)	262	Miscarriage (4); Fetal compromise (37)	CS (156) VD (106)	-	Yes (66)	Yes (3)	
17.	Kayem G et al (25)	176	Fetal loss <21 weeks (5)	CS (87) VD (89)	-	Yes (50)	Yes (2)	
18.	Nayak A et al (26)	134	Miscarriage (6)	CS (67) VD(67)	>2500 (92) <2500 (39)	Yes (38)	Yes (3)	
19.	Prabhu M et al (60)	70	PROM and Ab.CTG (4)	CS (32) VD(38)	3060.9-3149.6	Yes (11)	Yes (1)	
20.	Li N et al (66)	17	FD(1) ; PROM (1)	CS (14) VD(2)	3078.2 ± 565.0	Yes (4)	-	1 twin delivery
21.	Cao D et al (67)	11	FD (3); PROM (4)	CS (8) VD(2)	2050-3800	Yes (4)	-	1 twin delivery
22.	Hu X et al (42)	7	PROM (1)	CS (6) VD(1)	3180-3670	-	-	
23.	Yang P et al (81)	7	-	CS(7)	2096 ± 660	Yes (4)	-	
24.	Yang H et al (73)	13	-	CS (9) VD(4)	3063.2 ± 536.4	-	-	
25.	Ferrazzi E et al (28)	42	-	CS (18) VD(24)	2730-3226	Yes(11)	-	
26.	Govind A et al (61)	9	Ab.CTG (1)	CS (8) VD(1)	1200-4300	Yes(2)	-	
27.	Nie R et al (68)	28	FD (4); IM (1); PROM (3)	VD (5); CS (22)	2988(502)	Yes (10)	-	1 twin delivery
28.	Yin M et al (46)	17	IM (3)	VD (4); CS (13)	2580-3035	Yes (5)	-	
29.	Qadri F (115)	10		CS (2) VD (8)		Yes (1)		
30.	Doria M et al (71)	10	IUGR (6)	CS (6) VD(4)	2350-3380	-	-	
31.	Liu Y et al (69)	10	FD(3), PROM (1)	CS(10)		Yes (6)	Yes(1)	
32.	Perrone S et al (72)	4	IUGR(1)	VD(4)	2290-3790	-	-	
33.	Patane L et al (39)	2	-	VD (1) CS(1)	2660, 2686	Yes(1)	-	
34.	Fan C et al (48)	2	-	CS (2)	3440-2890	Yes (1)	-	
35.	Pulinx B et al (31)	2	IUFD (1)	VD (2)		Yes (1)	Yes (1)	DCDA twins
36.	Liu W et al (56)	3	FD (1); MSA ; chorioamnionitis	CS (2) VD (1)	3250-3670	-	-	

37.	Cooke W et al (83)	2	-	CS (2)	1530,1400	Yes(2)	-	
38.	Chen Y et al (58)	4	DFM (1) Ab.CTG (1)	CS (3) VD(1)	3050-3550	-	-	
39.	Gildof S et al (76)	2	-	CS (2)	2680,2160	Yes (2)	-	
40.	Khan S et al (85)	3	-	VD (3)	2890-3750	Yes (1)	-	
41.	Zambrano L et al (87)	1	-	VD(1)	1500	Yes(1)	-	
42.	Lowe B et al (62)	1	Ab.CTG (1)	VD (1)		-	-	
43.	Blauvelt C (84)	1	-	CS(1)	1880	Yes (1)	-	
44.	Kirtsman M et al (35)	1	-	CS(1)	2930	Yes (1)	-	
45.	Lyra J et al (74)	1	-	CS(1)	3110	-	-	
46.	Li Y et al (44)	1	FD(1)	CS(1)		Yes (1)	-	
47.	Dong L et al (55)	1	-	CS(1)	3120	Yes (1)	-	
48.	Wang X et al (77)	1	FD (1)	CS(1)	1830	Yes (1)	-	
49.	Alzamora M et al (78)	1	-	CS(1)	2970	-	-	
50.	Huang J et al (86)	1	-	VD(1)		-	-	
51.	Kalafat E et al (79)	1	-	CS(1)	2790	Yes (1)	-	
52.	Xiong S et al (50)	1	PROM	VD(1)	3070	-	-	
53.	Wang S et al (51)	1	FD (1)	CS(1)	3205	-	-	
54.	Zamaniyan M et al (30)	1	-	CS(1)	2350	Yes (1)	-	
55.	Song L et al (49)	1	-	CS(1)	3630	Yes (1)	-	
56.	Lee D et al (80)	1	-	CS (1)	3130	-	-	
57.	Iqbal S et al (105)	1		VD(1)				
58.	Vivanti A et al (29)	1	Ab.CTG (1)	CS(1)	2540	Yes (1)	-	
59.	Kulkarni et al (117)	1	-	VD(1)	3200	-	-	
60.	Sisman J et al (70)	1	PROM	VD(1)	3280	Yes (1)		

FD= Fetal distress; Ab.CTG= Non-reassuring/ Pathological fetal cardio-tocography ; PROM= Pre-labor rupture of membrane ; Fetal demise= IUFD ; MSA= Meconium stained amniotic fluid; DFM= Decreased fetal movement; IM= Induced miscarriage; CS= Caesarean Section; VD= Vaginal delivery; AGA= Appropriate for gestational age; IUGR= Intrauterine growth restriction; SGA= Small for gestational age; LGA= Large for gestational age



**Table-5: Perinatal outcome (Pooled data)**

<b>FETAL OUTCOME</b>				
<b>OUTCOME</b>	<b>Number of studies</b>	<b>Results</b>	<b>Indications</b>	
Preterm birth	43 studies [26 case series/cohort and 17 case reports]	-Preterm birth=330 out of 1273 neonates in the case series/cohort (25.9%) -Preterm birth= 19 out of 45 neonates in the case reports (42.2%)	-Iatrogenic prematurity to improve maternal COVID-19 related respiratory symptoms =153 -Spontaneous preterm labor=24 -Fetal compromise/ distress=17 -Unknown/ other = 156	Pooled Preterm birth in 26.4% of total births Spontaneous preterm birth- 1.8% of total births
Mode of delivery	59 studies [30 case series/cohort and 29 case reports]	-In case series/ cohorts, out of 1267 deliveries, CS=761 (60%) and VD=506 (40%) -In case reports, out of 44 deliveries, CS=25 (56.8%) and VD=19 (43.2%)	Maternal COVID-19 related conditions most common indication	Pooled data- CS= 786 (59.9%) VD= 525 (40.1%)
Still birth Miscarriage	Still birth=8 studies Miscarriage= 5 studies	Still birth=13 Spontaneous miscarriage= 15 Induced miscarriage=4	All induced miscarriages were due to maternal request	Stillbirth rate= 9.9
Fetal complications	FD= 21 studies PROM and PPRM= 15 studies	Fetal distress (87 out of 1311 pregnancies) (6.63%) PROM and PPRM (56 out of 1311 pregnancies) (4.27%)	-	-
IUGR and SGA	IUGR-5 studies SGA-2 studies	12 fetuses had IUGR (0.9%) 5 neonates had SGA (0.38%)	-	-
<b>NEONATAL OUTCOMES</b>				
<b>OUTCOME</b>		<b>Results</b>		
Neonatal symptoms		Respiratory symptoms= 23 neonates (1.79%) Neonatal pneumonia and pulmonary infection= 14 neonates (1.1%) Fever= 12 neonates (0.9%)	Most common symptom is respiratory distress in (1.17%)	
APGAR score		Score of less than 7 at 1minute and 5 minutes= neonates	Most common reason is preterm birth	
ICU admissions		In 276 neonates (21.5%)	Most common reason was for observation and isolation (32.6 %). Prematurity is second most common reason	

		ICU admissions for suspected or confirmed neonatal sepsis was reported in 6 neonates (0.46%).	
Neonatal death	7 neonates		Neonatal death rate=5.46 per 1000 live births

FD= Fetal distress; Ab.CTG= Non-reassuring/ Pathological fetal cardio-tocography ; PROM= Pre-labor rupture of membrane ; MSA= Meconium stained amniotic fluid; IM= Induced miscarriage; CS= Caesarean Section; VD= Vaginal delivery; IUGR= Intrauterine growth restriction; SGA= Small for gestational age

**Table-6: Neonatal outcome**

Serial number	Author (reference)	Number of neonates	APGAR score (1 minute, 5 minute)	Neonatal symptoms (n)	Neonatal ICU admission (n)	Neonatal death	Neonatal RTPCR status
1.	Alzamora M et al (78)	1	6, 8	Respiratory difficulty Cough on D6	(1) [due to maternal sedation]	-	<b>+ve</b>
2.	Chen H et al (45)	9	8-10	-	-	-	
3.	Fan C et al (48)	2	9-10	Fever, abdominal distension, lymphopenia (1) Mild NNP, lymphopenia (1)	-	-	<b>Negative</b>
4.	Dong L et al (55)	1	9-10	-	-	-	
5.	Zeng H et al (54)	6	9-10		-	-	
6.	Liu W et al (56)	3	8-10	decreased responsiveness and decreased muscle tone	-	-	<b>Negative</b>
7.	Zhu H et al (57)	10	8-10 in all 7-8 in 1	Shortness of breath (6), vomiting (1), rash (1), Fever (3)	Yes (2)	YES (1)	<b>Negative</b>
8.	Wang X et al (77)	1	9-10	-	Yes (1)	-	
9.	Liu Y et al (69)	10	10	-	-	-	
10.	Chen Y et al (58)	4	8-9 (3) 7-8 (1)	Edema (1), Rash (2),Dyspnea and TTN (1)	Yes (2)	-	<b>Negative</b>
11.	Gidlof S et al (76)	2	9-10	Breathing problem, cyanotic attack(1)			<b>Negative</b>
12.	Huang J et al (86)	1	8-9	-	-	-	
13.	Iqbal S et al (105)	1	9	-	-	-	
14.	Lee D et al (80)	1	9-10	-	Yes (1)	-	
15.	Khan S et al (85)	3	9-10	-	-	-	
16.	Khan S et al (64)	17	9-10 (16) 7-9 (1)	NNP (5)	-	-	<b>2 out of 5 with pneumonia were +ve</b>
17.	Xiong S et al (50)	1	9-10	-	-	-	
18.	Wang S et al (51)	1	8-9	Vomiting, lymphopenia, abnormal liver enzyme levels	Yes (1)	-	<b>Negative</b>
19.	Zeng L et al (41)	33	Preterm newborn-3,4 Term - Normal	RD (4=3 -ve, 1+ve). Cyanosis, feeding intolerance (3=2-ve,1+ve) Fever in 2, NNP in 3 of the 3 +ve Lethargy, fever(1) lethargy, fever, NNP, leukocytosis, lymphocytopenia, vomiting (1)	Yes (3)	-	<b>+ve</b>

				Preterm- Neonatal RDS, NNP, lymphocytopenia (1)			
20.	Zamaniyan M et al (30)	1	8,9	Fever (1)	-	-	<b>+ve</b>
21.	Breslin N et al (59)	18	>7, >9	RD/ sepsis (1)	Yes (3)	-	<b>Negative</b>
22.	Qiancheng X et al (107)	23	10,10		-	-	
23.	Hantoushzadeh S et al (75)	5	7 (2), 9-10	NNP, lymphopenia (1)	Yes (1)	YES(2)	<b>Negative</b>
24.	Shanes E et al (36)	15	7(8),8(7); 9				
25.	Zambrano L et al (87)	1	-	-	Yes (1)	-	
26.	Perez O et al (65)	82	<5 (3)	RD (2)	Yes (19)		<b>+ve</b>
27.	Savasi V et al (109)	57	10	-	Yes(9)	-	
28.	Song L et al (49)	1	8,9	-	-	-	
29.	Lokken E et al (40)	8					
30.	Yan J et al (24)	99	9,10	Neonatal asphyxia (1)	Yes(47)	YES (1)	<b>Negative</b>
31.	William R et al (63)	32	7.9±1.7	-	Yes (21)	-	
32.	Knight M et al (23)	262		Neonatal encephalopathy (1)	Yes (67)	YES (2)	<b>Unclear whether symptomatic neonate was +ve</b>
33.	Kayem G et al (25)	181		-	Yes (37)	YES (1)	
34.	Nayak A et al (26)	131	7-10 (128) <7 (6)	Neonatal seizures (1), MAS (1)	Yes (24)		<b>Unclear whether symptomatic neonates were +ve</b>
35.	Prabhu et al (60)	73	9	-	Yes (13)	-	<b>Negative</b>
36.	Vivanti A et al (29)	1	4,7	irritability, poor feeding, axial hypertonia and opisthotonos	Yes (1)	-	<b>+ve</b>
37.	Li N et al (66)	17	9.6 ± 0.5, 10	-	-	-	
38.	Cao D et al (67)	11	8-9,10	-	-	-	
39.	Hu X et al (42)	7	7-8,8-9	-	-	-	
40.	Yang P et al (81)	7	8-9,9-10	Vomiting(1), RD (2), Moaning (2)	Yes (5)	-	<b>Negative</b>
41.	Yang H et al (73)	13	9,10	Fever(1)	-	-	
42.	Patane L et al (39)	2	9,10	Mild feeding difficulty (2)	Yes (1)	-	<b>+ve</b>
43.	Ferrazzi E et al (28)	42	<7 (2)	Gastrointestinal symptoms, RD (2)	Yes (3)	-	<b>+ve</b>
44.	Govind A et al (61)	9	<7 (2)	NNP (1)	Yes (1)	-	<b>+ve</b>
45.	Nie R et al (68)	28	8-10, 10	Pulmonary infection (1)	Yes (1)	-	<b>+ve</b>
46.	Yin M et al (46)	17	8,9	-	-	-	
47.	Doria M et al (71)	10	9,10	-	-	-	
48.	Perrone S et al (72)	4	9,10	-	-	-	
49.	Romagano M et al (82)	7	1-7,4-9	RD	Yes(7)	-	<b>Negative</b>
50.	Cooke W et al (83)	2	1-6, 3-8	Bowel perforation D6(1)	Yes(2)	-	<b>Negative</b>
51.	Lowe B et al (62)	1	9,9	-	-	-	
52.	Blauvelt C (84)	1	4,8	RD	YES(1)	-	<b>Negative</b>
53.	Kirtsman M et al (35)	1	9,9	Neutropenia, hypothermia, feeding difficulties, hypoglycemia	YES(1)	-	<b>+ve</b>
54.	Lyra J et al (74)	1	8,9	-	-	-	<b>Negative</b>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

55.	Groß R et al (52)	2	-	Respiratory symptoms (2), icterus (1)	-	-	+ve
56.	Kulkarni et al (117)	1	6,9	Fever, icterus, and poor feeding	YES(1)	-	+ve
57.	Sisman J et al (70)	1	7,9	Fever, RD, Icterus	YES(1)	-	+ve

RD= Respiratory distress; MAS= Meconium aspiration syndrome; TTN= Transient Tachypnea of Newborn; NNP= Neonatal Pneumonia

Confidential: For Review Only

# BMJ Paediatrics Open

## COVID-19 in pregnancy; The fetal perspective- a systematic review

Journal:	<i>BMJ Paediatrics Open</i>
Manuscript ID	bmjpo-2020-000859.R2
Article Type:	Original research
Date Submitted by the Author:	21-Oct-2020
Complete List of Authors:	Dube, Rajani; RAK Medical and Health Sciences University, Obstetrics and Gynaecology Kar, Subhranshu; Ras Al Khaimah Medical and Health Sciences University, Pediatrics
Keywords:	Data Collection, Microbiology, Mortality, Neonatology, Virology

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



## Title Page

**Article Title- COVID-19 in pregnancy; The fetal perspective- a systematic review**

**Author information-****1. Rajani Dube**

**Highest academic degree- M.D. (Obstetrics and Gynaecology)**

**The name of the department / institution – Department of Obstetrics and Gynaecology, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras al Khaimah, United Arab Emirates**

**E Mail ID- [rajnidube@yahoo.com](mailto:rajnidube@yahoo.com)**

**Phone No- +971 551383304**

**ORCID - <https://orcid.org/0000-0002-1539-6162>**

**2. Subhranshu Sekhar Kar- Corresponding author**

**Highest academic degree- M.D. (Paediatrics), Fellowship in Paediatric Critical Care**

**The name of the department / institution – Department of Pediatrics, RAK College of Medical Sciences, RAK Medical and Health Sciences University, Ras al Khaimah, United Arab Emirates**

**E Mail ID- [drsskar@gmail.com](mailto:drsskar@gmail.com)**

**Phone No- +971 504314392**

**ORCID - <https://orcid.org/0000-0002-9379-7447>**

**Disclaimer-** The views expressed in the submitted article are our own and not an official position of the institution or funder.

**Source(s) of support-** None

**Word count-** 6759 excluding its abstract, figures, tables, acknowledgments and references

**Number of figures and tables-** Tables- 6 and Figures-2

**Disclosure of relationships and activities-** Nothing to disclose

**Keywords:** COVID-19, SARS-CoV-2, mother to child transmission, perinatal outcome, congenital anomaly

## **Title: COVID-19 in pregnancy; The fetal perspective- a systematic review**

### **Abstract:**

**Objective:** We aimed to conduct a systematic review of the available literature to determine the effects of confirmed cases of COVID-19 in pregnant women from the fetal perspective by estimation of mother to child transmission, perinatal outcome and possible teratogenicity.

### **Methods**

Data sources: Eligible studies between November 1, 2019 and August 10, 2020 were retrieved from PubMed, Embase, LitCovid, Google Scholar, EBSCO MEDLINE, CENTRAL, CINAHL, MedRXiv, BioRXiv, and Scopus collection databases. English language case reports, case series and cohort studies of SARS-CoV-2 confirmed pregnant women with data on perinatal outcome, congenital anomalies and mother to child transmission were analysed.

**Results:** 38 case reports, 34 cohort and case series describing 1408 neonates were included for evidence acquisition of mother to child transmission. 29 case reports and 30 case series and cohort studies describing 1318 fetuses were included for the evaluation of perinatal outcome and congenital anomalies. A pooled proportion of 3.67% neonates had positive SARS-CoV-2 viral RNA nasopharyngeal swab results and 7.1 % had positive cord blood samples. 11.7% of the placenta, 6.8% of amniotic fluid, 9.6% of fecal and rectal swabs, and none of the urine samples were positive. The rate of preterm labor was 26.4% (OR=1.45, 95% CI- 1.03 to 2.03 with p = 0.03) and Cesarean delivery (CS) was 59.9% (OR=1.54, 95% CI- 1.17 to 2.03 with p = 0.002). The most common neonatal symptom was breathing difficulty (1.79%). Stillbirth rate was 9.9 per 1000 total births in babies born to COVID-19 mothers.

**Conclusion:** Chances of mother to child transmission of the SARS-CoV-2 virus is low. The perinatal outcome for the fetus is favorable. There is increased chances of CS but not preterm delivery. The stillbirth and neonatal death rates are low. There are no reported congenital anomalies in babies born to SARS CoV-2 positive mothers.

**Keywords:** COVID-19, SARS-CoV-2, mother to child transmission, perinatal outcome, congenital anomaly

### **KEY MESSAGE:**

#### **A. What is known about the subject –**

Studies specifically analyzing all aspects of the fetus in SARS-CoV-2 positive mothers are not currently available. There are some systematic reviews reporting maternal outcomes, vertical transmission and neonatal outcomes involving a lesser number of pregnancies separately but aspects like fetal complications and teratogenicity are not adequately reported.

#### **B. What this study adds –**

1  
2  
3 The confirmed congenital transmission rate was found to be 9/1408 (0.63%). The risk of  
4 caesarean delivery is significantly higher in SARS-CoV-2 positive mothers but there is no  
5 significantly higher risk of prematurity. There is evidence of fetal distress, and neonatal  
6 respiratory symptoms in COVID-19 mothers but stillbirth is low.  
7  
8  
9

## 10 INTRODUCTION

11 Novel coronavirus infection and associated coronavirus disease-2019 (COVID -19)  
12 pandemic has changed our lives forever and has compelled us to reconsider almost  
13 everything we have long taken for granted. Among the different coronaviruses severely  
14 affecting human species, Middle East respiratory syndrome coronavirus (MERS-CoV),  
15 severe acute respiratory syndrome coronavirus (SARS-CoV), and SARS-CoV-2 are  
16 significant, causing MERS, SARS, and COVID-19 respectively. SARS-CoV-2 strains  
17 show significant sequence homology to SARS-CoV and MERS-CoV [1]. As the pandemic  
18 evolved, there were significant advances in our knowledge about various aspects of the  
19 COVID-19 including epidemiology, clinical features, transmission, detection, and  
20 management modalities. Discoveries along the process of evolution are still contributing  
21 to our management practices.  
22  
23  
24  
25  
26

27 There were concerns regarding the maternal and fetal effects since the beginning of the  
28 pandemic. The earlier evidence of COVID-19 in pregnancy pointed towards pregnancy  
29 being considered as low risk for the disease and no difference in disease behavior in  
30 pregnant and non-pregnant women was reported [2]. On the contrary, a newer study  
31 involving pooled data from more than 8000 women in the USA pointed towards a  
32 significantly higher rate of intensive care unit (ICU) admission [adjusted relative risk (aRR)  
33 = 1.5] and need for mechanical ventilation (aRR = 1.7) in pregnant women as compared  
34 to non-pregnant women, even when adjusted for race/ethnicity and underlying comorbid  
35 conditions [3]. Similar findings were reported from other studies from the US and Sweden  
36 [4-6].  
37  
38  
39  
40

41 However, these studies did not specify adequately fetal effects resulting from congenital  
42 or neonatal infection in SARS-CoV-2 positive mothers and consequent perinatal  
43 outcomes. Evidence of COVID-19 specifically focusing on fetal and neonatal outcomes  
44 are lacking. Most of the reported literature have smaller studies. Previous systematic  
45 reviews focusing on the outcomes of all coronaviruses have reported a higher risk of pre-  
46 eclampsia, preterm birth, miscarriage, and perinatal death.  
47  
48  
49

50 Through this article, we want to analyze the published evidence on the fetal perspective  
51 of COVID-19 infection concerning mother to child transmission (congenital or neonatal  
52 infection) and perinatal outcome through a systematic review. This will aid in alleviating  
53 uncertainties faced while doing patient counseling and help in subsequent management  
54 during these testing times.  
55  
56  
57  
58  
59  
60

## METHODS

**Search strategy:** A systematic search of PubMed, Embase, LitCovid, MedRxiv, BioRxiv, Google Scholar, EBSCO MEDLINE, CINAHL, and Scopus electronic database was done. Medical subject handling terms (MeSH) and free text term keywords like vertical transmission, perinatal outcome, fetal, neonate, newborn, pregnancy were used in combination with COVID-19, 2019-nCoV, SARS-CoV- 2 to search for data from 1<sup>st</sup> November 2019 till 10<sup>th</sup> July 2020. Thereafter manual update was done on weekly basis till 10<sup>th</sup> August 2020. The references of relevant studies were also searched.

The keywords detail and full search strategy used in each of PubMed, Embase, LitCovid, MedRxiv, BioRxiv, Google Scholar, EBSCO MEDLINE, CINAHL, and Scopus electronic database are as follows: Both medical subject headings (MeSH) and key-words: "2019 novel coronavirus infection" OR "COVID-19" OR "COVID19" OR "coronavirus disease 2019" OR "nCoV infection" OR "2019-nCoV" OR "2019 novel coronavirus" OR "2019 coronavirus" OR "novel coronavirus" OR (2019 AND coronavirus) OR "SARS CoV-2" OR "SARS CoV2" AND "vertical transmission" OR "fetal outcome" OR "perinatal outcome" OR "neonatal outcome" OR "pregnancy" OR "congenital infection" OR "mother-to-child transmission" OR "(transmission AND vertical)" OR "(transmission AND fetomaternal) " OR "teratogenicity".

**Selection criteria:** The search consisted of only English language articles (original English articles and other language articles with available English translation) including case reports, case series, and letters to editors containing case information. After a thorough screening, no randomized clinical trials or cohort studies were found.

**Inclusion criteria:** The studies fulfilling all of the following criteria (1,2 and 3) were included for review.

- 1- Studies reporting pregnant women with confirmed COVID-19 who had delivered.
- 2- Studies containing the results of the SARS-CoV-2 test [including reverse transcriptase-polymerase chain reaction (RT-PCR) and serological tests] in both mothers and newborns samples.
- 3- Studies that present the out-come of vertical transmission or congenital transmission or neonatal transmission or the perinatal outcome or congenital anomaly.

**Exclusion criteria:** Exclusions consisted of studies in pregnant women yet to deliver, duplicated studies, review articles, articles in languages other than English where translation was not possible, studies where infection in mothers is not confirmed, or where neonatal testing was not done. Conference abstracts, expert opinions, and critical appraisals were also excluded.

1  
2  
3 Both the authors (RD, SSK) reviewed all titles independently. The potential relevance of  
4 the studies to be included for review were agreed upon by discussion. Selected titles and  
5 abstracts were further screened between studies to reject overlap of cases.  
6  
7

8 Full-text copies of the selected papers were obtained and the relevant data regarding  
9 study characteristics, evidence of vertical transmission, and perinatal outcomes were  
10 extracted by the same two reviewers independently. In the case of individual case reports,  
11 if the same patient was included in more than 1 study with similar characteristics and  
12 findings, only the report with a larger number of patients was included. As far as possible,  
13 single case reports were cross-checked with other reports from the same location and  
14 hospital. If a case series included multiple locations, the individual reports from the same  
15 centers were excluded. Similarly, if the time-frame of the reported cases matched from the  
16 same center, the characteristics were compared to decide regarding the inclusion or  
17 exclusion from the study. Finally, studies were screened by assessing selection,  
18 comparability, and exposure for inclusion into evidence acquisition of mother to child  
19 transmission (congenital or neonatal transmission ) and/or perinatal outcome measures  
20 **[Table-1a,1b]**.  
21  
22  
23  
24  
25  
26

## 27 **Study Outcomes**

### 28 1. Mother to child transmission-

29  
30 Evidence of mother to child transmission (congenital or neonatal transmission) is indicated  
31 by positive RT-PCR status in different samples like the neonatal nasopharyngeal swab,  
32 cord blood, amniotic fluid, breast milk, and placental tissue. Transmission of infection from  
33 mother to fetus generally includes transmission through germ cells or the placenta during  
34 pregnancy, via the birth canal during labor and delivery, and the postpartum period  
35 through breastfeeding or close contact. The transfer of microorganisms during pregnancy  
36 is seen with many of the common pathogens with resultant effects ranging from  
37 asymptomatic infection, intrauterine growth restriction, intrauterine death, and structural  
38 anomalies as a sequel of infection. Some pathogens like cytomegalovirus (CMV) or Zika  
39 virus produce mild to no symptoms in the pregnant patient but can cause congenital  
40 infection with severe consequences [7]. Viruses specifically can be transmitted to the  
41 fetus via the maternal blood when it enters the placental villus, containing the fetal blood  
42 vessels, or by direct access to the placenta from the lower genital tract by ascending  
43 infection [8]. Again even when transferred trans-placentally during the antenatal period,  
44 the specific timing of maternal infection can have different effects on the fetus. The first-  
45 trimester infection can cause severe structural anomalies whereas second and third-  
46 trimester infections are more likely to cause functional organ abnormalities [9].  
47  
48  
49  
50  
51  
52  
53

54 Several factors are contributing to the concerns of mother to child transmission in Covid-  
55 19. It is known that the SARS-COV-2 uses angiotensin-converting enzyme 2 (ACE2)  
56  
57  
58  
59  
60

1  
2  
3 receptors for entry into the cells. ACE-2 receptors are detected in various parts of the  
4 uterus, vagina, decidual cells, and placenta [10-13]. Recently, the case definition for  
5 SARS-CoV-2 infection in pregnant women, fetuses, and neonates has been published  
6 with a categorization of infection into confirmed, probable, possible, unlikely, and not  
7 infected groups [14].  
8  
9

10  
11 Congenital infection with intrauterine fetal death/stillbirth is [14]-

- 12 • confirmed from fetal tissue or autopsy material if the virus is detected by PCR from  
13 fetal or placental tissue or electron microscopic detection of the viral particle in  
14 tissue or viral growth in culture from fetal or placental tissue.
- 15 • a probable infection if the virus is detected by PCR in the surface swab from the  
16 fetus or placental swab on the fetal side.
- 17 • unlikely if it is positive in the maternal side of the placenta but fetal tissues are not  
18 tested and not present if it is not detected in fetal tissue in an autopsy.

19  
20  
21  
22 Similarly, congenital infection in live-born symptomatic neonate is [14]-

- 23 • confirmed when the virus is detected by PCR in umbilical cord blood or neonatal  
24 blood collected within the first 12 hours of birth or amniotic fluid collected prior to  
25 the rupture of the membrane.
- 26 • a probable infection when there is the detection of the virus by PCR in  
27 nasopharyngeal swab at birth (collected after cleaning baby) AND placental swab  
28 from the fetal side of the placenta in a neonate born via cesarean section before  
29 rupture of membrane or placental tissue.
- 30 • possible when there are anti-SARS-CoV-2 IgM antibodies in umbilical cord blood  
31 or neonatal blood collected within the first 12 hours of birth or placental tissue but  
32 nasopharyngeal swab test at birth is negative.
- 33 • unlikely or absent when samples are negative within 12 hours of birth  
34 (nasopharyngeal swab, umbilical cord blood, or neonatal blood) and antibody  
35 testing is not done or negative, respectively.

36  
37  
38  
39  
40  
41  
42 If a live-born neonate has no clinical features of infection, congenital infection is [14]-

- 43 • confirmed by detection of the virus by PCR in cord blood or neonatal blood  
44 collected within the first 12 hours of birth.
- 45 • probable if the virus is detected by PCR in amniotic fluid collected prior to rupture  
46 of the membrane but no detection in umbilical cord blood or neonatal blood  
47 collected within the first 12 hours of birth.
- 48 • possible when there is anti-SARS-CoV-2 IgM in umbilical cord blood or detection  
49 of the virus by PCR in placental tissue but PCR in umbilical cord blood, amniotic  
50 fluid, and neonatal blood (<12hours of life) is negative.



1  
2  
3 Furthermore, infection acquired intrapartum in a symptomatic neonate is confirmed if the  
4 virus is detected by PCR in nasopharyngeal swab at birth (collected after cleaning the  
5 baby) AND at 24-48 hours of age AND alternate explanation for clinical features excluded  
6 **[14]**.  
7  
8

9 Intrapartum neonatal infection in asymptomatic neonate is confirmed by detection of the  
10 virus by PCR in nasopharyngeal swab at birth (collected after cleaning the baby) AND at  
11 24-48 hours of age **[14]**.  
12

13 Postpartum infection is confirmed if a neonate shows symptoms beyond 48 hours of life  
14 and the nasopharyngeal swab is positive beyond 48hours which was negative at birth**[14]**.  
15  
16

17 If a neonate is born with a specific structural sequel of an infection, intrauterine infection  
18 is a probability. The probability of infection also depends on the presence of the agent in  
19 the genital tract and time taken from exposure to detection by definitive tests to  
20 differentiate between intrapartum and postpartum infection. Furthermore, the sensitivity  
21 of RT-PCR testing is different for detecting SARS-CoV-2 in different samples. Therefore,  
22 it is rational to test samples from multiple sites to improve detection and reduce false-  
23 negative cases **[9, 15]**.  
24  
25  
26  
27

## 28 **2. Perinatal outcome**

29 Perinatal outcome measures included fetal outcomes like fetal complications in SARS-  
30 CoV 2 positive pregnant women, gestational age at delivery (preterm delivery), mode of  
31 delivery, birth weight, and stillbirth. The neonatal period is defined as the time period from  
32 birth until the end of the first 28 days of life. Events in the early neonatal period (first 7  
33 days) usually are related to the pregnancy more significantly and it is also included in the  
34 definition of the perinatal period. In this review, we have assessed the neonatal outcomes  
35 using the APGAR score at 1 minute and 5 minutes of life, neonatal symptoms, admission  
36 into neonatal intensive care unit (ICU), and neonatal death, as the parameters. An  
37 APGAR score of less than 7 at 1 minute and 5 minutes after birth in a newborn is defined  
38 as a low APGAR score in this study **[16]**. Any outcome measures not explicitly mentioned  
39 were considered not to have been reported.  
40  
41  
42  
43  
44

- 45 • Fetal distress (FD) is assessed during labor by non-reassuring or pathological  
46 cardiotocographic (CTG) findings and meconium-stained amniotic fluid **[17, 18]**.  
47 For this research, studies reporting FD, abnormal or non-re-assuring or  
48 pathological CTG, fetal compromise, meconium-stained amniotic fluid are included  
49 under FD. Other fetal complications were pre-labor rupture of membranes and  
50 preterm prelabor rupture of membranes.  
51
- 52 • Preterm delivery is defined as delivery of a viable product of conception before 37  
53 completed weeks of gestation.  
54  
55  
56  
57  
58  
59  
60

- Delivery can be vaginal delivery (including instrumental) and by caesarean section (CS). For this research, instrumental vaginal deliveries and normal vaginal deliveries were considered together (VD).
- Both the Royal College of Obstetrics and Gynecology and the American College of Obstetricians and Gynecologists have adopted the definition of Intrauterine growth restriction (IUGR) is defined as an estimated fetal weight less than 10<sup>th</sup> percentile. The term is IUGR has been used interchangeably with Small for gestational age (SGA). SGA is a term commonly used for a neonate with birth weight less than 10 percent [19,20].
- For this research, stillbirth was considered as fetal death beyond 24 weeks of gestation, and stillbirth rate (SBR) is calculated as the number of stillbirths per 1000 total births.

**Statistical analysis:** Pooled proportions of categorical variables were calculated with percentage after obtaining the positive rates of each of the SARS-CoV-2 testing methods used, wherever applicable. Odds Ratio was calculated for the fetal outcome of preterm delivery and mode of delivery in the SARS-CoV-2 positive mothers from the pooled data (combining the studies where the control group of SARS-CoV-2 negative pregnant women was available) with 95% confidence interval and p values. The percentage of the most common variables were also calculated.

**Public and patient involvement statement:** This research is not “coproduced” with patients, carers or members of the public.

## RESULTS

### 1. Mother to child transmission-

#### Search Results:

Out of 100 records selected for full-text review, 3 Chinese , 1 Italian , 1 Dutch and 1 Spanish studies were excluded due to nonavailability of English translation. 72 studies fulfilled the eligibility criteria and were included in the qualitative synthesis. 38 studies were case reports containing 4 or fewer number of cases and 34 studies had 5 or more number of patients (**Figure-1**).

Since evidence from randomized control trials were not available until the time of the search, 34 studies having 5 or more number of patients were considered for qualitative analysis [21, 22]. However, the findings from the case reports were also noted. The majority of earlier studies were from China but later studies contained cases from the rest of the world [**Table-1a,1b**].

**Table-1 (a): Analysis of the studies [Case series/ Cohort] -Supplemental material****Table-1 (b): Analysis of the studies [Case reports] -Supplemental material****Systematic review:**

Tests for diagnosis of SARS-CoV-2 was done in a total of 1408 neonates. The most common type of sample tested was neonatal nasopharyngeal samples (NP swab) (67 out of 72 studies) followed by the placenta, amniotic fluid, and cord blood. In the majority, samples were taken from more than one site. In a few studies, the same type of sample was repeated at different intervals (e.g., NP swab and breast milk samples) [Table-2].

**Table -2 Studies and type of samples**

Serial Number	Author (reference)	Number of neonates tested	Specimen tested	Results- neonatal and others	Positive/ Total tested
1.	Chen H et al (45)	6	NP, AF, Cord blood, BM	Negative	
2.	Cao et al (67)	5	NP	Negative	
3.	Hu X et al (42)	7	NP, Urine, AF	NP +ve at 36 hours, others negative	1/7
4.	Zhu H et al (57)	10	NP	Negative [within 72 hours (8); Between D7-D9 (2)]	
5.	Zhang I et al (102)	10	NP	Negative	
6.	Penfield C et al (103)	11	NP, Placental and membrane	NP- Negative (D1 and D5) Placenta and membrane +ve	3/11
7.	Knight M et al (23)	262	NP (n=244) ,Blood or aspirate	+ve at <12 hours +ve at >12 hours	6/244 6/244
8.	Kayem G et al (25)	181	NP	+ve	2/181
9.	Nayak A et al (26)	134	NP (n=131)	+ve on D1., -ve on D5	3/131
10.	Yan J et al (24)	86	NP (n=86); Cord blood (n=10),AF (n=10)	Negative	
11.	Khan S et al (64)	17	NP	+ve within 24 hours	2/17
12.	Zeng L et al (41)	33	NP , anal swab	Both +ve D2 and D4, negative on D6	3/33
13.	Breslin N et al (59)	18	NP	Negative	
14.	Breslin N et al (114)	7	NP	Negative	
15.	Qiancheng X et al (107)	23	NP	Negative	
16.	Prabhu M et al (60)	71	NP	Negative at 24 hours	
17.	Shanes E et al (36)	16	NP , Placenta	Negative	
18.	Savasi V et al (109)	57	NP	+ve	4/57
19.	London V et al (27)	48	NP	Negative	
20.	William R et al (63)	33	NP	Negative at 24 hours, +ve at 48 hours	1/33
21.	Perez O et al (65)	82	NP	NP +ve at birth and negative at 48 hours (3); NP negative at birth but +ve at D10 (2)	5/82
22.	Nie R et al (68)	26	NP, Cord blood, Placenta	NP +ve at 36 hours, Negative - All other samples, NP (D4,D8,D15)	1/26
23.	Yin M et al (46)	17	NP (n=17), BM (n=14), AF (n=2), placenta (n=2), Anal swab (n=5)	Negative	
24.	Yang P et al(81)	7	NP , Cord blood, AF	Negative	
25.	Yang H et al (73)	55	NP	Negative	
26.	Wu Y et al (47)	5	NP , Anal swab, BM	Negative, BM +ve	1/5
27.	Patane L et al (39)	22	NP , Placenta	NP +ve , Placenta- Chronic intervillitis, PCR +ve in placenta	2/22
28.	Ferrazzi E et al (28)	42	NP	NP +ve on D1,D3(2) NP equivocal at birth but +ve on D3(1)	3/42
29.	Govind A et al (61)	9	NP , Placenta, AF	NP +ve	1/9
30.	Vintzileos W et al (113)	29	NP	Negative	
31.	Baergen R et al (37)	21	NP	Negative	
32.	Zeng H et al (54)	6	NP Neonatal blood	NP negative; Elevated IgM and IgG (2); Elevated IgG ,normal IgM (3)	Cytokine IL-6 elevated in all infants
33.	Liu Y et al (69)	10	Fetal blood	Negative	
34.	Mulvey J et al (38)	5	Placenta	Negative	

35.	Hantoushzadeh et al (75)	4	NP	Negative at D1; +ve at D7	1/4
36.	Buonsenso et al (53)	2	NP, AF, Placenta, Cord blood, Rectal swab, BM	1 <sup>st</sup> - NP Negative on D1, D4 and +ve on D15, Placenta, AF, rectal swab-Negative, Weak IgG+ve, IgM negative 2 <sup>nd</sup> - Placenta, Breast milk- +ve but cord blood negative in neonate with NP negative result	1/2
37.	Fan C et al (48)	2	NP, AF, Cord blood, BM, Placenta, Vaginal swab	Negative	
38.	Liu W et al (56)	3	NP, Cord blood, Neonatal whole blood	Negative (D2)	
39.	Lowe B et al (62)	1	NP	Negative	
40.	Chen S et al (104)	3	NP, Placenta	Negative	
41.	Chen Y et al (58)	4	NP	Negative	
42.	Gidlöf S et al (76)	2	NP	Negative (34 hours and 4.5 days)	
43.	Khan S et al (85)	3	NP	Negative	
44.	Schnettler W et al (110)	1	NP, AF	AF Negative, NP negative on D1, D2	
45.	Blauvelt C et al (84)	1	NP, Rectal swab D2 Ig G and IgM	NP Negative on D1, D2, D14 Rectal swab negative on D2 Ig G and IgM negative (D5)	
46.	Alzamora M et al (78)	1	NP, Cord blood	Negative for IgM and IgG; NP +ve at 16 hours and 48hours	1/1
47.	Vivanti A et al (29)	1	NP, AF, Vaginal swab, NBAL, Neonatal blood and rectal swabs	NP +ve at 1hour, D3, D18; Rectal swab +ve at 1hour, D3, D18; Vaginal swab, NBAL, Neonatal blood, AF +ve,	1/1
48.	Song L et al (49)	1	NP, AF, Cord blood, BM	NP negative at D3, D7 All other negative	
49.	Zambrano L et al (87)	1	NP	Negative	
50.	Li Y et al (44)	1	NP, Neonatal Blood, feces, and urine	NP negative at birth and 48h All other negative	
51.	Dong L et al (55)	1	NP, Serum Vaginal swab	IgM level elevated NP negative at 2h, 16h	1/1
52.	Baud D et al (33)	1	NP, AF, Placenta Vaginal swabs	Placenta +ve All other negative	1/1; 2 <sup>nd</sup> trimester spontaneous miscarriage
53.	Wang X et al (77)	1	NP, AF, Placenta, Cord blood, gastric juice, feces	NP negative at D1, D3, D7, D9 All other negative	
54.	Huang J et al (86)	1	NP	Negative	
55.	Iqbal S et al (105)	1	NP	Negative	
56.	Kalafat E et al (79)	1	NP, Cord blood, Placenta	Negative	
57.	Lee D et al (80)	1	NP, AF, Cord blood, Placenta, neonatal serum, anal swab	Negative	
58.	Liao X et al (106)	1	NP, AF, Cord blood, Placenta	Negative	
59.	Xiong X et al (50)	1	NP, AF, BM, rectal swab	Negative	
60.	Wang S et al (51)	1	NP, Placenta, Cord blood, BM	NP +ve at 36 h Negative in all others	1/1
61.	Zamaniyan M et al (30)	1	NP, Cord blood, AF, Vaginal secretion	NP – Negative at 0 hours, +ve at D2, D4, D6 AF +ve, all others negative	1/1
62.	Kirtsman M et al (35)	1	NP, Placental, Stool, BM Neonatal plasma D4	NP +ve at D1, D2, D7 Placenta +ve Stool +ve D7, BM +ve	1/1
63.	Lyra J et al (74)	1	NP	Negative	
64.	Algorroba G et al (34)	1	NP	Negative at 0 h, D2, D7	
65.	Peng Z et al (43)	1	NP, NBAL Fluid, Sputum, Urine	Negative	
66.	Groß R et al (52)	2	BM, NP	Both NP +ve (>D7), BM +ve (1)	2/2, 1/2
67.	Perrone S et al (72)	4	NP (3), Placenta (1)	NP negative on D1, Placenta-negative	
68.	Hosier H et al (32)	1	Placenta, cord blood	Both +ve	1/1; D&E at 22 weeks
69.	Pulinx B et al (31)	2	AF, Placental	Both +ve	2/2, DCDA twin at 24 weeks
70.	Yu N et al (108)	2	AF in mid pregnancy	Negative	
71.	Kulkarni et al (117)	1	NP, Placenta, Cord stump, Neonatal blood	All +ve at 12 hours of life; Serology negative on D10 but +ve on D21	1/1

72.	Sisman J et al (70)	1	NP, Placenta	NP +ve at 24 hours, 48 hours, D14; Placenta +ve by electron microscopy	1/1
-----	---------------------	---	--------------	---	-----

AF= Amniotic fluid; NP= Neonatal Pharyngeal/throat swab; BM= Breast milk; NBAL= Non-bronchoscopic broncho-alveolar lavage fluid; D&E- dilatation and evacuation; D1= 1<sup>st</sup> day of life, D4= 4<sup>th</sup> day of life.

### i. Neonatal Nasopharyngeal swab

In our review, a total of 1388 neonates born to mothers with COVID-19 infection were tested by NP swabs. 51 neonates were found positive by the RT-PCR test constituting 3.67% of total pooled samples. [Table-3a].

**Table-3 (a): Mother to child transmission-Test positive (Pooled result) - Supplemental material**

SAMPLE Tested by RT-PCR for SARS-CoV-2	Number of studies	Number Tested	Number Positive	Pooled Percentage
Neonatal Naso-pharyngeal swab	67 [32 case series/cohort +35 case reports]	1388 [1335 case series/cohort+53 case reports]	51 [40 out of 1335 in case series/cohort+ 11 out of 53 case reports]	3.67% [3% in case series/cohort; 2.07% in case reports]
Placenta ± Membranes	22	111	13	11.7%
Amniotic fluid	19	58	4	6.8%
Breast milk	10	56	3	5.3%
Cord blood/ plasma	16	56	4	7.1%
Other neonatal samples				
-Anal swab	11	52	5	9.6%
-Urine	3	9	0	
Neonatal serology				
IgM	5	11	(Elevated) 3	27%
IgG	4	10	(Elevated) 6	60%

The largest cohort study from the UK involved 427 pregnant women with COVID-19. 244 out of the 262 neonates were tested by NP swab. 6 of the neonates were positive for SARS-CoV-2 within 12 hours of birth and 6 more were positive after 12 hours of birth (12 out of 244; 4.9%) [23]. Studies involving 181 women and 116 women in China showed 2 positive neonates out of 181 (2 out of 181; 1.1%) and no positive cases for SARS-CoV-2 in the other study [24, 25]. An analysis of 141 women from a hospital in India showed that 3 of the 131 neonates were tested positive for SARS-CoV-2 by NP swab [26]. In another study in a New York Hospital, 48 neonates born to 55 women were all tested negative on Day 0 of life [27]. However, One Italian study found three infants positive by NP swab out of 42 tested within 48 hours after birth [28].

One recent case report revealed that RT-PCR was positive for SARS-CoV-2 in all of the samples for amniotic fluid, vaginal swab, blood, and non-bronchoscopic bronchoalveolar lavage fluid as well as NP swab and rectal swabs collected at 1 hour of life, and then repeated at 3 days and 18 days suggesting a trans-placental transmission [29].

As stated earlier NP swab positivity at different neonatal ages plays an important role in confirming or ruling out the viral transmission from a SARS-CoV-2 positive mother. On further analysis of the positive samples, the congenital infection was confirmed in 5 live-born neonates, possible in 5 neonates, and probable in 2 neonates. Neonatal infection acquired intrapartum was confirmed in 2 neonates, probable in 5 neonates, and possible in 14 neonates. Similarly, neonatal infection acquired postpartum was confirmed in 7 neonates and infection was unlikely in 1 neonate [Table-3b].

**Table-3 (b): Analysis of evidence of congenital/ intrapartum/ postpartum transmission**

Author (reference) [samples positive/ total tested]	Samples +ve	Fetal/ Neonatal status	Alternate explanation for clinical features	Mother to child transmission (n)
Groß R et al (52) [2/2]	NP >D7	Respiratory symptoms (2), icterus (1)	Alternate explanation-excluded in 1 ; Respiratory syncytial virus +ve in 1	Neonatal infection acquired postpartum-Confirmed (1) Unlikely (1)
Buonsenso et al (53) [1/2]	1st- NP Negative on D1, D4 and +ve on D15, Placenta, AF, rectal swab-Negative, Weak IgG+ve, IgM negative 2nd - Placenta, Breast milk- +ve but cord blood negative in neonate with NP negative result	Symptoms- Absent	-	Neonatal infection acquired postpartum-Confirmed (asymptomatic) (1 <sup>st</sup> ) Possible congenital infection (2 <sup>nd</sup> )
Vivanti A et al (29) [1/1]	NP +ve at 1hour, D3, D18; Rectal swab +ve at 1hour, D3, D18; Vaginal swab, NBAL, Neonatal blood +ve	Irritability, poor feeding, axial hypertonia and opisthotonos	Alternate explanation-excluded	Confirmed congenital infection
Kirtsman M et al (35) [1/1]	NP +ve at birth, D2, D7 Placenta (fetal side) +ve Stool +ve D7, BM +ve	Hypothermia, feeding difficulties, hypoglycemia, neutropenia	Alternate explanation-excluded	Probable congenital infection
Zamanyan M et al (30) [1/1]	NP - negative at 0 hours, +ve at D2, D4, D6 AF before rupture of membranes +ve Cord blood and vaginal secretion - negative	Fever (1)	Alternate explanation-not identified	Confirmed congenital infection
Wang S et al (51) [1/1]	NP +ve at 36 hours Placenta, Cord blood, BM- Negative	Vomiting, lymphopenia, abnormal liver enzyme levels	Alternate explanation-excluded	Neonatal infection acquired intrapartum possible
Khan S et al (64) [2/17]	NP +ve within 24 hours	NNP	Alternate explanation-not identified	Neonatal infection acquired intrapartum- possible
Zeng L et al (41) [3/33]	NP +ve at D2, D4, negative at D6	RD (1); Cyanosis, feeding intolerance(1); Fever (2); NNP(3); Lethargy, fever(1); lethargy, fever, NNP, vomiting leukocytosis, lymphocytopenia, (1); Preterm- Neonatal RDS, NNP, lymphocytopenia (1)	Alternate explanation-excluded	Neonatal infection acquired intrapartum-possible NP not done at birth, no other samples tested
Hu X et al (42) [1/7]	NP +ve at 36 hours; fetal urine, AF are negative	Symptoms- Absent	-	Neonatal infection acquired intrapartum- Possible NP not done at birth
Knight M et al (23) [12/244]	NP +ve at <12 hours (6) NP +ve at >12 hours (6)	Neonatal encephalopathy (1)	-	Congenital infection possible(1) Other evidences lacking
Alzamora M et al (78) [1/1]	NP +ve at 16 hours and 48 hours	Respiratory difficulty and cough	Alternate explanation-excluded	Neonatal infection acquired intrapartum - confirmed NP not done at birth



	Cord Blood IgM and Ig G negative at D1 and D5			
Hantoushadeh et al (75) [1/4]	NP -ve on D1, +ve on D7	NNP, lymphopenia (1)	-	Neonatal infection acquired postpartum-Confirmed
William R et al (63) [1/33]	Negative at 24 hours, +ve at 48 hours	Symptoms- Absent	-	Neonatal infection acquired postpartum-Confirmed
Nayak A et al (26) [3/131]	NP +ve on D1;-ve on D5	Neonatal seizures, MAS (1)	-	Probable neonatal infection acquired intrapartum
Nie R et al (68) [1/26]	NP +ve at 36 hours, negative - D4, D8,D15; Cord blood, placenta-negative	Pulmonary infection (1)	Alternate explanation-not identified	Neonatal infection acquired intrapartum - Possible NP not done at birth
Savasi V et al (109) [4/57]	Timing of NP test could not be ascertained (early postpartum period)	-	-	-
Kayem G et al (25) [2/181]	Timing of test could not be ascertained	-	-	-
Patane L et al (39) [2/22]	1 <sup>st</sup> - NP +ve at birth,>24hours, >7 days 2 <sup>nd</sup> - NP negative at birth, +ve on D7 Placenta- Chronic intervillitis, PCR +ve in both placenta	Mild feeding difficulty (2)	-	Probable congenital infection (1) Possible congenital infection (1)
Ferrazzi E et al (28) [3/42]	NP +ve on D1, D3(2) NP equivocal at birth but +ve on D3(1)	Gastrointestinal symptoms, RD (2)	Alternate explanation-not identified	Neonatal infection acquired postpartum-Confirmed (1) Neonatal infection acquired intrapartum - possible(2) Other evidences lacking
Govind A et al (61) [1/9]	NP at birth	NNP (1)	Alternate explanation-excluded	Neonatal infection acquired intrapartum - confirmed? NP not done after 24 hours
Penfield C et al (103) [3/11]	NP- Negative (D1 and D5) Placenta and membrane +ve	Symptoms- Absent		Neonatal infection acquired intrapartum - Possible
Baud D et al (33) [1/1]	NP, AF, Vaginal swabs- Negative Placenta +ve	2nd trimester spontaneous miscarriage		Confirmed congenital infection
Hosier H et al (32) [1/1]	Placenta, cord blood-both +ve	D& E at 22 weeks		Confirmed congenital infection
Pulinx B et al (31) [2/2]	AF, Placenta-both +ve	DCDA twin at 24 weeks expelled		Confirmed congenital infection
Dong L et al (55) [1/1]	IgM level elevated NP negative at 2h,16h	Symptoms-absent	-	Possible congenital infection
Zeng H et al (54) [1/1]	NP negative; Elevated IgM and IgG (2); Elevated IgG ,normal IgM (3)	Symptoms-absent	-	Possible congenital infection
Perez O et al (65) [5/82]	NP +ve at birth and negative at 48 hours (3); NP negative at birth but +ve at D10 (2)	RD (2) Symptoms-absent (3)	Alternate explanation-not identified (2)	Neonatal infection acquired intrapartum – Probable (2) Neonatal infection acquired intrapartum – Possible (1) Neonatal infection acquired postpartum-Confirmed (2)
Kulkarni et al (117) [1/1]	NP, placenta, Cord stump RT PCR- All +ve at 12 hours of life NP at D5 and D10 +ve	Fever, icterus, and poor feeding	Alternate explanation-excluded	Confirmed congenital infection
Sisman J et al (70) [1/1]	NP +ve at 24 hours, 48 hours, D14 Placenta +ve by electron microscopy	Fever, RD, Icterus	Alternate explanation-excluded	Confirmed congenital infection

AF= Amniotic fluid; NP= Neonatal Pharyngeal/throat swab; BM= Breast milk; NBAL= Non-bronchoscopic broncho-alveolar lavage fluid; NNP=Neonatal Pneumonia; D&E- dilatation and evacuation; RD= Respiratory distress; DCDA- Dichorionic diamniotic twin

However, in a larger study, out of 12 neonates with positive NP result [6 within 12 hours of life and 6 at more than 12 hours of life], further analysis was not possible due to lack of followup swab results and unavailability of test results of other maternal samples like placenta and amniotic fluid [23].

## ii. Amniotic fluid

In our review, 58 samples of amniotic fluid were tested in 19 studies with a positive result in 4 samples [29, 30, 31]. Congenital infection is confirmed in 2 of the studies in live-born neonates [29, 30]. Congenital infection is also confirmed in a dichorionic, diamniotic (DCDA) twin expelled at 24 weeks by positive amniotic fluid result [31].

## iii. Placenta

A total of 22 studies were identified in our review where the placenta was examined for the presence of SARS-CoV-2 or related pathological changes. A total of 111 placental samples were tested and 13 were found positive for SARS-CoV-2. PCR for SARS-CoV-2 RNA was positive from the placenta in two case reports where there were spontaneous miscarriage and dilatation and curettage respectively confirming a congenital infection [32, 33]. In one of them, the umbilical cord was also positive for the virus, but the fetal organs were tested negative. The virus was confirmed to be localized mostly in the syncytiotrophoblastic cells of the placenta by immunohistochemistry for the SARS-CoV-2 spike protein as well as electron microscopy and it was identical to the typically locally isolated virus [32]. In another study, electron microscopy showed the presence of the virus in the fetal side of the placenta. The virions were present in the mesenchymal core of the terminal villus and were demonstrated to be invading a syncytiotrophoblast and a microvillus. However, the neonate delivered at 28 weeks in this pregnancy was tested negative for the virus [34].

Evidence of probable mother to child transmission was obtained in another case where the newborn was found positive for the virus by nasopharyngeal swab, plasma, and stool samples along with the placenta [35]. Similarly, confirmed congenital transmission of the virus was demonstrated by another study where SARS-CoV-2 was detected in amniotic fluid aspirated before the rupture of the membranes, vaginal swab, neonatal blood, bronchoalveolar lavage fluid, and neonatal swabs on repeated occasions at 1 hour, 3<sup>rd</sup> day and 18<sup>th</sup> day of life. The trophoblastic cells showed SARS-CoV-2 N protein on immunostaining [29].

Placental pathological examination showed an array of changes including vascular malperfusion, fibrin deposition, and chronic villitis, intervillitis, and villous infarctions in our review. Two of these studies showed vascular malperfusion in 10 out of 20 placentas and 12 out of 15 placentas respectively but there were no assessments of placentas in these studies for the presence of SARS-CoV-2 infection. However, neonatal swabs were negative for the virus [36, 37]. Similar pathological changes were seen in another study involving five SARS-CoV-2 positive pregnant women but the placentas were negative for the virus on direct testing for SARS-CoV-2 [38]. Chronic intervillitis was also seen in the pathological examination of the placentas of two women where the neonates were positive for SARS-CoV2 by nasopharyngeal swab testing [39]. Examination showed

1  
2  
3 severe chronic villitis in another case where there was a stillbirth at term but direct tests  
4 of fetal tissues and placenta did not show infection with the virus [40].  
5  
6

#### 7 **iv. Other samples**

8 Various other samples were tested for SARS-CoV-2 by different studies. Anal swab,  
9 rectal swab, or fecal sample was positive in 9.6% of neonates in our study. The stool  
10 sample was positive in two of the studies on Day 2 and Day 7 of life [35, 41]. The urine  
11 sample was tested in only 3 studies without any positive results [42- 44]. Breast milk was  
12 tested by RT-PCR in 10 of the studies with a pooled positive rate of 5.3% (3 out of 56)  
13 [35, 45- 53]. In one of the studies, the breast milk sample was positive in 4 consecutive  
14 days coinciding with the maternal symptoms in one woman but it was negative in milk  
15 samples of another woman. Both the babies were positive by the nasopharyngeal swab  
16 test and were symptomatic [52]. A vaginal swab was tested in 23 women with one positive  
17 result (4.3%) [29]. Since IgM cannot cross the placenta, elevated IgM levels in the  
18 neonate indicate possible congenital infection, as seen in some of the neonates in this  
19 review [54, 55]. However, the assay of IgM for the detection of infection has significant  
20 false-positive results.  
21  
22  
23  
24  
25  
26  
27

## 28 **2. Perinatal outcome-**

### 29 **Search results:**

30  
31 Out of 73 records selected for full-text review, 1 Chinese and 1 Spanish study were  
32 excluded due to unavailability of English translation. a total of 60 studies fulfilled the  
33 eligibility criteria and were included in the qualitative synthesis. 31 studies qualified as  
34 case series/cohort and 29 studies contained 4 or fewer cases in our review (Figure-2).  
35 No randomized control trials were available until the time of the search.  
36  
37  
38

### 39 **Systematic Review:**

#### 40 **2.1 Fetal Outcomes:**

##### 41 **i. Fetal complications in SARS-CoV-2 +ve pregnant women**

42 In our review, a total of 30 studies reported any fetal effects excluding all pregnancy  
43 losses or intrauterine fetal deaths (IUFD) [Table no-4]. The most commonly reported  
44 effect was fetal distress in 36 out of 1311 pregnancies (2.74%). In addition to fetal  
45 distress, some studies have reported non-reassuring or pathological cardiotocography  
46 (CTG) (11 out of 1311; 0.83 %), and some have mentioned meconium-stained amniotic  
47 fluid (3 out of 1311; 0.22%), both findings can also be considered as evidence of fetal  
48 distress [29, 56- 62]. In another study involving 262 deliveries, the fetal compromise was  
49 seen in 37 fetuses and an emergency caesarean section (CS) was done in 9 of them [23].  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Thus, the cumulative chance of fetal distress in pregnant women with a positive test for SARS-CoV-2 is 6.63%.

Premature rupture of membrane (PROM) was reported in 42 pregnancies from 13 studies and Preterm PROM was reported in (PPROM) in 14 pregnancies [24, 41, 42, 45, 50, 57, 60, 63-70]. Intrauterine growth restriction (IUGR) was reported in 12 fetuses in 5 studies [24, 63, 65, 71, 72]. The highest number of IUGR fetuses was reported in 6 out of 10 fetuses in another study [71]. Besides, small for gestational age was reported in another study in 2 out of 10 fetuses [57]. Chorioamnionitis was reported only in one study involving 3 fetuses [5].

**Table-4: Fetal outcome**

Serial number	Author (reference)	Number of neonates from SARS CoV-2 +ve pregnancies	Fetal complications (n)	Mode of delivery (n)	Birth weight in grams	Preterm delivery (n)	Still birth(n)	Comments
1.	Chen H et al (45)	9	FD (2) PROM (1)	CS (9)	1880-3730	Yes (2)	-	
2.	Romagano M et al (82)	7	-	CS(7)	1290-2580 (AGA)	Yes (7)	-	
3.	Zeng H et al (54)	6	-	CS (6)			-	
4.	Zhu H et al (57)	10	FD (6), PROM (3), MSA (2)	CS (7) VD (2)	SGA-2 LGA/Normal-8	Yes (6)	-	1 twin delivery
5.	Khan S et al (64)	17	PROM	CS (17)	2300–3750 <2700-3	Yes (5)	-	
6.	Zeng L et al (41)	33	PROM (3); FD (1)	VD (7); CS (26)	SGA (3) 1580-3360	Yes(4)	-	
7.	Breslin N et al (59)	18	Ab.CTG (3)	CS (8); VD (10)		Yes (1)	-	
8.	Qiancheng X et al (107)	23	-	CS (17) VD (5)	3130 (2915–3390)	Yes(1)	-	1 twin delivery
9.	Hantoushzadeh S et al (75)	5	IUFD (3)	CS (4)	1180-3200	Yes (3)	Yes (1)	1 twin delivery
10.	Perez O et al (65)	82	PROM (18) PPROM (7) IUGR (1)	VD (41) CS (41)	1450-3210	Yes (25)	-	
11.	Savasi V et al (109)	57	-	VD (34) CS (22)	3160 (840-4350)	Yes(12)	-	1 twin delivery
12.	London V et al (27)	56	DFM (1) IUFD (17 wks) (1)	CS (22) VD (33)	-	Yes(12)	-	
13.	Lokken E et al (40)	8	FD (3)	CS (3) VD (5)	-	Yes (1)	Yes(1)	
14.	Yan J et al (24)	99	FD (9); IUGR (2) PPROM (6)	CS (85) VD(14)	3108±526	Yes (21)	-	
15.	William R et al (63)	32	IUGR(2), PPRM (1)	CS (24) VD(8)	2403.3±858	Yes (19)	-	
16.	Knight M et al (23)	262	Miscarriage (4); Fetal compromise (37)	CS (156) VD (106)	-	Yes (66)	Yes (3)	
17.	Kayem G et al (25)	176	Fetal loss <21 weeks (5)	CS (87) VD (89)	-	Yes (50)	Yes (2)	
18.	Nayak A et al (26)	134	Miscarriage (6)	CS (67) VD(67)	>2500 (92) <2500 (39)	Yes (38)	Yes (3)	
19.	Prabhu M et al (60)	70	PROM and Ab.CTG (4)	CS (32) VD(38)	3060.9-3149.6	Yes (11)	Yes (1)	
20.	Li N et al (66)	17	FD(1) ; PROM (1)	CS (14) VD(2)	3078.2 ± 565.0	Yes (4)	-	1 twin delivery
21.	Cao D et al (67)	11	FD (3); PROM (4)	CS (8) VD(2)	2050-3800	Yes (4)	-	1 twin delivery

22.	Hu X et al (42)	7	PROM (1)	CS (6) VD(1)	3180-3670	-	-	
23.	Yang P et al (81)	7	-	CS(7)	2096 ± 660	Yes (4)	-	
24.	Yang H et al (73)	13	-	CS (9) VD(4)	3063.2 ± 536.4	-	-	
25.	Ferrazzi E et al (28)	42	-	CS (18) VD(24)	2730-3226	Yes(11)	-	
26.	Govind A et al (61)	9	Ab.CTG (1)	CS (8) VD(1)	1200-4300	Yes(2)	-	
27.	Nie R et al (68)	28	FD (4); IM (1); PROM (3)	VD (5); CS (22)	2988(502)	Yes (10)	-	1 twin delivery
28.	Yin M et al (46)	17	IM (3)	VD (4); CS (13)	2580-3035	Yes (5)	-	
29.	Qadri F (115)	10		CS (2) VD (8)		Yes (1)		
30.	Doria M et al (71)	10	IUGR (6)	CS (6) VD(4)	2350-3380	-	-	
31.	Liu Y et al (69)	10	FD(3), PROM (1)	CS(10)		Yes (6)	Yes(1)	
32.	Perrone S et al (72)	4	IUGR(1)	VD(4)	2290-3790	-	-	
33.	Patane L et al (39)	2	-	VD (1) CS(1)	2660, 2686	Yes(1)	-	
34.	Fan C et al (48)	2	-	CS (2)	3440-2890	Yes (1)	-	
35.	Pulinx B et al (31)	2	IUFD (1)	VD (2)		Yes (1)	Yes (1)	DCDA twins
36.	Liu W et al (56)	3	FD (1); MSA ; chorioamnionitis	CS (2) VD (1)	3250-3670	-	-	
37.	Cooke W et al (83)	2	-	CS (2)	1530,1400	Yes(2)	-	
38.	Chen Y et al (58)	4	DFM (1) Ab.CTG (1)	CS (3) VD(1)	3050-3550	-	-	
39.	Gildof S et al (76)	2	-	CS (2)	2680,2160	Yes (2)	-	
40.	Khan S et al (85)	3	-	VD (3)	2890-3750	Yes (1)	-	
41.	Zambrano L et al (87)	1	-	VD(1)	1500	Yes(1)	-	
42.	Lowe B et al (62)	1	Ab.CTG (1)	VD (1)		-	-	
43.	Blauvelt C (84)	1	-	CS(1)	1880	Yes (1)	-	
44.	Kirtsman M et al (35)	1	-	CS(1)	2930	Yes (1)	-	
45.	Lyra J et al (74)	1	-	CS(1)	3110	-	-	
46.	Li Y et al (44)	1	FD(1)	CS(1)		Yes (1)	-	
47.	Dong L et al (55)	1	-	CS(1)	3120	Yes (1)	-	
48.	Wang X et al (77)	1	FD (1)	CS(1)	1830	Yes (1)	-	
49.	Alzamora M et al (78)	1	-	CS(1)	2970	-	-	
50.	Huang J et al (86)	1	-	VD(1)		-	-	
51.	Kalafat E et al (79)	1	-	CS(1)	2790	Yes (1)	-	
52.	Xiong S et al (50)	1	PROM	VD(1)	3070	-	-	
53.	Wang S et al (51)	1	FD (1)	CS(1)	3205	-	-	
54.	Zamaniyan M et al (30)	1	-	CS(1)	2350	Yes (1)	-	
55.	Song L et al (49)	1	-	CS(1)	3630	Yes (1)	-	
56.	Lee D et al (80)	1	-	CS (1)	3130	-	-	
57.	Iqbal S et al (105)	1		VD(1)				
58.	Vivanti A et al (29)	1	Ab.CTG (1)	CS(1)	2540	Yes (1)	-	
59.	Kulkarni et al (117)	1	-	VD(1)	3200	-	-	
60.	Sisman J et al (70)	1	PROM	VD(1)	3280	Yes (1)		

FD= Fetal distress; Ab.CTG= Non-reassuring/ Pathological fetal cardio-tocography ; PROM= Pre-labor rupture of membrane ; Fetal demise= IUFD ; MSA= Meconium stained amniotic fluid; DFM= Decreased fetal movement; IM= Induced miscarriage; CS= Caesarean Section; VD= Vaginal delivery; AGA= Appropriate for gestational age; IUGR= Intrauterine growth restriction; SGA= Small for gestational age; LGA= Large for gestational age

## ii. Mode of delivery

Mode of delivery was available for a total of 1311 out of which 8 were twin pregnancies. 761 (60%) delivered by CS 506 (40%) by VD out of 1267 pregnancies in case series. In case reports, out of 44 deliveries, 25 were CS (56.8%) and 19 (43.2%) were VD bringing the percentage of CS to 59.9% and VD to 40.1% in the pooled data. [Table no-5]. Few



studies in our data compared the CS in the SARS-CoV-2 positive pregnant women to negative controls comprising 122 CS in the positive group out of 233 and 650 CS in the control group out of 1562 in the pooled data. ODDs Ratio (OR) for CS in SARS-CoV-2 positive mothers is 1.5421 [95% CI- 1.1701 to 2.0324] and P = 0.0021. which is statistically significant [26, 60, 66, 73].

CS was the only mode of delivery in the majority of early published case reports as in the early days of the pandemic, elective CS delivery was the mode preferred by most of the countries for maternal indications [29, 30, 35, 44, 45, 48, 49, 51, 54, 55, 64, 74-84]. As the pandemic progressed, favorable outcomes were reported from vaginal delivery by many studies [50, 62, 72, 85- 87]. It was also demonstrated that the chances of the virus being present in the vaginal fluid is very remote. In the later and larger case series, CS deliveries were only done for obstetrical indications [26]. In a study involving 134 deliveries, there were 67 CS and 67 vaginal deliveries. The rate of CS was not statistically different in women with positive SARS-CoV-2 as compared to negative pregnancies [26]. In yet another study, there were significantly higher rates of CS deliveries in cases (14 out of 16) as compared to the control group (57 out of 121) ( $p < 0.001$ ) but there was no difference in the groups with regards to chronic illnesses or pregnancy complications [66]. However, when done for maternal COVID-19 indications, the rate of cesarean was found to increase with the severity of the disease [25]. In another study, out of 41 CS deliveries, 12 were for COVID-19 symptoms without other obstetrical indications [4 with severe symptoms and 8 with mild/moderate symptoms] [65].

In the largest study in the UK, the CS delivery was seen in 156 women and vaginal birth was seen in 106 women from a total of 262 births. The indications of CS were maternal compromise (27%), fetal compromise (24%), failed induction of labor or failure to progress (19%), other obstetric reasons (16%), prior CS (10%), and maternal request (4%) [23]. Maternal COVID -19 related conditions were predominant indications in another larger study reporting CS for COVID-19 pneumonia in (33 out of 85), previous CS (16 out of 85), fetal distress (9 out of 85), and failure to progress in 5 out of 85 patients [24]. Many other studies similarly reported maternal condition requiring delivery as the commonest indication for CS [25, 28, 81].

**Table-5: Perinatal outcome (Pooled data)**

FETAL OUTCOME				
Outcome	Number of studies	Results	Indications	Remarks
Preterm birth	43 studies [26 case series/cohort and 17 case reports]	-Preterm birth=330 out of 1273 neonates in the case series/cohort (25.9%) -Preterm birth= 19 out of 45 neonates in the case reports (42.2%)	-Iatrogenic prematurity to improve maternal COVID-19 related respiratory symptoms =153 -Spontaneous preterm labor=24 -Fetal compromise/distress=17	Pooled Preterm birth in 26.4% of total births Spontaneous preterm birth- 1.8% of total births



			-Unknown/ other = 156	
Mode of delivery	59 studies [30 case series/cohort and 29 case reports]	-In case series/ cohorts, out of 1267 deliveries, CS=761 (60%) and VD=506 (40%) -In case reports, out of 44 deliveries, CS=25 (56.8%) and VD=19 (43.2%)	Maternal COVID-19 related conditions most common indication	Pooled data- CS= 786 (59.9%) VD= 525 (40.1%)
Still birth Miscarriage	Still birth=8 studies Miscarriage= 5 studies	Still birth=13 Spontaneous miscarriage= 15 Induced miscarriage=4	All induced miscarriages were due to maternal request	Stillbirth rate= 9.9
Fetal complications	FD= 21 studies PROM and PPROM= 15 studies	Fetal distress (87 out of 1311 pregnancies) (6.63%) PROM and PPRM (56 out of 1311 pregnancies) (4.27%)	-	-
IUGR and SGA	IUGR-5 studies SGA-2 studies	12 fetuses had IUGR (0.9%) 5 neonates had SGA (0.38%)	-	-
<b>NEONATAL OUTCOMES</b>				
<b>OUTCOME</b>		<b>Results</b>		
Neonatal symptoms		Respiratory symptoms= 23 neonates (1.79%) Neonatal pneumonia and pulmonary infection= 14 neonates (1.1%) Fever= 12 neonates (0.9%)	Most common symptom is respiratory distress in (1.17%)	
APGAR score		Score of less than 7 at 1minute and 5 minutes= neonates	Most common reason is preterm birth	
ICU admissions		In 276 neonates (21.5%)	Most common reason was for observation and isolation (32.6 %). Prematurity is second most common reason ICU admissions for suspected or confirmed neonatal sepsis was reported in 6 neonates (0.46%).	
Neonatal death		7 neonates		Neonatal death rate=5.46 per 1000 live births

FD= Fetal distress; Ab.CTG= Non-reassuring/ Pathological fetal cardio-tocography ; PROM= Pre-labor rupture of membrane ; MSA= Meconium stained amniotic fluid; IM= Induced miscarriage; CS= Caesarean Section; VD= Vaginal delivery; IUGR= Intrauterine growth restriction; SGA= Small for gestational age

### iii. Preterm Delivery

1  
2  
3 In our study, the outcome of preterm delivery was reported in a total of 43 studies involving  
4 1318 fetuses out of which 330 out of 1273 neonates in the case series and cohort (25.9%)  
5 and 19 out of 45 neonates in the case reports (42.2%) were delivered preterm. The  
6 pooled Preterm birth was seen in 26.4% of total births [Table no- 5]. However, the  
7 majority of them were elective deliveries to improve maternal respiratory conditions  
8 related to COVID-19. Spontaneous preterm delivery was only seen in 1.8% of neonates.  
9 The other indications included the preterm pre-labor rupture of membranes. In a  
10 substantial number of studies, data regarding the indications were not found. Few studies  
11 in our data compared the preterm delivery in the SARS-CoV-2 positive pregnant women  
12 to negative controls comprising of 52 preterm deliveries in the positive group out of 220  
13 and 267 preterm deliveries in the control group out of 1520 in the pooled data. ODDs  
14 Ratio (OR) for preterm delivery in SARS-CoV-2 positive mothers is 1.4526 [95% CI-  
15 1.0360 to 2.0366] and  $p = 0.0304$  [26, 60, 66].  
16  
17  
18

19 In a study involving 134 deliveries in COVID -19 patients, preterm delivery was reported  
20 in 38 pregnancies with positive SARS-CoV-2 and 239 out of 836 SARS-CoV-2 negative  
21 deliveries, which was not significantly different [26]. A similar report was seen in another  
22 study where 4 preterm deliveries were seen out of 17 SARS-CoV-2 confirmed group as  
23 compared to 7 out of 121 in the control group [66]. In another study, out of a total of 25  
24 preterm deliveries, iatrogenic preterm delivery was done in 12 and 13 were spontaneous  
25 preterm deliveries [65].  
26  
27  
28

29 Furthermore, comparing the outcomes of COVID-19 pregnancies with different disease  
30 severity involving 181 pregnant women, preterm delivery was seen in 13 out of 123  
31 (10.6%), 14 out of 29 (48.3%), and 23 out of 29 (79.3%) in women with non-severe,  
32 oxygen-requiring, and critical COVID-19, respectively. Delivery before 32 weeks was  
33 highest in 48.3% of women in the critical COVID-19 group. In severe disease, urgent  
34 delivery is required to stabilize the maternal condition, even when it results in iatrogenic  
35 preterm delivery [25].  
36  
37  
38

#### 39 iv. Birth weight

40 In our review, birth weight was missing in many studies and only the mean weight of the  
41 babies was mentioned in some of the series. IUGR was reported in 4 studies in 11 babies  
42 [24, 63, 71, 72]. Also, SGA was found in 2 studies in 5 babies [41, 57]. A maximum of 6  
43 babies had IUGR in one study but they were described as mild [71].  
44  
45  
46

#### 47 v. Miscarriage and stillbirth

48 Stillbirth was seen in 13 fetuses in 8 studies in our review and seven were second-  
49 trimester miscarriages [23, 25, 26, 31, 40, 60, 69, 75] [Table no-5]. 3 intrauterine deaths  
50 were observed in one of the studies which reported maternal deaths due to COVID-19  
51 [75]. Similarly, we found 15 spontaneous miscarriages, and 4 induced miscarriages  
52 reported in 5 studies [23, 25, 26, 46, 68]. Induced miscarriages were done on maternal  
53 request in both studies [46, 68]. Among the spontaneous miscarriages, 6 were seen in  
54  
55  
56  
57  
58  
59  
60

141 pregnancies in one study and 5 in 181 pregnancies in another study [25, 26]. In one of the studies, there were 3 stillbirths. However, the causes of these 3 stillbirths reported, were not related to COVID-19 in the mother [23].

## 2.2 Neonatal Outcomes:

**Table-6: Neonatal outcome**

Serial number	Author (reference)	Number of neonates	APGAR score (1 minute, 5 minute)	Neonatal symptoms (n)	Neonatal ICU admission (n)	Neonatal death	Neonatal RTPCR status
1.	Alzamora M et al (78)	1	6, 8	Respiratory difficulty Cough on D6	(1) [due to maternal sedation]	-	<b>+ve</b>
2.	Chen H et al (45)	9	8-10	-	-	-	
3.	Fan C et al (48)	2	9-10	Fever, abdominal distension, lymphopenia (1) Mild NNP, lymphopenia (1)	-	-	<b>Negative</b>
4.	Dong L et al (55)	1	9-10	-	-	-	
5.	Zeng H et al (54)	6	9-10	-	-	-	
6.	Liu W et al (56)	3	8-10	decreased responsiveness and decreased muscle tone	-	-	<b>Negative</b>
7.	Zhu H et al (57)	10	8-10 in all 7-8 in 1	Shortness of breath (6), vomiting (1), rash (1), Fever (3)	Yes (2)	YES (1)	<b>Negative</b>
8.	Wang X et al (77)	1	9-10	-	Yes (1)	-	
9.	Liu Y et al (69)	10	10	-	-	-	
10.	Chen Y et al (58)	4	8-9 (3) 7-8 (1)	Edema (1), Rash (2), Dyspnea and TTN (1)	Yes (2)	-	<b>Negative</b>
11.	Gidlof S et al (76)	2	9-10	Breathing problem, cyanotic attack(1)			<b>Negative</b>
12.	Huang J et al (86)	1	8-9	-	-	-	
13.	Iqbal S et al (105)	1	9	-	-	-	
14.	Lee D et al (80)	1	9-10	-	Yes (1)	-	
15.	Khan S et al (85)	3	9-10	-	-	-	
16.	Khan S et al (64)	17	9-10 (16) 7-9 (1)	NNP (5)	-	-	<b>2 out of 5 with pneumonia were +ve</b>
17.	Xiong S et al (50)	1	9-10	-	-	-	
18.	Wang S et al (51)	1	8-9	Vomiting, lymphopenia, abnormal liver enzyme levels	Yes (1)	-	<b>Negative</b>
19.	Zeng L et al (41)	33	Preterm newborn-3,4 Term - Normal	RD (4=3 -ve, 1+ve). Cyanosis, feeding intolerance (3=2-ve,1+ve) Fever in 2, NNP in 3 of the 3 +ve Lethargy, fever(1) lethargy, fever, NNP, leukocytosis, lymphocytopenia, vomiting (1) Preterm- Neonatal RDS, NNP, lymphocytopenia (1)	Yes (3)	-	<b>+ve</b>
20.	Zamaniyan M et al (30)	1	8,9	Fever (1)	-	-	<b>+ve</b>
21.	Breslin N et al (59)	18	>7, >9	RD/ sepsis (1)	Yes (3)	-	<b>Negative</b>
22.	Qiancheng X et al (107)	23	10,10		-	-	
23.	Hantoushzadeh S et al (75)	5	7 (2), 9-10	NNP, lymphopenia (1)	Yes (1)	YES(2)	<b>Negative</b>
24.	Shanes E et al (36)	15	7(8),8(7); 9				

25.	Zambrano L et al (87)	1	-	-	Yes (1)	-	
26.	Perez O et al (65)	82	<5 (3)	RD (2)	Yes (19)	-	<b>+ve</b>
27.	Savasi V et al (109)	57	10	-	Yes(9)	-	
28.	Song L et al (49)	1	8,9	-	-	-	
29.	Lokken E et al (40)	8					
30.	Yan J et al (24)	99	9,10	Neonatal asphyxia (1)	Yes(47)	YES (1)	<b>Negative</b>
31.	William R et al (63)	32	7.9±1.7	-	Yes (21)	-	
32.	Knight M et al (23)	262		Neonatal encephalopathy (1)	Yes (67)	YES (2)	<b>Unclear whether symptomatic neonate was +ve</b>
33.	Kayem G et al (25)	181		-	Yes (37)	YES (1)	
34.	Nayak A et al (26)	131	7–10 (128) <7 (6)	Neonatal seizures (1), MAS (1)	Yes (24)		<b>Unclear whether symptomatic neonates were +ve</b>
35.	Prabhu et al (60)	73	9	-	Yes (13)	-	<b>Negative</b>
36.	Vivanti A et al (29)	1	4,7	irritability, poor feeding, axial hypertonia and opisthotonos	Yes (1)	-	<b>+ve</b>
37.	Li N et al (66)	17	9.6 ± 0.5, 10	-	-	-	
38.	Cao D et al (67)	11	8-9,10	-	-	-	
39.	Hu X et al (42)	7	7-8,8-9	-	-	-	
40.	Yang P et al (81)	7	8-9,9-10	Vomiting(1), RD (2), Moaning (2)	Yes (5)	-	<b>Negative</b>
41.	Yang H et al (73)	13	9,10	Fever(1)	-	-	
42.	Patane L et al (39)	2	9,10	Mild feeding difficulty (2)	Yes (1)	-	<b>+ve</b>
43.	Ferrazzi E et al (28)	42	<7 (2)	Gastrointestinal symptoms, RD (2)	Yes (3)	-	<b>+ve</b>
44.	Govind A et al (61)	9	<7 (2)	NNP (1)	Yes (1)	-	<b>+ve</b>
45.	Nie R et al (68)	28	8-10, 10	Pulmonary infection (1)	Yes (1)	-	<b>+ve</b>
46.	Yin M et al (46)	17	8,9	-	-	-	
47.	Doria M et al (71)	10	9,10	-	-	-	
48.	Perrone S et al (72)	4	9,10	-	-	-	
49.	Romagano M et al (82)	7	1-7,4-9	RD	Yes(7)	-	<b>Negative</b>
50.	Cooke W et al (83)	2	1-6, 3-8	Bowel perforation D6(1)	Yes(2)	-	<b>Negative</b>
51.	Lowe B et al (62)	1	9,9	-	-	-	
52.	Blauvelt C (84)	1	4,8	RD	YES(1)	-	<b>Negative</b>
53.	Kirtsman M et al (35)	1	9,9	Neutropenia, hypothermia, feeding difficulties, hypoglycemia	YES(1)	-	<b>+ve</b>
54.	Lyra J et al (74)	1	8,9	-	-	-	<b>Negative</b>
55.	Groß R et al (52)	2	-	Respiratory symptoms (2), icterus (1)	-	-	<b>+ve</b>
56.	Kulkarni et al (117)	1	6,9	Fever, icterus, and poor feeding	YES(1)	-	<b>+ve</b>
57.	Sisman J et al (70)	1	7,9	Fever, RD, Icterus	YES(1)	-	<b>+ve</b>

RD= Respiratory distress; MAS= Meconium aspiration syndrome; TTN= Transient Tachypnea of Newborn; NNP= Neonatal Pneumonia

### i. Neonatal symptoms

The most common neonatal symptoms were respiratory problems reported as respiratory distress, shortness of breath, respiratory difficulty, dyspnea, and breathing problems [28, 41, 52, 57- 59, 65, 70, 76, 78, 81, 82, 84]. Respiratory distress was the most common symptom reported in 14 neonates but the test for SARS-CoV-2 was positive in only 4 neonates and negative in 8 [28, 41, 59, 65, 81, 82, 84]. Pneumonia was seen in 5 neonates who were positive for SARS-CoV-2 and 4 neonates who were negative [41, 48, 61, 64, 75]. Although usually respiratory symptoms are seen more in preterm babies due

1  
2  
3 to pulmonary immaturity, in a single case report there were no neonatal complications in  
4 a SARS-CoV-2 positive mother who delivered a preterm baby at 29 weeks 5 days by  
5 emergency CS for maternal indications [88].  
6  
7

8 Diffuse bilateral granular and hazy opacities in chest radiograph and thickened lungs on  
9 x-ray were found in two neonates but the neonatal test for SARS-Cov-2 was negative in  
10 both of them [51, 84]. In another SARS-CoV-2 +ve, newborn chest X-ray was consistent  
11 with pulmonary infection, 53 hours after birth [68]. In another study, neonatal symptoms  
12 are extensively described. The most common first clinical symptom in the neonates of  
13 SARS-CoV-2 Positive women was shortness of breath (n=6), followed by gastrointestinal  
14 symptoms like feeding intolerance, bloating, refusing milk, and gastric bleeding (n=4).  
15 Other symptoms included fever, rapid heart rate, and vomiting. Chest radiographic  
16 abnormalities included infections (n=4), neonatal respiratory distress syndrome (n=2),  
17 and pneumothorax (n=1). Another preterm baby suffered from frequent oxygenation  
18 fluctuations and thrombocytopenia and was cured 15 days later [57]. It was reported in  
19 yet another study that most of the complications in neonates were a result of prematurity  
20 (often iatrogenic) rather than SARS-CoV-2 infection [41]. Other presentations in SARS-  
21 CoV-2 positive neonates included fever, cyanosis, lethargy, irritability, poor feeding, axial  
22 hypertonia, opisthotonus, and feeding difficulties [29, 39, 41].  
23  
24  
25  
26  
27

## 28 ii. APGAR Score

29  
30 In our review, a total of 9 studies have reported a low APGAR score among babies born  
31 to SARS-CoV-2 positive mothers [26, 28, 29, 41, 61, 78, 82-84]. Seven of the neonates  
32 were very preterm or preterm and were SARS-CoV-2 negative. The APGAR score in  
33 these is likely to be due to pulmonary immaturity [26, 28, 29, 78, 82-84]. Two other babies  
34 were term deliveries and tested positive for SARS-CoV-2 [41, 61]. However, another  
35 study reported low APGAR scores of 0–3 in 2 babies of COVID positive mothers and 15  
36 babies in COVID negative mothers, indicating no statistically significant difference [26].  
37  
38  
39

## 40 iii. ICU admissions

41  
42 Admission to the neonatal ICU was done for various reasons. The majority of admissions  
43 were for observation and isolation. Neonates admitted due to complications of prematurity  
44 constitute another higher portion of the neonates. In a study, out of a total of 24 ICU  
45 admissions, it was found that 16 babies were admitted due to low birth weight, 2 for low  
46 APGAR score, and 6 others for other uncommon reasons like ABO incompatibility [26].  
47 In another study, it was found that rates of admission to ICU increased with the severity  
48 of the disease in the mother [25]. In our review, ICU admissions for suspected or  
49 confirmed neonatal sepsis was reported in 6 neonates out of which Enterobacter and  
50 Respiratory syncytial virus was found in 2 neonates. The culture was negative for 4 others  
51 [35,41,51,52,59,70].  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### iv. Neonatal death

Neonatal death was reported among 7 neonates in 5 studies [23-25, 57, 75]. It was unclear whether COVID-19 in mothers contributed to the deaths in 2 neonates in one of the studies [23]. In another study, neonatal death occurred in a preterm baby on the 9<sup>th</sup> day of life who was admitted with shortness of breath and moaning and later developed refractory shock, multiple organ failure and disseminated intravascular coagulation (DIC) [57]. The calculated neonatal death rate is 5.47 per 1000 live births. [Table-6]

#### 3. Congenital anomaly:

We could not find any studies describing structural anomalies in the fetus associated with COVID-19. Due to an evolving pandemic, the teratogenicity of the virus has not yet been explored adequately. However, in a few of the studies, the findings of anomaly scans during pregnancy were included and they did not show any difference between fetuses of SARS-CoV-2 positive and negative women [46, 57]. In two case reports, a multicystic dysplastic kidney was detected by antenatal ultrasound in one and after delivery in the other [36, 59]. In another study bilateral gliosis of the deep white periventricular and subcortical matter was detected in an 11 days old neonate born to SARS-CoV-2 positive mother by magnetic resonance imaging [29]. However, these cannot be attributed to SARS-CoV-2. Furthermore, autopsy finding in a stillborn baby born to COVID-19 mother did not show any abnormality in another report [40].

#### DISCUSSION AND CONCLUSION

We wanted to analyze the published evidence on the fetal perspective of COVID-19 infection concerning mother to child transmission, perinatal outcome, and congenital anomalies through a systematic review.

The present available data do not provide a clear conclusion into the fetal outcomes and its clinical implications. Few other reviews have explored the evidence of vertical transmission. There is varied positivity rate of different samples. The positivity of NP swab in this study is 3.67% which is in accordance with other reviews reporting 3.2% (22/936), 2% (9/493), and 3.48% (3/86), respectively [89- 91]. In a couple of other reviews, however, the NP samples were negative [(0/113) and (0/9)] [92, 93]. No evidence of vertical transmission was found in other reviews [2, 94, 95].

The placental sample was positive in our review in 11.7% of pregnancies. It is similar to the review by Kotlyar reporting 9.7% (3/31) sample positivity [89]. The placenta was extensively studied in another review where it was shown that there is a low likelihood of placental infection and vertical transmission of SARS-CoV-2 since the receptors and proteases, are only minimally expressed by the human placenta throughout pregnancy [96]. Placenta was also negative for 54 samples in another review [90].



1  
2  
3 Amniotic fluid collected before the rupture of membranes was positive in 6.8% of  
4 pregnancies in our review, in contrast to the review by Kotlyar (0/51) and Ashraf (1/16)  
5 **[89, 91]**.

6  
7 The serological analysis was found in some studies within our review showing IgM  
8 positive results at birth indicating possible congenital transmission. Using the criteria by  
9 Shah et al, we found that there is confirmed congenital transmission in 5 live-born  
10 neonates and 2 DCDA twins expelled at 24 weeks **[14]**. Similarly, the possible congenital  
11 transmission was found in 5 neonates and probable in 2 neonates. These analyses were  
12 not reported in earlier reviews involving more than 1300 pregnancies in total.

13  
14 The chance for CS is more in women with COVID-19 and in most instances for maternal  
15 indications. Preterm delivery is also high (26.4%) most commonly due to adverse  
16 maternal condition, although spontaneous preterm labor is low (1.8%). This is in  
17 accordance with another systematic review with regards to the indication but they found  
18 a trend towards spontaneous preterm labour **[97]**. In contrast, an earlier review reported  
19 6.4% of preterm deliveries as spontaneous **[98]**.

20  
21 Fetal distress (6.63%) was the most common complication seen in the fetus followed by  
22 PROM and PPRM (4.27%) in our review. Similar findings were seen in other reviews  
23 **[91, 94]**. One earlier review did not report any fetal complications **[92]**. PPRM was  
24 reported in 14 pregnancies in our review. While PROM and PPRM are unlikely to  
25 contribute to mother to child transmission as the SARS-CoV-2 has not been positive in  
26 the vaginal swab, PPRM is a significant cause of preterm labor. Through our review, it  
27 was not possible to ascertain whether COVID-19 in mothers increases the risk for PROM.  
28 IUGR was reported in 12 fetuses in 5 studies (0.9%). IUGR can be multifactorial and need  
29 to be analyzed with the presence of maternal risk factors. SARS-CoV-2 has not been  
30 associated with IUGR and it was not possible to ascertain whether COVID-19 in mother  
31 increases the risk for IUGR in our study.

32  
33 The rates of stillbirth and neonatal death in our study were 9.9 and 5.46 respectively. In  
34 another study, it was found that stillbirth was significantly higher during the pandemic  
35 compared to the non-pandemic period due to reasons non-associated with COVID-19  
36 (difference, 6.93 [95% CI, 1.83-12.0] per 1000 births; P= .01) **[99]**. So it is unlikely that the  
37 stillbirth and neonatal death rate are increased in COVID-19 mothers. The symptoms  
38 when present in the infected neonates were most often mild and neonatal outcomes were  
39 found to be good **[100, 101]**. There is no reported teratogenicity or congenital anomalies  
40 associated with SARS-CoV-2 infection.

41  
42 The outcome so far is favorable for the fetus despite the risks to the mother for ICU  
43 admissions and mechanical ventilation seen in other studies **[3]**. Maternal outcomes were  
44 not explored in this study. There is no significant increase in preterm birth but there is a  
45 significantly increased risk of CS in mothers with COVID-19.

46  
47 Though the fetal perspective seems good in the case of maternal COVID-19, it will be  
48 reasonable to consider these findings with caution. Prospective studies and randomized  
49  
50  
51  
52  
53  
54  
55  
56  
57

control trials were missing from the evidence due to the recent nature of the infection. Therefore, larger and better quality studies are required to address the knowledge gaps and to reach at a definite guideline for management.

### **Strengths and Limitations of the study**

There are many strengths to this study. The studies included in the review contained only confirmed maternal cases by RT-PCR and not the suspected cases or clinically diagnosed cases. The studies contained the results of neonatal testing. Studies included in this review were from countries across the world and not restricted to a specific region, making the findings from the study globally applicable. The case series/cohorts were chosen only when the total number of cases was more than 4. Moreover, various aspects of vertical transmission as well as fetal and neonatal outcomes were analyzed from the chosen studies.

Nonetheless, there are many limitations to our study. Only a limited number of available case series and cohorts were included in this review as high-quality evidence involving a higher number of subjects is lacking due to the new kind of infection and still evolving nature of the pandemic. In our review, studies in languages other than English were excluded due to unavailability of English translation. Almost all of the reports are retrospective reviews showing incomplete data with significant heterogeneity within the included studies with a chance of selection or recall bias. Different types of samples were used for the diagnosis of SARS-CoV-2 in different studies. Though nasopharyngeal swab was used for diagnosis in most studies, there were different types of kits used. Again the same kit may have different sensitivity and specificity in different types of samples. Universal testing of pregnant women was not done in many studies, resulting in missing fetal and perinatal effects in asymptomatic women. As maternal outcomes were not studied, the effects of the severity of maternal disease on the fetal outcomes could not be looked into.

### **Future Implications:**

Whether there is an intrauterine infection of the fetus with respect to SARS-CoV-2 needs to be studied. What are the effects of intrauterine infection, whether there is different susceptibility at different stages of pregnancy, and whether susceptibility depends on disease severity in the mother, needs to be explored. Follow up studies are required to see long term effects of neonatal infection with SARS-CoV-2.

### **AUTHORSHIP STATEMENT**

Manuscript title: **COVID-19 in pregnancy; The fetal perspective- a systematic review**

1  
2  
3 All persons who meet authorship criteria are listed as authors, and all authors certify that  
4 they have participated sufficiently in the work to take public responsibility for the content,  
5 including participation in the concept, design, analysis, writing, or revision of the  
6 manuscript. Furthermore, each author certifies that this material or similar material has  
7 not been and will not be submitted to or published in any other publication before its  
8 appearance in the BMJ Pediatrics-open access.  
9  
10  
11  
12  
13  
14

### 15 **Authorship contributions**

16  
17 **Conception and design of the study:** Rajani Dube, Subhranshu Sekhar Kar

18 **Acquisition of data:** Subhranshu Sekhar Kar, Rajani Dube

19 **Analysis and/or interpretation of data:** Subhranshu Sekhar Kar, Rajani Dube

20 **Drafting the manuscript:** Rajani Dube, Subhranshu Sekhar Kar

21 **Revising the manuscript critically for important intellectual content:** Rajani Dube,  
22 Subhranshu Sekhar Kar

23 **Approval of the version of the manuscript to be published (the names of all  
24 authors must be listed):** Subhranshu Sekhar Kar, Rajani Dube

25 **Acknowledgments- None**

26 Author's name

27 Rajani Dube

28 Subhranshu Sekhar Kar

29 **Disclaimer-** The views expressed in the submitted article are our own and not an  
30 official position of the institution or funder.

31 **Source(s) of support/Funding - None**

32 **Disclosure of relationships and activities-** Nothing to disclose

33 **Patient consent for publication-** not required

34 **Conflicts of interest-**None

35 **References:**

- 1  
2  
3 [1] Rasmussen SA, Smulian JC, Lednicky JA, *et al.* Coronavirus disease 2019 (COVID-  
4 19) and pregnancy: what obstetricians need to know. *Am J Obstet Gynecol.*  
5 2020;222:415–26. doi: [10.1016/j.ajog.2020.02.017](https://doi.org/10.1016/j.ajog.2020.02.017)  
6
- 7 [2] Muhidin S, Behboodi Moghadam Z, Vizheh M. Analysis of Maternal Coronavirus  
8 Infections and Neonates Born to Mothers with 2019-nCoV; a Systematic Review. *Arch*  
9 *Acad Emerg Med.* 2020;8:e49. PMID: 32440660; PMCID: PMC7211430.  
10
- 11 [3] Ellington S, Strid P, Tong VT, *et al.* Characteristics of Women of Reproductive Age  
12 with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United  
13 States, January 22–June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69:769–75. doi:  
14 <http://dx.doi.org/10.15585/mmwr.mm6925a1>  
15
- 16 [4] Rajewska A, Mikołajek-Bedner W, Lebdowicz-Knul J, *et al.* COVID-19 and  
17 pregnancy – where are we now? A review. *J. Perinat. Med.* 2020;48:428–34. doi:  
18 [10.1515/jpm-2020-0132](https://doi.org/10.1515/jpm-2020-0132)  
19
- 20 [5] Woodward A. A pregnant mother infected with the coronavirus gave birth, and her  
21 baby tested positive 30 hours later. Available at:  
22 [https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-](https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2)  
23 [mother-2020-2](https://www.businessinsider.com/wuhan-coronavirus-in-infant-born-from-infected-mother-2020-2) Accessed June 15, 2020.  
24
- 25 [6] Collin J, Byström E, Carnahan A, *et al.* Public Health Agency of Sweden’s brief  
26 report: pregnant and postpartum women with SARS-CoV-2 infection in intensive care in  
27 Sweden. *Acta Obstet Gynecol Scand* 2020;99:819–22. doi: 10.1111/aogs.13901.  
28
- 29 [7] Rogan SC, Beigi RH. Treatment of viral infections during pregnancy. *J Perinatol*  
30 2019;46:235–56.  
31 doi: 10.1016/j.clp.2019.02.009.
- 32 [8] Racicot K, Mor G. Risks associated with viral infections during pregnancy. *J Clin*  
33 *Invest* 2017;127:1591–9. doi: 10.1172/JCI87490  
34
- 35 [9] Lamouroux A, Bitach TA, Martinovic J, *et al.* Evidence for and against vertical  
36 transmission for severe acute respiratory syndrome coronavirus 2 (coronavirus disease  
37 2019). *Am J Obstet Gynecol* 2020;223:91.e1–91.e4. doi: 10.1016/j.ajog.2020.04.039  
38
- 39 [10] Li M, Chen L, Zhang J, *et al.* The SARS-CoV-2 receptor ACE2 expression of  
40 maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One.*  
41 2020;15:e0230295. <https://doi.org/10.1371/journal.pone.0230295>  
42
- 43 [11] Jing Y, Run-Qian L, Hao-Ran W, *et al.* Potential influence of COVID-19/ACE2 on  
44 the female reproductive system. *Mol Hum Reprod.* 2020;gaaa030,  
45 <https://doi.org/10.1093/molehr/gaaa030>.  
46
- 47 [12] Levy A, Bursztyn M, Barkalifa R, *et al.* ACE2 expression and activity are enhanced  
48 during pregnancy. *Am J Physiol Regul Integr Comp Physiol.* 2008;295:R1953-61. doi:  
49 [10.1152/ajpregu.90592.2008](https://doi.org/10.1152/ajpregu.90592.2008).  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [13] Valdes G, Neves LA, Anton L, *et al.* Distribution of angiotensin-(1-7) and ACE2 in  
4 human placentas of normal and pathological pregnancies. *Placenta*. 2006;27:200-7. doi:  
5 10.1016/j.placenta.2005.02.015.  
6  
7  
8 [14] Shah PS, Diambomba Y, Acharya G, Morris SK, Bitnun A. Classification system and  
9 case definition for SARS-CoV-2 infection in pregnant women, fetuses, and neonates.  
10 *Acta Obstet Gynecol Scand* 2020;99: 565-8. doi:10.1111/aogs.13870  
11  
12 [15] Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in different types of clinical  
13 specimens. *JAMA* 2020;323:1843-4. doi:10.1001/jama.2020.3786  
14  
15 [16] Razaz N, Cnattingius S, Persson M, *et al.* One-minute and five-minute Apgar  
16 scores and child developmental health at 5 years of age: a population-based cohort  
17 study in British Columbia, Canada. *BMJ Open* 2019;9:e027655  
18 doi:10.1136/bmjopen-2018-027655  
19  
20  
21 [17] Desai D, Chauhan K, Chaudhary S. A study of meconium stained amniotic fluid, its  
22 significance and early maternal and neonatal outcome. *Int J Reprod Contracept Obstet*  
23 *Gynecol*. 2013;2:190–3. doi: 10.5455/2320-1770.ijrcog20130616.  
24  
25 [18] Ajah LO, Ibekwe PC, Onu FA, Onwe OE, Ezeonu TC, Omeje I. Evaluation of  
26 Clinical Diagnosis of Fetal Distress and Perinatal Outcome in a Low Resource Nigerian  
27 Setting. *J Clin Diagn Res*. 2016;10:QC08-11. doi:10.7860/JCDR/2016/17274.7687.  
28  
29 [19] Royal College of Obstetricians and Gynaecologists.  
30  
31 [http:// www.rcog.org.uk/womens-health/investigation-and-managementsmall-](http://www.rcog.org.uk/womens-health/investigation-and-managementsmall-gestational-age-fetus-green-top-31)  
32 [gestational-age-fetus-green-top-31](http://www.rcog.org.uk/womens-health/investigation-and-managementsmall-gestational-age-fetus-green-top-31). Published November 1,2002. Accessed 9 Oct 2020.  
33  
34 [20] American College of Obstetricians and Gynecologists. Intrauterine growth  
35 restriction. Practice Bulletin no. 12, 2000, Washington DC. <http://www.acog.org>.  
36 Accessed 9 Oct 2020.  
37  
38 [21] Abu-Zidan FM, Abbas AK, Hefny AF. Clinical "case series": a concept analysis. *Afr*  
39 *Health Sci*. 2012;12:557-62. PMID: 23515566; PMCID: PMC3598300.  
40  
41 [22] Murad MH, Sultan S, Haffar S, *et al.* Methodological quality and synthesis of case  
42 series and case reports. *BMJEvidBasedMed* 2018;23:60–3.doi:10.1136/bmjebm-2017-  
43 110853.  
44  
45 [23] Knight M, Bunch K, Vousden N, *et al.* Characteristics and outcomes of pregnant  
46 women hospitalized with confirmed SARS-CoV- 2 infection in the UK: a national cohort  
47 study using the UK Obstetric Surveillance System (UKOSS). *BMJ* 2020;369:m2107. doi:  
48 <https://doi.org/10.1136/bmj.m2107>  
49  
50 [24] Yan J, Guo J, Fan C, *et al.* Coronavirus disease 2019 in pregnant women: a report  
51 based on 116 cases. *Am J Obstet Gynecol* 2020;223:111.e1- 14.  
52 doi:10.1016/j.ajog.2020.04.014.  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 [25] Kayem G, Alessandrini V, Azria E, *et al.* A snapshot of the Covid-19 pandemic  
4 among pregnant women in France. *Journal of Gynecology Obstetrics and Human*  
5 *Reproduction*. 2020 :101826. doi: 10.1016/j.jogoh.2020.101826.  
6  
7 [26] Nayak AH, Kapote DS, Fonseca M, *et al.* Impact of the Coronavirus Infection in  
8 Pregnancy: A Preliminary Study of 141 Patients. *J Obstet Gynecol India* 2020;70:256–  
9 61. <https://doi.org/10.1007/s13224-020-01335-3>  
10  
11 [27] London V, McLaren Jr R, Atallah F, *et al.* The relationship between status at  
12 presentation and outcomes among pregnant women with covid-19. *Am J Perinatol*  
13 2020;37:991–94. doi: 10.1055/s-0040-1712164  
14  
15 [28] Ferrazzi E, Frigerio L, Savasi V, *et al.* Vaginal delivery in SARS-CoV-2infected  
16 pregnant women in Northern Italy: a retrospective analysis. *BJOG*. 2020;127:1116-21.  
17 <https://doi.org/10.1111/1471-0528.16278>  
18  
19 [29] Vivanti AJ, Vauloup-Fellous C, Prevot S, *et al.* Transplacental transmission of  
20 SARS-CoV-2 infection. *Nat Commun* 2020;11:3572. doi: 10.1038/s41467-020-17436-6  
21  
22 [30] Zamaniyan M, Ebadi A, Aghajanpoor Mir S, *et al.* Preterm delivery, maternal death,  
23 and vertical transmission in a pregnant woman with COVID-19 infection [published  
24 online ahead of print, 2020 Apr 17]. *Prenat Diagn*. 2020;10.1002/pd.5713.  
25 doi:10.1002/pd.5713  
26  
27 [31] Pulinx B, Kieffer D, Michiels I, *et al.* Vertical transmission of SARS-CoV-2 infection  
28 and preterm birth. *Eur J Clin Microbiol Infect Dis* 2020. [https://doi.org/10.1007/s10096-](https://doi.org/10.1007/s10096-020-03964-y)  
29 [020-03964-y](https://doi.org/10.1007/s10096-020-03964-y)  
30  
31 [32] Hosier H, Farhadian S, Morotti RA, *et al.* First case of placental infection with SARS  
32 CoV-2. *medRxiv*. 2020; doi: <https://doi.org/10.1101/2020.04.30.20083907>  
33  
34 [33] Baud D, Greub G, Favre G, *et al.* Second-trimester miscarriage in a pregnant  
35 woman with SARS-CoV-2 infection. *JAMA*. 2020;323:2198-2200.  
36 doi:10.1001/jama.2020.7233  
37  
38 [34] Algarroba GN, Rekawek P, Vahanian SA, *et al.* Visualization of SARS-CoV-2 virus  
39 invading the human placenta using electron microscopy. *Am J Obstet Gynecol*.  
40 2020;223:275-78. doi: 10.1016/j.ajog.2020.05.023.  
41  
42 [35] Kirtsman M, Diambomba Y, Poutanen S, *et al.* Probable congenital SARS-CoV-2  
43 infection in a neonate born to a woman with active SARS-CoV-2 infection. *CMAJ*. 628  
44 2020;192:E647-E5. doi: 10.1503/cmaj.200821.  
45  
46 [36] Shanes ED, Mithal LB, Otero S, *et al.* Placental pathology in COVID-19. *Am J Clin*  
47 *Pathol*. 2020;154:23–32. doi: 10.1093/ajcp/aqaa089.  
48  
49 [37] Baergen RN, Heller DS. Placental Pathology in Covid-19 Positive Mothers:  
50 Preliminary Findings. *Pediatr Dev Pathol*. 2020;23:177-80.  
51 doi: [10.1177/1093526620925569](https://doi.org/10.1177/1093526620925569)  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 [38] Mulvey JJ, Magro C, Ma LX, *et al.* Analysis of complement deposition and viral  
4 RNA in placentas of COVID-19 patients. *Ann Diagn Pathol.* 2020;46:151530. doi:  
5 10.1016/j.anndiagpath.2020.151530  
6
- 7 [39] Patane L, Morotti D, Giunta MS, *et al.* Vertical transmission of COVID-19: SARS-  
8 CoV-2 RNA on the fetal side of the placenta in pregnancies with COVID-19 positive  
9 mothers and neonates at birth. *AJOG-MFM.* 2020;100145. doi:  
10 10.1016/j.ajogmf.2020.100145  
11  
12
- 13 [40] Lokken EM, Walker CL, Delaney S, *et al.* Clinical characteristics of 46 pregnant  
14 women with as sars-cov-2 infection in Washington state. *Am J Obstet Gynecol* 2020.  
15 doi:10.1016/j.ajog.2020.05.031. [Epub ahead of print]  
16
- 17 [41] Zeng L, Xia S, Yuan W, *et al.* Neonatal Early-Onset Infection With SARS-CoV-2 in  
18 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. *JAMA Pediatr.*  
19 2020;174:722-25. doi: 10.1001/jamapediatrics.2020.0878.  
20  
21
- 22 [42] Hu X, Gao J, Luo X, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2  
23 (SARS CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus  
24 Disease 2019 (COVID-19) Pneumonia. *Obstet Gynecol.*2020;136:65-67. doi:  
25 10.1097/AOG.0000000000003926.  
26
- 27 [43] Peng Z, Wang J, Mo Y, *et al.* Unlikely SARS-CoV-2 vertical transmission from  
28 mother to child: A case report. *J Infect Public Health.* 2020;13:818-20.  
29 <https://doi.org/10.1016/j.jiph.2020.04.004>  
30  
31
- 32 [44] Li Y, Zhao R, Zheng S, *et al.* Early release - lack of vertical transmission of severe  
33 acute respiratory syndrome coronavirus 2, China. *Emerging Infectious Diseases*  
34 2020;26:1335-36. <https://dx.doi.org/10.3201/eid2606.200287>  
35
- 36 [45] Chen H, Guo J, Wang C, *et al.* Clinical characteristics and intrauterine vertical  
37 transmission potential of COVID-19 infection in nine pregnant women: a retrospective  
38 review of medical records. *Lancet* 2020;395:809–815.  
39  
40
- 41 [46] Yin M, Zhang L, Deng G, *et al.* Severe Acute Respiratory Syndrome Coronavirus 2  
42 (SARS CoV-2) Infection During Pregnancy In China: A Retrospective Cohort Study.  
43 medRxiv. 2020. doi.org/10.1101/2020.04.07.20053744.  
44
- 45 [47] Wu Y, Liu C, Dong L, *et al.* Coronavirus disease 2019 among pregnant Chinese  
46 women: case series data on the safety of vaginal birth and breastfeeding. *BJOG.*  
47 2020;127:1109-15. doi:10.1111/1471-0528.16276 [Published online ahead of print,  
48 2020 May 5].  
49  
50
- 51 [48] Fan C, Lei D, Fang C, *et al.* Perinatal transmission of COVID-19 associated SARS-  
52 CoV-2: should we worry? *Clin Infect Dis.* 2020: ciaa226. [Published online 2020 Mar  
53 17]. doi: 10.1093/cid/ciaa226  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [49] Song L, Xiao W, Ling K, *et al.* Anesthetic Management for Emergent Cesarean  
4 Delivery in a Parturient with Recent Diagnosis of Coronavirus Disease 2019 (COVID-  
5 19): A Case Report. *Transl Perioper & Pain Med* 2020; 7:234-7. doi: 10.31480/2330-  
6 4871/118  
7  
8  
9 [50] Xiong X, Wei H, Zhang Z, *et al.* Vaginal delivery report of a healthy neonate born to  
10 a convalescent mother with COVID19. *J Med Virol.* 2020;10.1002/jmv.25857.  
11 doi:10.1002/jmv.25857. [E-pub ahead of print].  
12  
13 [51] Wang S, Guo L, Chen L, *et al.* A case report of neonatal 2019 coronavirus disease  
14 in China. *Clin Infect Dis.* 2020;71:853-7. doi: 10.1093/cid/ciaa225.  
15  
16 [52] Groß R, Conzelmann C, Müller JA, *et al.* Detection of SARS-CoV-2 in human  
17 breastmilk. *Lancet.* 2020;395:1757–58. Published online 2020 May 21. doi:  
18 10.1016/S0140-6736(20)31181-8  
19  
20 [53] Buonsenso D, Costa S, Sanguinetti M, *et al.* Neonatal Late Onset Infection with  
21 Severe Acute Respiratory Syndrome Coronavirus 2. *Am J Perinatol.* 2020;37:869-72.  
22 doi: 10.1055/s-0040-1710541.  
23  
24 [54] Zeng H, Xu C, Fan J, *et al.* Antibodies in infants born to mothers with COVID-19  
25 pneumonia. *JAMA.* 2020;323:1848-9. doi:10.1001/jama.2020.4861  
26  
27 [55] Dong L, Tian J, He S, *et al.* Possible vertical transmission of SARS CoV- 2 from an  
28 infected mother to her newborn. *JAMA.* 2020;323:1846-8. doi:10.1001/jama.2020.4621  
29  
30 [56] Liu W, Wang Q, Zhang Q, *et al.* Coronavirus disease 2019 (COVID-19) during  
31 pregnancy: a case series. *Preprints.*2020 ;2020020373.  
32  
33 [57] Zhu H, Wang L, Fang C, *et al.* Clinical analysis of 10 neonates born to mothers with  
34 2019-nCoV pneumonia. *Transl Pediatr* 2020;9:51-60. doi: 10.21037/tp.2020.02.06  
35  
36 [58] Chen Y, Peng H, Wang L, *et al.* Infants born to mothers with a new coronavirus  
37 (COVID-19). *Front. Pediatr.* 2020;8:104. doi: 10.3389/fped.2020.00104  
38  
39 [59] Breslin N, Baptiste C, Gyamfi-Bannerman C, *et al.* COVID-19 infection among  
40 asymptomatic and symptomatic pregnant women: two weeks of confirmed  
41 presentations to an affiliated pair of New York City hospitals. *Am J Obstet Gynecol*  
42 *MFM.* 2020;2:100118. doi: 10.1016/j.ajogmf.2020.100118.  
43  
44 [60] Prabhu M, Cagino K, Matthews KC, *et al.* Pregnancy and postpartum outcomes in a  
45 universally tested population for SARS-CoV-2 in New York City: a prospective cohort  
46 study. *BJOG* 2020; <https://doi.org/10.1111/1471-0528.16403>. 00: 1– 9.  
47  
48 [61] Govind A, Essien S, Karthikeyan A, *et al.* Re: Novel Coronavirus COVID-19 in late  
49 pregnancy: Outcomes of first nine cases in an inner city London hospital. *Eur J Obstet*  
50 *Gynecol Reprod Biol.* 2020;251: 272–74. doi:10.1016/j.ejogrb.2020.05.004.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 [62] Lowe B, Bopp B. COVID 19 vaginal delivery - A case report. *Aust N Z J Obstet*  
4 *Gynaecol.* 2020;60:465-6. <https://doi.org/10.1111/ajo.13173>  
5  
6  
7 [63] Pierce-Williams RAM, Burd J, Felder L, et al. Clinical course of severe and critical  
8 COVID-19 in hospitalized pregnancies: a US cohort study. *Am J Obstet Gynecol MFM.*  
9 2020 May 8;100134. doi: 10.1016/j.ajogmf.2020.100134.  
10  
11 [64] Khan S, Jun L, Siddique R, et al. Association of COVID-19 with pregnancy  
12 outcomes in health-care workers and general women. *Clin Microbiol Infect.*  
13 2020;26:788-90. doi: 10.1016/j.cmi.2020.03.034  
14  
15 [65] Martínez-Perez O, Vouga M, Cruz Melguizo S, et al. Association between mode of  
16 delivery among pregnant women with COVID-19 and maternal and neonatal outcomes  
17 in Spain. *JAMA.* 2020. <https://doi.org/10.1001/jama.2020.10125> .  
18  
19  
20 [66] Li N, Han L, Peng M, et al. Maternal and neonatal outcomes of pregnant women  
21 with COVID-19 pneumonia: a case-control study. *Clinical Infectious Diseases* 2020. doi:  
22 10.1093/cid/ciaa352  
23  
24 [67] Cao D, Yin H, Chen J, et al. Clinical analysis of ten pregnant women with COVID-  
25 19 in Wuhan, China: A retrospective study. *Int J Infect Dis.* 2020;95:294-300.  
26 <https://doi.org/10.1016/j.ijid.2020.04.047>.  
27  
28  
29 [68] Nie R, Wang S, Qiong Y, et al. Clinical features and the maternal and neonatal  
30 outcomes of pregnant women with coronavirus disease 2019. medRxiv. 2020; doi:  
31 <https://doi.org/10.1101/2020.03.22.20041061>  
32  
33  
34 [69] Liu Y, Chen H, Tang K, et al. Clinical manifestations and outcome of SARS-CoV-2  
35 infection during pregnancy. *J Infect.*2020. doi: 10.1016/j.jinf.2020.02.028. Online ahead  
36 of print.  
37  
38 [70] Sisman J, Jaleel M, Moreno W, et al. Intrauterine transmission of SARS-CoV-2  
39 infection in a preterm infant. *Pediatr Infect Dis J.* 2020.  
40 <https://doi.org/10.1097/inf.00000000000002815>.  
41  
42  
43 [71] Doria M, Peixinho C, Laranjo M, et al. Covid-19 during pregnancy: a case series  
44 from an universally tested population from the north of Portugal. *Eur J Obstet Gynecol*  
45 *Reprod Biol.* 2020;250:261-2. doi: 10.1016/j.ejogrb.2020.05.029. Epub 2020 May 15.  
46  
47  
48 [72] Perrone S, Deolmi M, Giordano M, et al. Report of a series of healthy term  
49 newborns from convalescent mothers with COVID-19. *Acta Bio Med [Internet].*  
50 2020;91:251-5. Available from:  
51 <https://mattioli1885journals.com/index.php/actabiomedica/article/view/9743>  
52  
53
- 
-

1  
2  
3 [73] Yang H, Sun G, Tang F, *et al.* Clinical features and outcomes of pregnant women  
4 suspected of coronavirus disease 2019. *J Infect.* 2020;81:e40-e44. .  
5 doi: [10.1016/j.jinf.2020.04.003](https://doi.org/10.1016/j.jinf.2020.04.003)  
6

---

7  
8  
9  
10 [74] Lyra J, Valente R, Rosario M, *et al.* Cesarean Section in a Pregnant Woman with  
11 COVID- 19: First Case in Portugal. *Acta Medica Portuguesa.* 2020;33:429-31.  
12 <https://doi.org/10.20344/amp.13883>  
13

14 [75] Hantoushzadeh S, Shamshirsaz AA, Aleyasin A, *et al.* Maternal death due to  
15 COVID-19 disease. *Am J Obstet Gynecol.* 2020; 223: 109.e1–109.e16. Published  
16 online 2020 Apr 28. doi: [10.1016/j.ajog.2020.04.030](https://doi.org/10.1016/j.ajog.2020.04.030)  
17

18  
19 [76] Gidlöf S, Savchenko J, Brune T, *et al.* CO-VID-19 in pregnancy with comorbidities:  
20 more liberal testing strategy is needed. *Acta Obstet Gynecol Scand.* 2020;99:948-9. doi:  
21 [10.1111/aogs.13862](https://doi.org/10.1111/aogs.13862). Epub 2020 Apr 17.  
22

23  
24 [77] Wang X, Zhou Z, Zhang J, *et al.* A Case of 2019 Novel Coronavirus in a Pregnant  
25 Woman With Preterm Delivery. *Clin Infect Dis.* 2020;71:844-6. doi:[10.1093/cid/ciaa200](https://doi.org/10.1093/cid/ciaa200)  
26

27 [78] Alzamora MC, Paredes T, Caceres D, *et al.* Severe COVID-19 during Pregnancy  
28 and Possible Vertical Transmission. *Am J Perinatol* 2020;37:861–5. doi: [10.1055/s-](https://doi.org/10.1055/s-0040-1710050)  
29 [0040-1710050](https://doi.org/10.1055/s-0040-1710050).  
30

31 [79] Kalafat E, Yaprak E, Cinar G, *et al.* Lung ultrasound and computed tomographic  
32 findings in pregnant woman with COVID-19. *Ultrasound Obstet Gynecol.* 2020;55: 835-  
33 7. <https://doi.org/10.1002/uog.22034>  
34

35 [80] Lee DH, Lee J, Kim E, *et al.* Emergency cesarean section on severe acute  
36 respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed patient. *Korean J*  
37 *Anesthesiol.* 2020;73:347-51. doi: [10.4097/kja.20116](https://doi.org/10.4097/kja.20116).  
38

39  
40 [81] Yang P, Wang X, Liu P, *et al.* Clinical characteristics and risk assessment of  
41 newborns born to mothers with COVID-19. *J Clin Virol.* 2020;127:104356. doi:  
42 [10.1016/j.jcv.2020.104356](https://doi.org/10.1016/j.jcv.2020.104356).  
43

44 [82] Romagano MP, Guerrero K, Spillane N, *et al.* Perinatal outcomes in critically ill  
45 pregnant women with covid-19. *Am J Obstet Gynecol MFM.* 2020; 100151.  
46 <https://doi.org/10.1016/j.ajogmf.2020.100151>  
47

48  
49 [83] Cooke WR, Billett A, Gleeson S, *et al.* SARS-CoV-2 infection in very preterm  
50 pregnancy: experiences from two cases. *Eur J Obstet Gynecol Reprod Biol.*  
51 2020;250:259–60. Published online 2020 May 15. doi: [10.1016/j.ejogrb.2020.05.025](https://doi.org/10.1016/j.ejogrb.2020.05.025)  
52

53 [84] Blauvelt CA, Chiu C, Donovan AL, *et al.* Acute Respiratory Distress Syndrome in a  
54 Preterm Pregnant Patient With Coronavirus Disease 2019 (COVID-19). *Obstet Gynecol.*  
55 2020;136:46-51. doi:[10.1097/AOG.0000000000003949](https://doi.org/10.1097/AOG.0000000000003949)  
56  
57

- 1  
2  
3 [85] Khan S, Peng L, Siddique R, *et al.* Impact of COVID-19 infection on pregnancy  
4 outcomes and the risk of maternal-to-neo-natal intrapartum transmission of COVID-19  
5 during natural birth. *Infect Control Hosp Epidemiol.* 2020;41:748-50.  
6 doi: [10.1017/ice.2020.84](https://doi.org/10.1017/ice.2020.84)  
7  
8  
9 [86] Huang JW, Zhou XY, Lu SJ, *et al.* Dialectical behavior therapy-based psy-  
10 chological intervention for woman in late preg-nancy and early postpartum suffering  
11 from COV-ID-19: a case report. *J Zhejiang Univ Sci B.* 2020; 21(5):394-9.  
12 doi: [10.1631/jzus.B2010012](https://doi.org/10.1631/jzus.B2010012)  
13  
14 [87] Zambrano L, Fuentes-Barahona I, Bejarano-Torres D, *et al.* A pregnant woman with  
15 COVID-19 in Central America. *Travel Med Infect Dis.* 2020;101639. doi:  
16 10.1016/j.tmaid.2020.101639. Online ahead of print.  
17  
18 [88] González Romero D, Ocampo Pérez J, González Bautista L, *et al.* Pronóstico  
19 perinatal y de la paciente embarazada con infección por COVID-19. *Rev Clin Esp.*  
20 2020. doi: [10.1016/j.rceng.2020.04.005](https://doi.org/10.1016/j.rceng.2020.04.005) [Epub ahead of print]  
21  
22 [89] Kotlyar A, Grechukhina O, Chen A, *et al.* Vertical Transmission of COVID-19: A  
23 Systematic Review and Meta-analysis. *American Journal of Obstetrics and Gynecology*  
24 2020, S0002-9378(20)30823-1. [Advance online publication].  
25 <https://doi.org/10.1016/j.ajog.2020.07.049>.  
26  
27 [90] Lopes de Sousa AF, Félix de Carvalho HE, Braz de Oliveira L, *et al.* Effects of  
28 COVID-19 Infection during Pregnancy and Neonatal Prognosis: What Is the Evidence?  
29 *Int. J. Environ. Res. Public Health* 2020;17:4176. doi:10.3390/ijerph17114176.  
30 Available at [www.mdpi.com/journal/ijerph](http://www.mdpi.com/journal/ijerph)  
31  
32 [91] Ashraf MA, Keshavarz P , Hosseinpour P, *et al.* Coronavirus Disease 2019  
33 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical  
34 Transmission. *J Reprod Infertil.* 2020;21:157-68.  
35  
36 [92] J.Juan, Gil M M , Rong Z *et al* Effect of coronavirus disease 2019 (COVID-19) on  
37 maternal, perinatal and neonatal outcome: systematic review. *Ultrasound Obstet*  
38 *Gynecol* 2020;56:15–27 Published online in Wiley Online Library  
39 ([wileyonlinelibrary.com](http://wileyonlinelibrary.com)). DOI: [10.1002/uog.22088](https://doi.org/10.1002/uog.22088).  
40  
41 [93] Irani M, Pakfetrat A,Mask MK. Novel coronavirus disease 2019 and perinatal  
42 outcomes. *J Edu Health Promot* 2020;9:78.  
43  
44 [94] Akhtar H, Patel C, Abuelgasim E, Harky A: COVID-19 (SARS-CoV-2) Infection in  
45 Pregnancy: A Systematic Review. *Gynecol Obstet Invest* 2020;85:295-306. doi:  
46 [10.1159/000509290](https://doi.org/10.1159/000509290)  
47  
48 [95] Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, *et al.* Vertical Transmission of  
49 Coronavirus Disease 19 (COVID-19) from Infected Pregnant Mothers to Neonates: A  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Review, Fetal and Pediatric Pathology.2020;39:246-50, DOI:  
4 10.1080/15513815.2020.1747120  
5

6 [96] Pique-Regi R, Romero R, Tarca A, *et al.* Does the human placenta express the  
7 canonical cell entry mediators for SARS-CoV-2? *eLife* 2020;9:e58716 doi:  
8 10.7554/eLife.58716  
9

10 [97] Gatta AND, Rizzo R, Pilu G, *et al.* Coronavirus disease 2019 during pregnancy: a  
11 systematic review of reported cases. *Am J Obstet Gynecol.* 2020;223: 36–41. doi:  
12 10.1016/j.ajog.2020.04.013  
13  
14

15 [98] Huntley BJF, Huntley ES, Di Mascio D, *et al.* Rates of Maternal and Perinatal  
16 Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute  
17 Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review.  
18 *Obstet Gynecol.* 2020;136:303-12. doi: 10.1097/AOG.0000000000004010. PMID:  
19 32516273.  
20  
21

22 [99] Khalil A, Von Dadelszen P, Draycott T, *et al.* Change in the Incidence of Stillbirth  
23 and Preterm Delivery During the COVID-19 Pandemic. *JAMA.* 2020;324:705-6;  
24 Available at <https://jamanetwork.com/> on 10/11/2020  
25

26 [100] Wei M, Yuan J, Liu Y, *et al.* Novel Coronavirus Infection in Hospitalized Infants  
27 Under 1 Year of Age in China. *JAMA.* 2020;323:1313–4. doi:10.1001/jama.2020.2131  
28

29 [101] Dumpa V, Kamity R, Vinci AN, *et al.* Neonatal coronavirus 2019 (COVID-19)  
30 infection: a case report and review of literature. *Cureus* 2020;2019. e8165.  
31 doi:10.7759/cureus.8165  
32  
33

34 [102] Zhang I, Jiang Y, Wei M, *et al.* Analysis of the pregnancy outcomes in pregnant  
35 women with COVID-19 in Hubei Province [in Chinese]. *Zhonghua Fu Chan Ke Za Zhi.*  
36 2020;55:166-71. doi: 10.3760/cma.j.cn112141-20200218-00111.  
37

38 [103] Penfield CA, Brubaker SG, Limaye MA, *et al.* Detection of SARS-CoV-2 in  
39 placental and fetal membrane samples. *Am J Obstet Gynecol MFM.* 2020;2:100133.  
40 <https://doi.org/10.1016/j.ajogmf.2020.100133>  
41

42 [104] Chen S, Chen S, Huang B, *et al.* Pregnant women with new coronavirus infection:  
43 a clinical characteristics and placental pathological analysis of three cases. *Zhonghua*  
44 *Bing Li Xue Za Zhi.* 2020;49:418-23. doi: 10.3760/cma.j.cn112151-20200225-00138.  
45  
46


47 [105] Iqbal SN, Overcash R, Mokhtari N, *et al.* An uncomplicated delivery in a patient  
48 with COVID-19 in the United States. *N Engl J Med* 2020;382:e34. doi:  
49 10.1056/NEJMc2007605  
50

51 [106] Liao X, Yang H, Kong J, *et al.* Chest CT findings in a pregnant patient with 2019  
52 novel corona-virus disease. *Balkan Med J.* 2020;37:226-8.  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 [107] Qiancheng X, Jian S, Lingling P, *et al.* sixth batch of Anhui medical team aiding  
4 Wuhan for COVID-19. *Coronavirus disease 2019 in pregnancy. Int J Infect Dis.*  
5 2020;95:376-83. doi: 10.1016/j.ijid.2020.04.065.  
6
- 7 [108] Yu N, Li W, Kang Q, *et al.* No SARS-CoV-2 detected in amniotic fluid in mid-  
8 pregnancy. *The Lancet Infectious Diseases* 2020;S1473-3099(20)30320-0. doi:  
9 10.1016/S1473-3099(20)30320-0  
10
- 11 [109] Savasi VM, Parisi F, Patane L, *et al.* Clinical findings and disease severity in  
12 hospitalized pregnant women with coronavirus disease 2019 (covid-19). *Obstet*  
13 *Gynecol.* 2020;136:252-8. doi: 10.1097/AOG.0000000000003979.  
14
- 15 [110] Schnettler WT, Al Ahwel Y, Suhag A. Severe acute respiratory distress syndrome  
16 in coronavirus disease 2019–infected pregnancy: obstetric and intensive care  
17 considerations. *AJOG-MFM* 2020. doi.org/10.1016/j.ajogmf.2020.100120.  
18
- 19 [111] Lang G, Zhao H. Can SARS-CoV-2-infected women breastfeed after viral  
20 clearance? *J Zhejiang Univ Sci B.* 2020;12:405-7. doi: 10.1631/jzus.B2000095  
21
- 22 [112] Buonsenso D, Raffaelli F, Tamburrini E, *et al.* Clinical role of lung ultrasound for  
23 the diagnosis and monitoring of COVID19 pneumonia in pregnant women [published  
24 online ahead of print, 2020 Apr 26]. *Ultrasound Obstet Gynecol.*  
25 2020;10.1002/uog.22055. doi:10.1002/uog.22055.  
26
- 27 [113] Vintzileos WS, Muscat J, Hoffmann E, *et al.* Screening all pregnant women  
28 admitted to labor and delivery for the virus responsible for coronavirus disease 2019.  
29 *Am J Obstet Gynecol.* 2020;223:284-6. doi: 10.1016/j.ajog.2020.04.024.  
30
- 31 [114] Breslin N, Baptiste C, Miller R, *et al.* COVID-19 in pregnancy: early lessons. *Am J*  
32 *Obstet Gynecol MFM.* 2020;2:100111. <https://doi.org/10.1016/j.ajogmf.2020.100111>  
33
- 34 [115] Qadri F, Mariona F. Pregnancy affected by SARS-COV-2 infection: a flash report  
35 from Michigan. *J Matern Fetal Neonatal Med.*2020:13.  
36 doi:10.1080/14767058.2020.1765334  
37
- 38 [116] Sentilhes L, De Marcillac F, Jouffrieau C, *et al.* Coronavirus disease 2019 in  
39 pregnancy was associated with maternal morbidity and preterm birth. *Am J Obstet*  
40 *Gynecol.* 2020. doi: [10.1016/j.ajog.2020.06.022](https://doi.org/10.1016/j.ajog.2020.06.022) [Epub ahead of print]  
41
- 42 [117] Kulkarni R, Rajput U, Dawre R, *et al.* Early-onset symptomatic neonatal COVID-19  
43 infection with high probability of vertical transmission. *Infection* (2020).  
44 <https://doi.org/10.1007/s15010-020-01493-6>  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60






Table-1 (a): Analysis of the studies [Case series/ Cohort]

Serial number	Author (reference)	Number of pregnancies	Country	Outcomes included	Selection Contains diagnosed COVID-19 in Pregnancy	Comparability Data on pregnant women and fetus available	Outcome; Assessment and reporting	Evidence of mother to child transmission	Perinatal Outcome
1.	Chen H et al (45)	9	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
2.	Zeng H et al (54)	6	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
3.	Zhu H et al (57)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
4.	Zhang I et al (102)	61	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
5.	Penfield CA et al (103)	11	China	Placental, membrane and neonatal samples	****		**	√	
6.	Liu Y et al (69)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
7.	Khan S et al (64)	17	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
8.	Zeng L et al (41)	33	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
9.	Qianheng X et al (107)	23	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
10.	Yang P et al (81)	7	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
11.	Yang H et al (73)	55	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	*	*	√	√

12.	Wu Y et al (47)	13	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	*	*	√	
13.	Yan J et al (24)	116	China	pregnancy and neonatal outcomes	****	**	***		√
14.	Li N et al (66)	16	China	Symptoms, maternal outcomes, neonatal outcomes	****	**	***		√
15.	Cao D et al (67)	10	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
16.	Yin M et al (46)	31	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
17.	Hu X et al (42)	7	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
18.	Nie R et al (68)	33	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***	√	√
19.	Patane L et al (39)	22	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
20.	Ferrazzi E et al (28)	42	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
21.	Savasi V et al (109)	77	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
22.	Mulvey J et al (38)	5	US	Placental characteristics	***			√	
23.	Vintzileos W et al (113)	32	US	Symptoms, maternal characteristics, Test results	***	*	***	√	
24.	Breslin N et al (59)	18	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
25.	Baergen R et al (37)	20	US	Maternal characteristics, maternal outcomes, Placental characteristics	***			√	

26.	Williams R et al (63)	64	US	Maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
27.	Shanes E et al (36)	16	US	Symptoms, maternal characteristics, Placental pathology, pregnancy and neonatal outcomes	****	**	***	√	√
28.	Breslin N et al (114)	7	US	Symptoms, maternal characteristics, test result	**	**	**	√	
29.	London V et al (27)	68	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
30.	Lokken E et al (40)	46	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	***		√
31.	Qadri F et al (115)	16	US	Maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	_*		√
32.	Prabhu M et al (60)	70	US	Symptoms, obstetric and neonatal outcomes, and placental pathology	****	**	***	√	√
33.	Romano M et al (82)	7	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcomes	****	**	*		√
34.	Govinda A et al (61)	9	UK	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
35.	Knight M et al (23)	427	UK	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
36.	Sentilhes, et al (116)	38	France	Symptoms, maternal outcomes, neonatal outcomes	****	**	***	√	√
37.	Kayem G et al (25)	617	France	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
38.	Nayak A et al (26)	141	India	Symptoms, maternal outcomes, neonatal outcomes	****	**	***		√
39.	Hantoushzadeh et al (75)	7	Iran	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√



40.	Perez O et al (65)	82	Spain	Symptoms, maternal characteristics, pregnancy outcomes	****	**	**	√	√
41.	Doria M et al (48)	10	Portugal	Symptoms, maternal characteristics, pregnancy outcomes	****	**	*		√

**Table-1 (b): Analysis of the studies [Case reports]**

Serial number	Author (reference)	Number of pregnancies	Country	Outcomes included	Selection Contains diagnosed COVID-19 in Pregnancy	Comparability Data on pregnant women and fetus available	Outcome; Assessment and reporting	Evidence of vertical transmission	Perinatal Outcome
1.	Alzamora et al (78)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
2.	Li Y et al (44)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
3.	Dong L et al (55)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
4.	Liao X et al (106)	1	China	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
5.	Wang X et al (77)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
6.	Huang J et al (86)	1	China	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
7.	Xiong X et al (50)	1	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
8.	Wang S et al (51)	1	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
9.	Song L et al (49)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
10.	Fan C et al (48)	2	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√

11.	Chen Y et al (58)	4	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
12.	Peng Z et al(43)	1	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
13.	Liu W et al (56)	3	China	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
14.	Chen S et al (104)	3	China	Symptoms, laboratory parameters, pregnancy outcomes, samples	****	**	***	√	√
15.	Khan S et al (85)	3	China	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
16.	Yu N et al (108)	2	China	Symptoms, maternal characteristics, amniotic fluid in mid pregnancy	****	*	*	√	
17.	Schnettler W et al (110)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcome	****	**	**	√	
18.	Blauvelt C et al (84)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
19.	Iqbal S et al (105)	1	US	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
20.	Algorroba et al (34)	1	US	Symptoms, maternal characteristics, laboratory parameters, pregnancy outcome	***	*	*	√	
21.	Hosier H et al(32)	1	US	Symptoms, maternal characteristics, test result	****	**	**	√	
22.	Sisman J et al (70 )	1	US	Symptoms, maternal characteristics, pregnancy outcomes	****	**	***	√	√
23.	Kalafat E et al (79)	1	Turkey	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
24.	Kirtsman M et al (35)	1	Canada	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√

25.	Lyra J et al (74)	1	Portugal	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
26.	Buonsenso et al (53)	4	Italy	Symptoms, maternal findings, test results	****	*	**	√	
27.	Perrone S et al (72)	4	Italy	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
28.	Buonsenso D et al (112)	2	Italy	Maternal characteristics, Samples for detection	****	**	*	√	
29.	Groß R et al (52)	2	Germany	Symptoms, maternal findings, test results	****	*	*	√	
30.	Cooke W et al (83)	2	UK	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	**		√
31.	Pulinx B et al (31)	2	Belgium	Symptoms, maternal characteristics, laboratory parameters, second trimester miscarriage	****	*	*	√	
32.	Lee D et al (80)	1	Korea	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
33.	Gidlöf S et al (76)	2	Sweden	Symptoms, maternal characteristics, pregnancy and neonatal outcomes	****	**	***	√	√
34.	Baud D et al (33)	1	Switzerland	Symptoms, maternal characteristics, laboratory parameters, second trimester miscarriage	****	*	*	√	
35.	Zamaniyan M et al (30)	1	Iran	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcomes	****	**	***	√	√
36.	Zambrano L et al (87)	1	Central America	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
37.	Vivanti A et al (29)	1	France	Symptoms, maternal outcomes, neonatal outcomes	****	**	***	√	√
38.	Lowe B et al (62)	1	Australia	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

39.	Kulkarni et al (117)	1	India	Symptoms, maternal characteristics, laboratory parameters, pregnancy and neonatal outcome	****	**	***	√	√
-----	----------------------	---	-------	---	------	----	-----	---	---

**Selection-** \* Representativeness of the patients \*Ascertained exposure to SARS-CoV-2 \*Ascertained outcome- Symptoms of COVID-19 in the mother \* Ruling out other causes- Test result of mother positive [\*\*\*\*-Contains all 4 components; \*\*\*-Contains first 3 out of 4 components; \*\*-Contains first 2 out of 4 components;\*- Contains first 1 out of 4 components]

**Comparability-** Data on both mother and fetus available [\*\*- Both maternal and fetal data available; \*- Only maternal data available ]

**Outcome-** \* Evidence of mother to fetal/neonatal transmission, \* Evidence of Fetal outcome, \*Evidence of neonatal outcome [\*\*\*-Contains all 3 components; \*\*- Contains first 2 out of 3 components;\*- Contains first 1 out of 3 components]

√- Included in analysis of mother to fetal/neonatal transmission or included in analysis of perinatal outcome or both

Confidential: For Review Only